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Kynurenine 3-monooxygenase (KMO) is an enzyme that converts L-kynurenine to 3-
hydroxykynurenine as part of the kynurenine pathway. In humans this pathway metabolises 
over 95% of dietary L-tryptophan, an essential amino acid. KMO has been implicated in a 
number of diseases including Alzheimer’s disease, Huntington’s disease and acute 
pancreatitis. In these conditions, a raised level of KMO occurs causing an increase in the 
level of 3-hydroxykynurenine present in cells to a potentially toxic level. As studies in 
animal models of disease and examination of samples from patients have implicated KMO, 
there is significant interest in understanding both the chemistry of this enzyme and also in 
developing effective inhibitors that could potentially provide drugs to treat these conditions. 
The KMO enzyme studied in this thesis is from the bacterium Pseudomonas fluorescens, as 
the human enzyme is insoluble. 
The reaction catalysed by KMO occurs in the active site of the enzyme which contains a 
number of amino acids involved in recognising and binding L-kynurenine. By altering the 
identity of specific amino acids and studying the difference in the properties of the enzyme it 
is possible to determine the role of a particular amino acid in the original enzyme. Four 
amino acids in the active site have been investigated using kinetic experiments, which show 
changes in binding affinity of L-kynurenine or in the catalytic efficiency, and crystallography 
experiments, from which structural changes are observed. Three of the active site residues 
were shown to contribute to substrate binding, although changing two of these to structurally 
similar amino acids did not have a major effect on the chemistry of KMO whereas the slight 
change to the other caused the enzyme to become inactive.  
There is only one difference in the active site amino acids present in Pseudomonas 
fluorescens and human KMO, and kinetic studies demonstrated that this amino acid does not 
have a major effect on substrate binding and therefore suggest that this enzyme is a good 
model for the human enzyme.  
The ability of a set of inhibitor molecules to bind to the active site of the enzyme has also 
been investigated using kinetic and crystallographic methods. These inhibitors have been 
shown through kinetic assays to bind tightly but reversibly to the enzyme and provide useful 
insights both into the potential development of drugs targeting this enzyme and also into the 





Kynurenine 3-monooxygenase (KMO) is a flavoprotein which has been implicated in 
Huntington’s disease, Alzheimer’s disease and acute pancreatitis. Recently there has been 
important research published about this enzyme including the structure of a truncated 
Saccharomyces cerevisiae KMO enzyme and KMO inhibition studies in animal models of 
disease. In previous work from this research group the complete Pseudomonas fluorescens 
KMO enzyme has been successfully crystallised both with and without the substrate,           
L-kynurenine, from which significant insights were gained into function and the potential 
role of domain movement. 
To examine substrate binding in KMO and to consolidate previous structural studies, key 
residues in the active site have been investigated using site directed mutagenesis, 
crystallography and kinetic analysis using steady-state techniques. This analysis has 
identified the interactions between the enzyme and the substrate and provides a basis for 
inhibitor design. The residues implicated in substrate binding are N369, Y404 and R84. For 
N369 and Y404, minor changes to the amino acid in the mutations N369S and Y404F were 
shown to cause a decrease in binding affinity of the substrate but the enzyme remained 
active. For the mutations Y404A and R84K enzyme activity was significantly affected. 
Crystal structures of N369S, Y404F and R84K were also obtained. 
Another residue in the active site studied was H320 which is the only amino acid to differ in 
the active sites of the human and Pseudomonas fluorescens enzymes. This residue was 
therefore of interest to determine whether the bacterial enzyme used in this work is likely to 
be a good model for the human enzyme, which has not yet been successfully isolated in 
significant quantities for in vitro research. Modifying this residue to obtain H320F KMO 
revealed that this residue does not have a significant role in substrate binding. 
Potent inhibitor molecules have been studied with this enzyme and shown in kinetic assays 
to have nanomolar Ki values. These inhibitors are the most potent inhibitors studied with 
Pseudomonas fluorescens to date and continue previous inhibitor studies carried out with 
this enzyme. This group of inhibitors contain different substituents in the part of the 
molecule shown to bind closest to the C-terminal domain of the protein. These novel 
inhibitors do not allow the flavin to be reduced by NADPH (which results in unwanted 
peroxide production) unlike a number of previously studied molecules and therefore have the 
potential to be clinically useful. 
vi 
 
This research therefore answers many questions about this enzyme, in particular about the 
role of particular residues in the active site, substrate recognition and inhibition of this 








Amino Acid Name Three letter code One letter code 
Alanine Ala A 
Asparagine Asn N 
Aspartic Acid Asp D 
Arginine Arg R 
Cysteine Cys C 
Glutamic Acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
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Methionine Met M 
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Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 









AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
BLAST basic local alignment search tool 
DMSO dimethyl sulfoxide 





E. coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
FAD flavin adenine dinucleotide 
FPLC fast protein liquid chromatography 
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IDO indoleamine 2,3-dioxygenase 
IFN-γ interferon-γ 
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LB Luria broth 
LDS lithium dodecyl sulfate 
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MHPCO 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase 
M/mM/µM/nM molar/millimolar/micromolar/nanomolar 
MW molecular weight 
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NADPH nicotinamide adenine dinucleotide phosphate 
NMDA N-methyl-D-aspartate 
ºC degrees Celsius 
PCR polymerase chain reaction 
PDB Protein Data Bank 
PEG polyethylene glycol 
PfKMO* C252S C461S Pseudomonas fluorescens kynurenine 3-monooxygenase 
PHB para-hydroxybenzoate 
PHBH para-hydroxybenzoate hydroxylase 
PLP pyridoxal 5´-phosphate 
PMSF phenylmethylsulfonyl fluoride 
RNA ribonucleic acid 
rpm revolutions per minute 
s seconds 
S. cerevisiae Saccharomyces cerevisiae 
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SDS-PAGE sodium dodecyl sulfate – polyacrylamide gel electrophoresis 
SOC Super optimal broth with catabolite repression 
TAE tris-acetate-EDTA buffer 
TDO tryptophan 2,3-dioxygenase 
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Chapter 1: Introduction 
 
 
1.1 The kynurenine pathway 
 
1.1.1 Overview of the kynurenine pathway 
The kynurenine pathway in mammals metabolises over 95% of dietary L-tryptophan, an 
essential amino acid. 
1
 This pathway has been implicated in numerous diseases including 
Huntington’s disease, Alzheimer’s disease, cancer, Parkinson’s disease, acute pancreatitis 
and schizophrenia resulting in considerable interest in identifying new therapeutic strategies 
targeting this pathway. 
1-4
 
L-Tryptophan is converted to N-formyl-L-kynurenine by either indoleamine 2,3-dioxygenase 
(IDO) or tryptophan 2,3-dioxygenase (TDO) in the rate-limiting step of the pathway (Figure 
1.1). This is then converted to L-kynurenine which can be metabolised by three different 
enzymes at the key branching point in the pathway. 
L-kynurenine is a substrate for kynureninase, kynurenine aminotransferase (KAT) and 
kynurenine 3-monooxygenase (KMO). KAT converts L-kynurenine to kynurenic acid which 
is one of the three main neuroactive metabolites of the kynurenine pathway. KMO converts 
kynurenine to 3-hydroxykynurenine, a neuroactive metabolite, which can then metabolised 
further to quinolinic acid which is also neuroactive and implicated in disease. The 
conversion of quinolinic acid to nicotinamide adenine dinucleotide (NAD) is the end of the 
pathway. 
The pathway is split into two separate and independent branches in the brain as different 
cells contain different pathway enzymes.  Kynurenine is metabolised to kynurenic acid in 
astrocytes and to 3-hydroxykynurenine and further metabolites in microglia. 
5,6
 Kynurenine 
is metabolised to quinolinic acid in macrophages which, when treated with interferon   
(IFN)-γ, release enough harmful kynurenine pathway metabolites to cause death to 
surrounding neuronal tissue. 
7
 This may affect kynurenine pathway metabolite levels in the 






Figure 1.1: The major steps in the kynurenine pathway. Abbreviations used are IDO, 
indoleamine 2,3-dioxygenase; TDO, tryptophan 2,3-dioxygenase; KAT, kynurenine 
aminotransferase; KMO, kynurenine 3-monooxygenase; 3-HAO, 3-hydroxyanthranilic acid 





1.1.2. Kynurenine pathway metabolites 
Kynurenic acid is an antagonist at glutamate receptors including the NMDA (N-methyl-D-
aspartate), AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and kainite 
receptors. 
1
 At the NMDA receptor it binds competitively at the glycine binding site and 
counteracts the action of quinolinic acid, an agonist at this receptor. 
1,8,9
 Kynurenic acid is 
recognised as a non-competitive inhibitor at the AMPA receptor although some researchers 
argue that in low (nanomolar to micromolar) concentrations kynurenic acid does not inhibit 
but instead acts as a “positive allosteric modulator”, an effect also reported at the NMDA 
receptors at nanomolar concentrations. 
10,11
  
Kynurenic acid also binds to the α7 nicotinic acetylcholine receptor at concentrations found 
in healthy cell conditions (reported as low nanomolar to micromolar levels). 
3,12,13
 These 
receptors are more sensitive to the non-competitive binding of kynurenic acid than the 
glutamate receptors, suggesting that these receptors are more important for understanding the 
effects of kynurenic acid. 
12
  
While increased levels of kynurenic acid have been considered beneficial in some diseases 
(for example in Huntington’s disease where it can counteract the harmful effects of other 
kynurenine pathway metabolites), increased levels of kynurenic acid have harmful effects. 
1
 
Kynurenic acid has been implicated in Alzheimer’s disease and schizophrenia through its 
inhibitory effect on glutamate and α7 nicotinic acetylcholine receptors, resulting in cognitive 
problems. 
2,14,15
 Kynurenic acid-related cognitive deficits have also been identified in patients 
post-surgery as imbalances in the immune system cause changes to kynurenine pathway 
metabolite levels with increased levels of tumour necrosis factor (TNF)-α causing increases 
in kynurenic acid levels. 
16
 
Kynurenic acid is also reported to be an agonist at the aryl hydrocarbon receptor. 
17,18
 This 
receptor was known for some time to bind toxins including 2,3,7,8-tetrachlorodibenzo-p-
dioxin but endogenous ligands have recently been discovered. 
17
 Activation of this receptor 
increases the production of interleukin-6 which has been linked to cancer and potentially to a 
positive feedback mechanism as interleukin-6 increases IDO levels. 
18
 Recent research into 
this receptor has shown that L-kynurenine is an agonist and is implicated in the mechanism 
of immune escape of cancer. 
19,20
  
Another receptor that kynurenic acid has recently been shown to bind to is G coupled-protein 
receptor (GPR) 35. 
21
 The concentrations of kynurenic acid required to observe this effect 
4 
 
were higher than found under normal physiological conditions (micromolar compared to 
nanomolar concentrations) but it is argued that levels of kynurenic acid are raised in some 
circumstances and tagging of proteins in research studies have affected the levels of affinity 
observed. 
17,21
 The effects of kynurenic acid binding to this receptor are not fully understood 
but are thought to potentially include an increase in calcium concentrations. 
21
 In addition to 
its action at receptors, kynurenic acid can also scavenge hydroxyl and superoxide radicals 




Quinolinic acid is a potent agonist at the NMDA glutamate receptor and through this action 
causes toxicity. 
22,23
 High levels of quinolinic acid cause cell death by necrotic processes 
thought to involve the generation of nitric oxide via induction of nitric oxide synthase. 
23,24
 
Quinolinic acid has also been shown to cause lipid peroxidation through complex formation 
with Fe(II). 
25,26
 Through its actions at the NMDA receptor, increased levels of quinolinic 
acid have been reported to indirectly cause increases in tau phosphorylation measured in 
neuronal tissue which could have implications for understanding Alzheimer’s disease. 
27
 
Other reported toxic effects of quinolinic acid include affecting the blood brain barrier, death 
of neurons and microglia, and mitochondrial dysfunction. 
23,28
 Therapeutic strategies to 
combat increased levels of quinolinic acid have focussed on KMO inhibition as this alters 
the balance of kynurenine metabolites to favour increased levels of kynurenic acid, which 
can counteract the effect of quinolinic acid. 
3,29
 
The toxicity of 3-hydroxykynurenine is thought to arise through an oxidation reaction 
producing significant quantities of superoxide radicals and hydrogen peroxide. 
30
 Cell death 
is observed in the presence of high levels of this metabolite that can be decreased by 
blocking apoptotic pathways. 
24
 It has also been found that 3-hydroxykynurenine toxicity 
arises from the direct action of H2O2 formed in the presence of Cu(II) ions that may damage 
DNA. 
31-33
 3-hydroxykynurenine is found in the lens of the eye and is thought to contribute 
to the formation of cataracts through cross-linking of crystallin proteins. 
30,32
 It was recently 
reported that 3-hydroxykynurenine is able to oxidise methionine residues of α-crystallin 
resulting in aggregation. 
34
 
In contrast to the detrimental effects outlined above, other researchers have suggested that   
3-hydroxykynurenine may have antioxidant properties and be a potent nitric oxide and 
hydroxyl radical scavenger. 
35,36
 To reconcile the different theories about                              
3-hydroxykynurenine, it has been suggested that many studies look at phenomena observed 
at concentration ranges not found in healthy cells and that at normal levels                                
5 
 
3-hydroxykynurenine may play a positive role as an antioxidant. 
30
 A recent study has 
investigated these two effects of 3-hydroxykynurenine using striatal tissue and has shown 
that it does not cause cell death even in high quantities, perhaps because the necessary 
enzymes to degrade kynurenine pathway metabolites are present in this tissue and therefore 
3-hydroxykynurenine should perhaps be considered as a redox modulator rather than as a 
cytotoxic molecule. 
37
 3-hydroxyanthranilic acid has also been reported to have similar toxic 
effects to 3-hydroxykynurenine including damaging proteins, generating hydrogen peroxide 
and the potentially beneficial scavenging of NO radicals. 
32,35
  
KMO knock-out mice have been used to investigate pathway regulation. In these animals the 
levels of kynurenic acid is increased significantly in the periphery but only by 20% in the 
brain. 
38
 In the brain the levels of anthranilic acid were increased resulting in only a moderate 
decrease of quinolinic acid in the brain that may have major implications for KMO inhibition 




1.1.3 Key kynurenine pathway enzymes 
TDO is mainly expressed in the liver and was first discovered in hepatic tissues from 
mammalian and avian species in the 1950s. 
39
 Although TDO and IDO catalyse the same 
reaction and are both heme-containing proteins they have less than 10% sequence identity. 
40
 
TDO is a homotetrameric enzyme and has higher substrate specificity than monomeric   
IDO. 
40
 Expression of TDO has recently been found in tumours and it has been shown in 
glioma that TDO is responsible for producing L-kynurenine which acts on aryl hydrocarbon 
receptors resulting in tumour immune escape. 
19,20
 A study in mice showed that inhibiting 
TDO decreased tumour progression and targeting this enzyme could be useful in 
chemotherapy. 
41
 Antitumour agents which are specific inhibitors for TDO rather than IDO 
have since been identified. 
42
 
IDO is also expressed in a number of tumours as a mechanism of immune escape. 
43
 It has 
been shown in a mouse model that IDO expression protects the tumour against immune 
responses and IDO inhibition results in decreased tumour progression. 
43
 The Bin1 gene 
(which controls transcription of the indo gene which expresses IDO) is suppressed in breast 
cancer thus causing an increase in the expression of IDO. 
44
 The use of IDO inhibitors in 
combination with other drugs has been found to be effective in a mouse model. 
44
 The 





Lipopolysaccharide, a component of bacterial cell membranes, activates the pathway 
independently of IFN-γ suggesting the relationship between the pathway and immune system 
is complex and may differ in different cell types. 
46,47
 A study into the effect of the immune 
system on downstream enzymes of the pathway in rats found that immune activation also 
induces expression of KMO. 
46
   
Kynureninase is a pyridoxal-5´-phosphate (PLP)-dependent enzyme that converts                
L-kynurenine and 3-hydroxykynurenine to anthranilic acid and 3-hydroxyanthranilic acid 
respectively. 
48
 The preferred substrate of the human enzyme is 3-hydroxykynurenine, unlike 
the bacterial enzyme from Pseudomonas fluorescens which preferentially metabolises         
L-kynurenine. Studies with substituted kynurenines have shown that human kynureninase 
prefers substrates with polar substituents at the 3´ position of L-kynurenine but the substrate 
specificity can be changed from a preference for 3-hydroxykynurenine to only accepting     
L-kynurenine by mutating three of the active site residues to be the same as those found in 
Pseudomonas fluorescens kynureninase. 
49,50
  
There are four different KAT enzymes that have been identified from mammalian tissue, all 
of which are PLP-dependent. 
51-53
 KAT I and KAT II are the most important of these 
enzymes in the brain but although they catalyse the same reaction, they have only 15% 
sequence identity. 
51,54
 KAT II is responsible for the majority of kynurenic acid formation in 
the brain in rats and humans and is localised in astrocytes, particularly in those found close 
to neurons. 
51,55
 The crystal structures of KATs I, II and III have been solved and reveal that 





1.2 KMO in disease 
 
Under normal physiological conditions the levels of kynurenine pathway metabolites in the 
brain are controlled by cytokines, growth factors and steroids but under inflammatory 
conditions, upregulation of enzymes including IDO and KMO significantly affect the levels 
of kynurenine pathway metabolites in the brain (Figure 1.2). These increased levels of         
3-hydroxykynurenine and quinolinic acid can result in toxic effects as discussed above in 




Figure 1.2: The kynurenine pathway in the mammalian brain under (a) normal physiological 
conditions and (b) when activated by the immune system. Under normal conditions the 
activity in the periphery of IDO, TDO and KMO is controlled by cytokines, growth factors 
and steroids. Tryptophan, kynurenine and 3-hydroxykynurenine can cross the blood brain 
barrier from the periphery. Astrocytes convert kynurenine to kynurenic acid and microglia 
convert tryptophan and kynurenine to 3-hydroxykynurenine and downstream metabolites, 
including quinolinic acid. Cytokines can induce both IDO and KMO in the periphery resulting 
in increased levels of kynurenine and 3-hydroxykynurenine which enter the brain resulting 
in a slight increase in kynurenic acid and a significant increase in quinolinic acid through the 
action of microglial cells that are activated by infiltrating macrophages which also have 
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upregulated KMO. Abbreviations used are IDO, indoleamine 2,3-dioxygenase; TDO, 
tryptophan dioxygenase; KMO, kynurenine 3-monooxygenase; 3-HK, 3-hydroxykynurenine; 
QUIN, quinolinic acid; and KYNA, kynurenic acid. Figure taken from Schwarcz et al. 1 
 
Imbalances in the kynurenine pathway and the relative levels of metabolites from this 
pathway have been implicated in a number of diseases including Huntington’s disease and 
Alzheimer’s disease. To counteract the harmful effects of increased levels of                        
3-hydroxykynurenine and quinolinic acid, there has been a focus on KMO inhibition as a 
potential strategy to treat these conditions. KMO is located at a key branching point of the 
kynurenine pathway and by inhibiting KMO, it is hoped both to decrease the levels of               
3-hydroxykynurenine and quinolinic acid and to increase levels of kynurenic acid as more  
L-kynurenine will be available for metabolism by kynurenine aminotransferase. Some of the 
diseases in which this strategy is thought likely to be beneficial are discussed in more detail 
below. 
 
1.2.1 Huntington’s disease 
Huntington’s disease is caused by an increased number of CAG repeats in the IT15 gene 
resulting in expression of mutant huntingtin protein with extended glutamine repeats at the 
N-terminus. 
59
 Disease occurs in individuals with more than 35 CAG repeats and the onset of 
disease correlates with the degree of repetition. 
59
  
Growing evidence over the last thirty years has implicated the kynurenine pathway as 
causing the neurodegenerative effects observed in patients (Figure 1.3). Increased levels of 
the potentially harmful metabolites 3-hydroxykynurenine and quinolinic acid have been 
detected in tissue from early stage patients, particularly in the striatum, and decreased 
kynurenic acid concentrations have also been detected. 
60,61
 Increased activity of                  
3-hydroxyanthranilate oxygenase has also been reported in brain tissue from deceased 
patients although in a mouse model this increase was not found to be statistically   
significant. 
62,63
 One study examined 3-hydroxykynurenine levels from post-mortem tissue 
samples and found increases in the frontal and temporal cortex and the putamen. 
64
 Other 
researchers have also found increased levels of 3-hydroxykynurenine and recorded increased 
levels (although to a lesser extent) of kynurenic acid in samples from early stage patients and 
from mouse models. 
65
 As well as changes to the balance of metabolites, decreased levels of 
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the free radical scavenger glutathione have been detected, suggesting a possible role for 
radical toxicity although most research has focussed on toxicity caused by quinolinic acid 




Figure 1.3: In Huntington’s disease, the presence of mutant huntingtin protein in microglia 
(green) is thought to causes increases in the levels of 3-hydoxykynurenine and quinolinic 
acid leading to an increase in reactive oxygen species in both microglia and neurons 
(orange) and over-activation of the NMDA receptors. Other pathological symptoms 
observed in Huntington’s disease including transcriptional dysregulation, mitochondrial 
impairment and changes to vesicle transport. 67 Abbreviations used are KYN, kynurenine; 
3HK, 3-hydroxykynurenine; QUIN, quinolinic acid, NMDA-R, N-methyl-D-aspartate receptor; 
ROS, reactive oxygen species. Figure taken from Giorgini et al. 67 
 
These findings establishing a link between kynurenine pathway metabolites and 
Huntington’s disease have been validated by genetic studies and animal models. In studies of 
different mouse models of disease, significantly increased levels of 3-hydroxykynurenine 
and quinolinic acid were detected shortly before neurodegenerative effects of disease were 
observed. 
68
 Another study on a mouse model found increased levels of                                 
3-hydroxykynurenine due to increased KMO expression but no significant increase in 
quinolinic acid. 
63
 Increased levels of 3-hydroxykynurenine and quinolinic acid have also 
10 
 
been observed in Drosophila models and the ratio of 3-hydroxykynurenine and quinolinic 
acid has been shown to affect neurodegeneration. 
69
 
Other work carried out in S. cerevisiae has shown a link between suppression of the yeast 
gene expressing KMO and decreased toxicity caused by mutant huntingtin protein. 
67
 In this 
study of 28 yeast gene deletions that suppress mutant huntingtin toxicity, the majority caused 
a decrease in the levels of 3-hydroxykynurenine and quinolinic acid, suggesting that the 
kynurenine pathway is strongly linked to neurodegeneration in this disease. 
70,71
 Further work 
suggests ribosome activity is affected by mutant huntingtin although it is thought that there 




The increase in 3-hydroxykynurenine and quinolinic acid and the decrease in neuroprotective 
kynurenic acid have led to KMO inhibition being considered as a therapeutic strategy in the 
treatment of Huntington’s disease. 
3,73
 This approach has been tested in different animal 
models including Drosophila where KMO inhibition has been shown to decrease 
neurodegeneration and increase the levels of kynurenic acid observed. 
69
 A further finding 
was that feeding 3-hydroxykynurenine to Drosophila reversed this effect, showing clearly 
the importance of the ratio between these two branches of the kynurenine pathway. 
69
 
Another study of KMO inhibition was carried out in mice models using a prodrug which 
increased the levels of kynurenic acid and increased the life span of the mice and decreased 
symptoms of neurodegeneration. 
29
 The prodrug is metabolised to form Ro 61-8048 (a KMO 
inhibitor discussed in Section 1.5.2) that inhibits KMO causing an increase in kynurenic acid 
that decreases the levels of glutamate and is an antagonist at NMDA receptors. 
29
 One of the 
interesting aspects of this study is that the prodrug and the KMO inhibitor are unable to cross 




1.2.2 Alzheimer’s disease 
Microglia and macrophages, capable of producing significant quantities of quinolinic acid, 
have been known to surround amyloid plaque, and studies from the hippocampus of 
Alzheimer’s disease patients show significantly increased levels of quinolinic acid (and an 
increase in IDO levels) in close proximity to plaque. 
75,76
 A decrease in the level of 
tryptophan in patients has also been recorded, and while this is partly due to aging it could be 
responsible for an increase in levels of kynurenine metabolites. 
77
 The increased levels of 
11 
 
quinolinic acid are proposed to increase tau phosphorylation which is implicated in 
neurodegeneration in Alzheimer’s disease. 
27
 These findings support the hypothesis that in 
Alzheimer’s disease there is oxidative stress leading to over-activation of glutamate 
receptors, perhaps exacerbated by quinolinic acid, resulting in damage to neurons. 
1,78
  
Significant increases in the levels of tumour necrosis factor-α (TNF-α) have been detected in 
serum samples from Alzheimer’s disease patients and this, along with IFN-γ, is known to 
induce IDO. 
45,79
 In a mouse model of Alzheimer’s disease it was found that when the IFN-γ 
receptor type 1 was suppressed there was decrease in gliosis and plaque formation and no 
induction of IFN-γ or TNF-α. 
80
 In comparison, the mice without the IFN-γ receptor 




Studies in animal models have been used to validate these findings. Rats that have had 
quinolinic acid infused into the brain performed more poorly than control animals in maze 
tests, and exhibited impaired short-term memory but no other behavioural changes. 
81
 A 
recent study tested a KMO inhibitor on mouse models of Alzheimer’s disease and 
Huntington’s disease (as mentioned in Section 1.2.1). 
29
 The inhibitor increased the levels of 
kynurenic acid (from approximately 25 nM in the plasma of untreated model mice to over 
150 nM in mice treated with the inhibitor where wild type mice had plasma concentrations of 
approximately 60 nM), prevented synaptic loss and improved spatial memory. 
29
 It is 
suggested that the beneficial effect of kynurenic acid is caused by both indirect effects at the 
glutamate receptors (due to levels of kynurenic acid being too low for direct effects) and by 




1.2.3 Ischaemic stroke 
Kynurenine pathway metabolites have also been implicated in brain damage following 
ischaemic stroke. One early study showed that in gerbils there is a delayed increase in 
quinolinic acid in some brain tissues after an ischaemic event which correlates with the 
degree of damage caused. 
82
 The levels of several kynurenine pathway enzymes were also 
found to be elevated, including IDO, KMO and 3-hydroxyanthranilate oxidase but not   
KAT. 
82
 An increase in KMO mRNA is detected after an increase of IDO mRNA but the 
levels of KAT mRNA are unaffected. 
46
 The levels of KAT are significantly higher than 





KMO inhibitors have been tested on animal models and tissues to determine whether shifting 
the balance of the kynurenine pathway towards kynurenic acid is beneficial. An in vivo study 
on gerbils and rats using Ro 61-8048 and m-nitrobenzoylalanine showed that KMO 
inhibition decreased damage and neuronal death. 
83
 These inhibitors were also used in an in 
vitro study of oxygen deprived tissue slices and were again found to prevent neuronal   
death. 
84
 The authors of this study were; however, unable to fully explain their results 
through the action of kynurenic acid. 
84
  
Further studies on human patients show that the levels of kynurenic acid are significantly 
increased in patients who die following a stroke. 
85
 The reasons for this increase are unclear 
but it is hypothesised that it is due to the overall activation of the kynurenine pathway. 
71,85
 In 
addition these samples showed a marked change in the ratio of 3-hydroxyanthranilic acid: 
anthranilic acid, and it has been suggested that the decrease in 3-hydroxyanthranilic acid is 
due to generation of reactive oxygen species by this metabolite. 
85
 This research may help 
fully explain some of the earlier findings with KMO inhibitors, as use of these compounds 
would decrease the levels of 3-hydroxyanthranilic acid which may be responsible for toxic 
effects as well as for increasing the levels of kynurenic acid. 
 
1.2.4 Schizophrenia 
Recent research has suggested that KMO expression is lower in patients with   
schizophrenia. 
86,87
 KMO expression and activity is also reduced in brain tissue samples 
taken from deceased patients with schizophrenia. 
87
 Some researchers have hypothesised that 
in this disease the kynurenine pathway produces greater quantities of kynurenic acid which 
leads to impairment of oculomotor response. 
87
  
There are reports of an increased occurrence of R452C KMO in patients which may cause 
the observed decrease in KMO activity and is proposed to interfere with the ability of KMO 
to interact with the outer mitochondrial membrane, although this has not been confirmed. 
86
 
Other researchers were unable to find any significant link between schizophrenia and 








1.2.5 KMO in other conditions 
Metabolites of the kynurenine pathway have also been implicated in the pathophysiology of 
acute pancreatitis, a condition in which there is inflammation of the liver, most commonly 
caused by gallstones or alcoholism. 
89,90
 In approximately 20% of cases, acute pancreatitis 
leads to multiple organ failure, which is fatal in 30-50% of these patients. 
91
 Increased levels 
of both kynurenine and 3-hydroxykynurenine have been found in mesenteric lymph tissue 
from patients and rat models of disease and it is hypothesised that 3-hydroxykynurenine 
causes some of the symptoms of acute pancreatitis through oxidative damage to cells. 
89
 
KMO inhibition is therefore seen as a potential therapeutic strategy to decrease mortality 
rates by decreasing the level of 3-hydroxykynurenine. 
Increased levels of kynurenine and significantly higher levels of 3-hydroxykynurenine and 
quinolinic acid have been identified in experimental chronic renal failure leading to the 
hypothesis that oxidative stress caused by kynurenine pathway metabolites is connected to 
renal disease. 
92
 Significant changes in kynurenine pathway metabolites were later observed 
in samples from patients with end stage renal disease and a correlation was shown between 
the levels of kynurenine, 3-hydroxykynurenine and quinolinic acid and those of von 
Willebrand factor and thrombodulin, known to be markers for endothelial dysfunction. 
93
  
Another use of KMO inhibitors is to increase the concentration of kynurenic acid 
antagonising α7 nicotinic acetylcholine receptors to counteract the effect of 
tetrahydrocannabinol. 
94
 A study on squirrel-monkeys and rats showed that the KMO 
inhibitor Ro 61-8048 resulted in a decrease in self-administration of cannabinoid compounds 
and the authors hope that this may have an application in prevention of drug use relapse. 
94
 
Ro 61-8048 has also been reported to decrease the severity of paroxysmal dyskinesia in mice 
models by inhibiting KMO and increasing kynurenic acid levels, resulting in potential 





1.3 Flavoprotein aromatic hydroxylases 
 
Flavoproteins that catalyse a monooxygenation reaction have been divided into six 
categories. KMO is characterised as Class A flavoprotein aromatic hydroxylase as it fulfils 
14 
 
the following criteria: it is transcribed from a single gene, it contains a flavin adenine 
dinucleotide (FAD) cofactor, it uses NADPH for flavin reduction and then releases NADP
+ 
and it contains a Rossmann fold. 
96,97
  
Class A Encoded by one gene 
FAD cofactor 





 after flavin reduction 
One dinucleotide binding domain 
Class B Encoded by one gene 
FAD cofactor 
Uses NADPH  
NADP
+
 released when reaction is completed 
Two dinucleotide binding domains  
Hydroxylation of atoms other than carbon possible 
Class C Encoded by more than one gene 
Reduced FMN cofactor 
Use NADPH and/or NADH 
Monooxygenase subunit has a TIM-barrel fold 
Example enzymes include bacterial luciferases  
Class D Monooxygenase and reductase components each encoded from 
one gene 
Reduced FAD cofactor 
Use NADPH and/or NADH 
Class E Monooxygenase and reductase components each encoded from 
one gene 
Reduced FAD cofactor 
Use NADPH and/or NADH 
Thought to have some structural similarities with Class A 
enzymes 
The known Class E enzyme is styrene monooxygenase 
Class F Monooxygenase and reductase components each encoded from 
one gene 
Reduced FAD cofactor 
Use NADPH and/or NADH 
One FAD binding domain and a helical domain 
Known Class F enzymes are halogenases 
Table 1.1: Overview of the general characteristics of the six classes of flavin-dependant 





1.3.1 Class A flavoprotein aromatic hydroxylases 
The typical reaction mechanism for this family of enzymes has the following steps: reduction 




 is released by the enzyme; the 
reduced flavin reacts with oxygen to form a peroxyflavin which is immediately protonated to 
form a hydroperoxyflavin which hydroxylates the substrate, typically an aromatic molecule 
with an amino or hydroxyl substituent. 
97,98
 In Class A enzymes the reaction with oxygen is 
thought to be carefully controlled, with a small cavity holding O2 close to the isoalloxazine 
moiety of the FAD cofactor to ensure formation of a peroxyflavin. 
99
 Conserved motifs have 
been identified in this family for binding NADPH and FAD. 
100
 Class A enzymes have been 
widely studied for their catalytic potential in regioselective oxidation of aromatic substrates 
using molecular oxygen. 
97,98,101
 
A number of Class A flavoprotein aromatic hydroxylase enzymes have been well 
characterised and KMO has been considered in the context of these enzymes especially as 
structural information about KMO has only recently been obtained. An overview of some of 
these enzymes is given below to explore some of the details of the mechanism and chemistry 
of these enzymes. 
 
1.3.2 p-Hydroxybenzoate hydroxylase 
One of the most extensively characterised enzymes related to KMO is p-hydroxybenzoate 
hydroxylase (PHBH, EC 1.14.13.2). Both the Pseudomonas fluorescens and Pseudomonas 
aeruginosa enzymes have been used in these studies as they are extremely similar, differing 
only in two surface residues. 
102
 The overall structure of the enzyme is shown below as well 




Figure 1.4: Structure of Pseudomonas fluorescens PHBH (left) and main interactions in the 
active site (right) between PHBH residues (green) and para-hydroxybenzoate (orange) with 
the isoalloxazine moiety of the FAD cofactor (yellow) also shown. Coordinates used are 
from PDB ID 1PBE. 103  
 
Residues in the active site important for substrate recognition and for conformational 
dynamics have been identified. Y222 forms a hydrogen bond to the carboxylate of               
p-hydroxybenzoate (PHB) important for conformational control. 
104
 Y201 forms a hydrogen 
bond to the hydroxyl group and is part of a hydrogen-bonding network stretching to the 
protein surface. 
105
 S221 forms a hydrogen bond to the carboxylate group of PHB but this 
interaction is not critical for catalysis. 
106
 R214 forms an ion-pair interaction with the 




A schematic of the mechanism of PHBH below (Figure 1.5) suggests the major 
intermediates formed indicating the conformation of the protein in each step. There are three 
conformations observed in PHBH and understanding control of conformational change is 




Figure 1.5: Overview of the mechanism of the hydroxylation of p-hydroxybenzoate to     
3,4-dihydroxybenzoate catalysed by PHBH. The isoalloxazine moiety of the FAD cofactor is 
shown, with the rest of the cofactor represented by R. The open (red), in (black) and out 
(blue) conformations observed at each stage are indicated in the mechanism.  
 
The substrate binds to the enzyme in the open conformation when the active site is solvent   
accessible. 
108
 This conformation was first observed in R220Q PHBH and the crystal 
structure showed that the substrate-binding β-sheets rotate away from the FAD-binding 
domain (Figure 1.6). 
109
 The conversion to the open conformation is thought to be driven by 
relieving of conformational strain around R44 and neighbouring residues that are part of a 
conserved loop close to the active site. 
110
 Another mutation, A45V, causes stabilisation of 
the open conformation and work on both mutated enzymes has shown that they have lower 
affinities for the substrate but binding occurs more rapidly. 
111
 The crystal structure of 
R220Q variant PHBH showed that the residue R214 (shown in Figure 1.4) is rotated out of 





and A45V PHBH are inactive due to their inability to change conformation rapidly which is 





Figure 1.6: Overlay comparing in (green) with open (blue) conformation. The open 
conformation has the β-sheets positioned further from the FAD binding domain. The in 
structure is Pseudomonas fluorescens wild-type PHBH and the out is Pseudomonas 
aeruginosa R220Q PHBH constructed from PDB IDs 1PBE 103 and 1K0I 109 respectively. 
 
Once PHB is in the active site the conformation changes to in, a solvent-inaccessible active 
site environment. In this conformation all the possible interactions between the substrate and 
enzyme have formed. 
112
 For catalysis to proceed, the FAD must be reduced by NADPH 
which requires a solvent accessible environment for the isoalloxazine ring. 
111
 In the change 
to the out conformation (Figure 1.7) the isoalloxazine ring of the FAD cofactor moves 7 to   







Figure 1.7: Overlay showing the active site in the in and out conformations. The in 
conformation (green) is the wild-type Pseudomonas fluorescens enzyme with PHB bound 
from PDB 1PBE, 103 the out conformation (purple) is wild-type Pseudomonas aeruginosa 
PHBH with 2,4-dihydroxybenzoic acid from PDB 1DOD. 104 
 
PHB is deprotonated by a proton-transfer network extending from H72 at the protein surface 
to the active site (Y201). 
114,115
 This network appears to be unique for PHBH among the 
Class A FAH enzymes. 
116
 The deprotonated substrate repels the carbonyl of P293 which is a 
rigid residue in a loop near the active site. 
102
 This repulsion of a rigid residue in the loop 
causes a global conformational change to the out conformation.
102
 The requirement for a 
substrate to be deprotonated increases the specificity of the catalytic cycle and has been 
described as “substrate recognition by password” and loss of the hydrogen-bonding network 
significantly decreases the rate of hydroxylation. 
105,117
 This tight control is thought to be 
necessary for PHBH to avoid hydroxylating a similar metabolite, 4-aminobenzoate, which 
has been observed in the active site by crystallography. 
108,118
 The mutation P293S increased 
flexibility which reduces the ability of PHB to repel this residue and uncoupled the 
conformational change, thus significantly slowing the reduction of the FAD cofactor. 
102
 In 




Once in the out conformation, FAD is reduced by NADPH. 
113
 The enzyme then returns to 




 The reduced FAD cofactor reacts 
20 
 
with a molecule of oxygen to form a peroxyflavin which must occur in a solvent inaccessible 
environment to prevent the loss of H2O2. 
113
 PHB is deprotonated by the peroxyflavin to form 
a more electrophilic hydroperoxyflavin and also results in a more nucleophilic substrate. 
112
 
The deprotonated substrate is hydroxylated and re-aromatises to form the product,            
3,4-dihydroxybenzoate. These steps of the catalytic cycle are stabilised by the positive 
environment of the active site and rate of hydroxylation can be modified by changing the 
electrostatic environment. 
119
 Mutations made to PHBH which increase its positive charge 
increase the rate of hydroxylation, and those that decrease the positive environment decrease 
the rate. 
119,120
 The product, 3,4-dihydroxybenzoate, is released upon conversion to the open 
conformation and the catalytic cycle is complete.  
 
1.3.3 Phenol hydroxylase 
Phenol hydroxylase differs from PHBH as it is a far larger protein and has lower substrate 
specificity. Phenol hydroxylase converts phenol to catechol but also accepts substituted 
phenols as substrates. 
121
 While there are similarities in the active site residues between this 
enzyme and PHBH, there is no evidence from kinetic studies to suggest that they play the 




The enzyme from Trichosporon cutaneum has been crystallised and the crystal structure 
showed two separate conformations of the enzyme (Figure 1.8). 
123
 There is a major 
conformational change that is associated with the movement of the FAD cofactor from an in 
to an out conformation, the largest difference in residue position is reported as 30 Å. 
124
 The 
region of the protein involved in this change is described as a “lid” and is thought to control 









Figure 1.8: The structure of the in conformation of phenol hydroxylase (left) coloured from 
N-terminus (blue) to C-terminus (orange) with FAD cofactor and phenol hydroxylase (red). 
On the right is an overlay of the in (blue) and out (green with FAD cofactor in yellow) 
conformations, showing the phenol substrate and residues 170 – 216, the region of phenol 
hydroxylase where there is significant conformational change when the FAD cofactor 
moves between the in and out conformations. Images generated from PDB 1PN0. 123 
 
1.3.4 MHPCO 
2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase (MHPCO) is a tetrameric Class A 
flavoprotein aromatic hydroxylase containing one FAD cofactor per monomer. 
125
 The 
reaction catalysed by this enzyme is unusual for this family as, after the substrate is 




The structure of the Mesorhizobium loti enzyme has been obtained and shows that the active 
site is large (15 by 12 by 10 Å) and interactions between residues and the substrate are 
mediated through water molecules. 
127
 The substrate gains access to the active site through a 






Figure 1.9: A view of the active site of MHPCO showing most of the active site residues 
(left) and the tunnel leading from the protein surface to the active site (right) with the 
substrate in magenta and FAD cofactor in yellow. Two tyrosine residues interact with the 
substrate through water-mediated hydrogen bonding interactions (distances indicated in 
the figure in Å) in the active site. The interaction between Asp201 and Arg211 is thought to 
prevent Arg211 interacting with the substrate due to its orientation in the active site. Figure 
constructed using PDB 3GMC. 127 
 
In contrast to PHBH, no evidence from structural studies or using substituted FAD cofactor 
analogues has been found to support the idea of a “wavin flavin” in this enzyme as the FAD 
cofactor is observed in the in conformation only. 
127,128
 The hydroxylation reaction is thought 
to proceed by the same mechanism common to Class A flavoprotein aromatic hydroxylases 
but the mechanism of the ring-opening reaction has been debated in the literature. 
129
 It is 
currently thought that that the mechanism involves a Baeyer-Villiger rearrangement before 





1.3.5 Other enzymes in this family 
Other enzymes in this class which have been structurally characterised have shown similar 
properties of flavin movement, control of substrate access to the active site, and overall 
23 
 
structural folds to the proteins described above although the high level of catalytic control 
achieved with three conformations and a hydrogen transfer network appears to be unique to 
PHBH. A summary of the features of some of these characterised Class A enzymes is given 




Crystallised with flavin in the out conformation, modelling 




Route for substrate access to the active site unconfirmed. 
131
 




RebC Accepts a highly reactive substrate as part of an eight-electron 
oxidation reaction in the biosynthesis of rebeccamycin. 
132,133
 
Active site is accessed via a disordered region which folds into 
a helix once the substrate is bound. 
132
 










Substrate (unconfirmed identity) enters the active site through a 
tunnel from the surface of the protein. 
134
 
C-terminal domain is disordered in the substrate-unbound 






Substrate enters the active site through a tunnel which is 






Binds a lipid molecule with the hydrophilic end on the protein 
surface and the hydrophobic end in the active site which in the 
crystal structure appears to be involved in substrate binding. 
136
 
Table 1.2: Summary of observed conformational changes and features of substrate access 





1.4 Kynurenine 3-monooxygenase 
 
1.4.1 Efforts to isolate and characterise KMO  
Despite extensive characterisation of other Class A flavoprotein aromatic hydroxylases, 
KMO has not been well-characterised even though it has been implicated in disease. Like 
other enzymes in this family, KMO hydroxylates the substrate in a redox reaction requiring a 




Figure 1.10: The hydroxylation of L-kynurenine catalysed by KMO 
 
One of the major challenges in obtaining active mammalian KMO enzyme is overcoming 
solubility problems. Work with mammalian KMO enzymes has mostly been carried out with 
recombinant enzymes expressed in cell lines. Active human KMO has been expressed in 
HEK (human embryonic kidney)-293 cells and later in COS-1 cells where it was confirmed 
that the human enzyme contains one non-covalently bound FAD cofactor per enzyme 
monomer. 
138,139
 The pig KMO enzyme has been expressed in COS-7 cells where it was 
shown that the C-terminal domain was essential for activity and that residues in the last 
twenty amino acids of this domain are necessary for localisation of the enzyme in the outer 
mitochondrial membrane which is thought to cause the insolubility of KMO. 
140
 
Significant amounts of recombinant protein for in vitro work have been obtained using 
recombinant Pseudomonas fluorescens KMO (PfKMO), which has 36% sequence identity 
with human KMO. 
96
 This construct (a kind gift from Graham Moran, University of 
Minnesota) was also used for the work described here on PfKMO, using a similar 
purification method (Section 2.4). PfKMO was successfully purified in sufficient levels to 
allow stopped-flow kinetic experiments to be carried out, demonstrating that the enzyme 
mechanism is broadly similar to that of related flavoprotein aromatic hydroxylase enzymes 
25 
 
such as PHBH. 
137
 The efficacy of a number of KMO effector molecules was also tested 
against this enzyme as discussed in Section 1.5. 
In the last year, an attempt to purify human KMO was published although the full-length 
protein was insoluble and efforts to remove it from the insoluble fraction during purification 
were unsuccessful. 
141
 A truncated protein was prepared which, although soluble, lacked 
activity supporting previous work showing that the C-terminus is necessary for activity. A 
FLAG-tagged fusion protein was prepared and partially purified by the same group and has 
been shown to be active. 
141
 
Another KMO enzyme to be successfully purified is from Saccharomyces cerevisiae which 
was expressed in E. coli and from which the first published KMO structure was obtained. 
142
 
The crystal structure of S. cerevisiae KMO was of a truncate (truncated at residue 394) 
without the C-terminal domain that nevertheless was reported to retain activity, in contrast to 




1.4.2 KMO mechanism and properties 
The proposed reaction mechanism for KMO was developed after studying PfKMO with pre-
steady-state kinetic techniques. The mechanism (Figure 1.11) is consistent with those of 
previously characterised Class A flavoprotein aromatic hydroxylases such as PHBH.  
In the reductive half-reaction, L-kynurenine and NADPH bind to PfKMO and the FAD 
cofactor is reduced by NADPH which then dissociates from the enzyme as NADP
+
. The 
dissociation constant for the KMO·L-kynurenine complex was measured and determination 
of the reduction potential of the FAD cofactor both in the presence and absence of               
L-kynurenine showed that the reduction potential was unaffected by substrate binding. The 
dissociation constant for the KMO·NADPH complex was shown to be unaffected by the 
presence or absence of L-kynurenine but the rate of reduction of PfKMO by NADPH was 
increased in the presence of L-kynurenine by a factor of 2500. This suggests that while        
L-kynurenine does not affect the ability of NADPH to bind to PfKMO, it has to be present 




The evidence from stopped flow kinetic experiments studying absorbance changes on mixing 
the anaerobic reduced PfKMO·L-kynurenine complex with oxygen suggests that the reduced 
26 
 
flavin reacts with a molecule of oxygen, resulting in its one-electron reduction to superoxide;  
the two radical species rapidly react to form a peroxyflavin which is protonated to form a 
hydroperoxyflavin. The hydroperoxyflavin can then hydroxylate the substrate resulting in 
hydroxyflavin that re-forms the oxidised flavin independent of product release. The release 
of 3-hydroxykynurenine is the rate-limiting step of the mechanism and causes a change in 
the spectrum of the oxidised enzyme and it was hypothesised that the release of                   




Figure 1.11: Overview of the proposed mechanism of KMO, figure adapted from work by 
Crozier-Reabe et al. 137 
  
These kinetic investigations also studied the effects of 3,4-dichlorobenzoylalanine and       
m-nitrobenzoylalanine, molecules that are structurally similar to L-kynurenine. It was found 
that these molecules are able to bind to PfKMO and increase the rate of flavin reduction, 
although not to the same extent as L-kynurenine, but are not hydroxylated. 
137
 This suggests 
that the activating substituent on the aromatic ring (in this case NH2) required by most 
flavoprotein aromatic hydroxylases is necessary for hydroxylation to proceed but is not vital 
to the recognition of substrate that controls FAD reduction. 
27 
 
In earlier work on PfKMO, enzyme activity was observed to decrease with time in the 
absence of a reductant. Using a DNTB assay with Ellman’s Reagent (5,5´-dithio-bis-[2-
nitrobenzoic acid]) it was shown that this was related to the number of free thiols suggesting 
that in the absence of a reducing agent, cysteine residues in different monomers form 
disulfide bonds leading to aggregation and loss of activity. 
96
 PfKMO has four cysteine 
residues and to stabilise the enzyme and successfully obtain crystal structures, two of these 
were mutated to serine residues. The C252S C461S PfKMO (PfKMO*) had similar kinetic 




 KM (μM) kcat (s
-1) kcat/KM (s
-1μM-1) 
PfKMO 14.5 ± 2.5 9.1 ± 1.6 0.63 
C252S C461S PfKMO (PfKMO*) 8.8 ± 1.5 8.9 ± 1.1 1.01 
Table 1.3: Kinetic parameters of wild-type PfKMO and PfKMO* which contains two cysteine 
to serine mutations. Both enzymes have similar values of KM and kcat which were 
determined using a kinetic assay that monitored NADPH consumption. 143 
 
1.4.3 Structure of PfKMO* with L-kynurenine  
Until recently there was no structural information about KMO which has made attempts to 
design potent inhibitors challenging. In 2013 the first structure of KMO was published in 
Nature of a truncated S. cerevisiae enzyme (PDB entries include 4J36 and 4J33). 
142
 In 
addition to this structure, there is significant work on PfKMO including solved structures 
with no ligand in the active site, with L-kynurenine bound and with inhibitors bound. 
143
 
Crystals of PfKMO with L-kynurenine bound in the active site were successfully grown after 
two mutations, C252S and C461S, had been introduced in the enzyme (PfKMO*). The 
structure had a high solvent content of approximately 84% and diffracted poorly resulting in 
a resolution of 3.4 Å for this structure. 
143,144
 
The main domain contains the Rossmann fold common to all Class A flavoprotein aromatic 
hydroxylases. 
97
 This domain non-covalently binds the FAD cofactor and also contains the 
active site of the enzyme. In the active site, the substrate and the isoalloxazine moiety of the 




Figure 1.12: Structure of PfKMO* with FAD cofactor (yellow) and L-kynurenine (cyan) bound 
in the active site. The main domain of the protein is shown in green and the C-terminal 
domain in blue. The two cysteines mutated to serines (S252 and S461) are labelled as are 
the two remaining cysteine residues (C168 and C326). 
 
The active site contains a number of residues that are thought to be important in substrate 
binding and recognition. Close to the carboxylate group of the substrate there are a number 
of hydrophilic residues including R84, Y98, N369 and Y404 (Figure 1.13). Also present 
closer to the aromatic ring of the substrate are hydrophobic residues including L213, I224, 
L226, F238 and M373. An understanding of the key interactions between the substrate and 
the protein, based both on structural information and also kinetic data, will be necessary to 
validate this structure and also to understand substrate binding and to apply this knowledge 
to the design of effective inhibitors. The key interactions between PfKMO* and                   
L-kynurenine appear from this structure to include potential interactions between the 





Figure 1.13: View of some of the active site residues of PfKMO* with L-kynurenine (L-kyn, 
cyan) and the FAD cofactor (yellow) with approximate distances indicated are in Å. The 
carboxylate moiety of L-kynurenine is hypothesised to interact with R84, Y98, N369 and 
potentially Y404 although this residue appears to be over 4 Å from the substrate. The 
carbonyl of H320 is 3.1 Å from the amine of L-kynurenine. There is also a possible 
interaction between N369 and the carbonyl of F319. 
 
1.4.4 Structure of PfKMO* in the absence of substrate 
A crystallographic model of the structure of PfKMO* was also obtained in the absence of 
substrate in the space group P21221 and at a higher resolution of 2.26 Å. 
143
 This structure 
also consisted of two domains with the main domain containing the Rossmann fold, the 
active site and the non-covalently bound FAD cofactor and a C-terminal domain (Figure 
1.14). The main domain of both PfKMO* structures is similar in both the presence and 
absence of substrate but there is a significant conformational change in the position of the  
C-terminal domain.  
This significant movement of the C-terminal domain is thought to play an important role in 
substrate binding. 
143
 The substrate free form of PfKMO* is an open conformation 
hypothesised to allow rapid substrate binding and product release. The C-terminal domain 
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moves in the event of substrate binding in the active site resulting in the closed conformation 
observed in the L-kynurenine bound structure. 
 
 
Figure 1.14: On the left is PfKMO* with FAD (yellow) bound in the main domain (green) and 
the C-terminal domain (blue) in the absence of substrate, on the right is a comparison of 
the L-kynurenine bound (green) and substrate free (purple) structures. 
 
The residues that are thought to control this movement of the C-terminal domain (Figure 
1.15) are R84, E372, Y382 and R386. Three of these residues have been investigated in 
previous work using site-directed mutagenesis, crystallography and steady-state kinetics to 










Figure 1.15: Proposed network of interactions resulting in the closed conformation, where 
the C-terminal domain is in closer proximity to the active site with distances indicated in Å. 
The residues thought to be involved in this interaction are Arg84, Glu372 and the                 
C-terminal domain residues Tyr382 and Arg386. The distance between the site of 
hydroxylation in L-kynurenine (L-kyn) and the FAD cofactor is also indicated. 
 
The mutations E372T, R386K, R386T and Y382F were made in PfKMO* and the resulting 
proteins were successfully crystallised. The disruption of this network of interactions at any 
of these three residues resulted in a mixed conformation in the L-kynurenine bound structure 
and no conformational changes in the structures in the absence of substrate relative to that 
obtained for PfKMO*. 
143
 
 In the structure of Y382F with L-kynurenine bound, the C-terminal domain was moved 
further from the main domain resulting in a more open conformation although the extent of 
this movement is not as great as is observed in the substrate free structure of PfKMO* 
(Figure 1.16). The C-terminal domain residues F382 and R386 are orientated towards the 
active site in the Y382F PfKMO* structure although the distances between these residues 
and E372 are too large to maintain the network of interactions responsible for the closed 
conformation. The interactions between L-kynurenine, R84 and E372 are maintained in 
Y382F PfKMO* and the positions of these residues are closer to those in the PfKMO* with 






Figure 1.16: The positions of the substrate and residues implicated in the movement from 
the open to closed conformation in the structures of PfKMO* with L-kynurenine bound 
(green), Y382F PfKMO* with L-kynurenine bound (purple) and PfKMO* in the absence of 
substrate (cyan). In the structures of Y382F PfKMO* and PfKMO* with L-kynurenine bound, 
the positions of L-kynurenine, R84 and E372 are similar but the mutation Y382F results in a 
loss of the interactions between this residue and both E372 and R386. The movement of 
F382 and R386 in this structure, compared to PfKMO* with L-kynurenine bound and in the 
absence of substrate shows that Y382 PfKMO* is in neither the open nor the closed 
conformation. The loss of interactions between these residues appears to prevent the 
closed conformation occurring, but in the presence of L-kynurenine, the interactions 




1.4.5 S. cerevisiae KMO 
S. cerevisiae KMO has been expressed in E. coli and purification resulted in the isolation of 
truncated KMO thought to be due to proteolysis at residue 396. 
142
 This KMO was shown in 
an HPLC-based assay to convert L-kynurenine to 3-hydroxykynurenine even though it has 
no C-terminal domain, in contrast to previous work on truncated pig KMO. 
140,142
 
Both the proteolysed form of S. cerevisiae KMO and an engineered truncate (truncated at 
residue 394) have been crystallised and the solved structures were the first published 
structures of a KMO enzyme. The structure of S. cerevisiae KMO truncated at residue 394 
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with no ligand bound in the active site (Figure 1.17) has been solved as a putative dimer with 
a resolution of 1.82 Å (PDB 4J33) and is the highest resolution KMO structure published to 
date. S. cerevisiae KMO has been co-crystallised with UPF 648 (Figure 1.19) in the active 




Figure 1.17: The structure of S. cerevisiae KMO (PDB 4J33) in the absence of ligand from    
N-terminus (dark blue) to Lys390 (orange), the last residue present in the structure. In the 
presence of UPF 648, residues Arg359 to Lys390 are disordered and their position could not 
be determined in PDB 4J36. On the right the secondary structures of S. cerevisiae KMO with 
no ligand (lilac) with FAD cofactor (purple) is compared with S. cerevisiae KMO with UPF 
648 bound (green) with FAD cofactor (yellow) and UPF 648 (orange) from PDB 4J33 and 
4J36 respectively. 142 In the presence of UPF 648 there is a conformational change resulting 
in a change of position of residues 322 – 325, Arg83 and Phe246.  
 
When UPF 648 is bound in the active site of S. cerevisiae KMO, there is a conformational 
change with active site residues 322 – 325 forming a helix rather than a loop. In the absence 
of ligand, Y323 occupies space in the active site and the position of F322 causes 
displacement of F246, which is in a different orientation when UPF 648 is bound. The 
position of R83 is different in the two structures, probably due to a possible interaction with 
the carboxylate of UPF 648. This is similar to R84 from PfKMO* suggesting that perhaps 
this residue might play a similar role in ligand binding and conformational control. 
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In the active site R83 and Y97 interact with the carboxylate group of UPF 648, the aromatic 
ring of UPF 648 is surrounded by hydrophobic residues and the carbonyl of P231 located 
about 3.2 Å from the aromatic ring of UPF 648. 
142
 An alignment of KMO sequences shows 
that many of these active site residues are conserved across different species including 
residues A53, R83, Y97, I104, M230, I232, L234, P321 and F322. Y323 is not conserved, 
and in PfKMO the equivalent residue is H320. In the absence of any structural data for the 
C-terminal domain it is not possible to determine whether there are equivalents to the 
interactions observed between L-kynurenine and N369 and Y404 in PfKMO* or whether 
there is a similar movement of the C-terminal domain occurring when ligands bind in the 
active site and how it is controlled in S. cerevisiae KMO. 
 
 
1.5 KMO inhibitors 
 
1.5.1 KMO inhibition by substrate analogues 
Interest in developing KMO inhibitors for clinical use has been hindered by the lack of 
structural information. Assays for finding inhibitors have developed from measuring tritiated 
water released after hydroxylation to high-throughput assays combining liquid 
chromatography techniques with mass spectrometry using mitochondrial membrane fractions 
of human KMO which can rapidly identify potential lead compounds. 
145,146
 
In the absence of structural information early inhibitors of KMO were based on analogues of 
L-kynurenine (Figure 1.18). Early work showed that nicotinylalanine was a weak non-
specific inhibitor of both KMO and kynureninase and was capable of causing an in vivo 






Figure 1.18: Chemical structures of L-kynurenine and KMO inhibitors developed from 
structural analogues. 
 
The first inhibitor specific for KMO was m-nitrobenzoylalanine which increased levels of 
kynurenic acid and had anticonvulsant properties in rats. 
148-150
 Reports of an enantiopure 
sample were published soon after showing that the S-enantiomer was the active    
component. 
151
 This competitive inhibitor was used in a few studies of disease, particularly 
ischaemia, but more potent inhibitors have since been discovered. 
83,84
  
(R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) has an increased affinity for KMO and 
causes a longer-lasting increase in kynurenic acid levels in rat brain tissue. 
152
           
Structure-activity relationship analysis of 3,4-dichlorobenzoylalanine has shown that        
3,4-dichloro substitution of the aromatic ring results in the most potent inhibitors, although 
3,4-difluoro and 3-chloro derivatives are also potent. 
153
 Removing the carboxylic acid group 
results in an inactive molecule but the amine group is not necessary and substituting the 
amine with a (S)-hydroxyl or (S)-benzyl group can decrease the IC50 value observed in an 
assay using rat KMO from mitochondrial extracts. 
153
  
Incorporation of a double bond resulted in further derivatives that maintained an inhibitory 
effect and similar compounds were further investigated in a later study on 4-aryl-2-hydroxy-
4-oxobut-2-enoic acids and esters. 
154
 The effect of the substitution pattern on the aromatic 
ring was investigated with these compounds and again it was observed that 3,4-difluoro or 
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3,4-dichloro compounds were the most potent and that 2-substituted compounds were not 
good inhibitors. The ester derivatives were active but were always slightly less potent than 
the acid derivatives. This study also demonstrated that some derivatives were able to 
decrease quinolinic acid formation in human macrophage tissue cultures. 
154
   
While these inhibitors were among the first molecules found to inhibit KMO it was also later 
found that they act as not as inhibitors but as effector molecules. It has been shown that    
3,4-dichlorobenzoylalanine and m-nitrobenzoylalanine bind in the active site of KMO and 
stimulate NADPH reduction resulting in the formation of the unstable hydroperoxyflavin 





1.5.2 Development of potent KMO inhibitors 
A significant breakthrough in the development of potent KMO inhibitors was the 
development of N-(4-phenylthiazol-2-yl)benzenesulfonamide derivatives developed from the 
substrate analogue m-nitrobenzoylalanine by researchers at Hoffman-La Roche. In this series 
of inhibitors the carboxylic acid moiety was replaced by sulfonamides to improve the ability 
of the compound to pass through the blood brain barrier as well as to improve potency. 
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Some inhibitors in this series were found to be significantly more potent than either            
m-nitrobenzoylalanine or 3,4-dichlorobenzoylalanine (FCE 28833) particularly the patented 
Ro 61-8048 (Figure 1.19) that has been used extensively in research with animal models of 
disease (Section 1.2). In developing Ro 61-8048, it was found that for potent inhibition, the 
best substitution on the aromatic ring near the sulfonamide was 3,4-diOMe and that the 
inclusion of 4-
i
Pr, a large hydrophobic substituent, lead to significantly reduced inhibition. 
While this was thought to be due to combination of factors including substituent size, in 
view of our work with novel inhibitors, the loss of potency is probably due to the 
hydrophobic nature of the substituent as large substituents are tolerated by PfKMO*. In this 
series, 3-NO2 substitution resulted in more potent compounds than the 3,4-dichloro 
substitution unlike the research summarised above on substrate analogue derivatives; 






Figure 1.19: Chemical structures of further KMO inhibitors.  
 
Other KMO inhibitors include UPF 648 which has been used to study the kynurenine 
pathway in the rat brain, inhibit KMO in a model of Huntington’s disease, and was 
crystallised in the active site of S. cerevisiae KMO. 
5,69,142
 UPF 648 is also an effector rather 
than a true inhibitor and increases the production of H2O2 by a factor of 20. 
142
 A recent 
publication reported the discovery of Ianthellamide A, a naturally occurring KMO inhibitor 
isolated from the sponge Ianthella quadrangulata. 
156
  
The development of Ro 61-8048 and UPF 648 resulted in more potent KMO inhibitors being 
available for studying the kynurenine pathway in animal models of disease; however, it was 
still necessary to design inhibitors that would not stimulate FAD reduction by NADPH. A 
new scaffold was designed and tested in vitro in collaboration with Gavin Milne, a PhD 
student supervised by Nigel Botting and David O’Hagan at St Andrews University. A series 
of molecules were synthesised by G. Milne and optimisation has resulted in the development 
of extremely promising inhibitor molecules which do not cause H2O2 production. Study of 
most of the early molecules in this series was carried out by other members of the Mowat 
research group but kinetic and crystallographic data for the latest series of potent compounds 
is contained in Chapter 3. 
The inhibitors designed on the GM compound scaffold are significantly larger than              
L-kynurenine and while the 3,4-dichloro substituted ring binds in the same position as the 





 This causes changes in the position of active site residue sidechains to 
accommodate the inhibitor and the interactions responsible for connecting the two domains 
in the closed conformation are disrupted. In the structure of PfKMO* with inhibitors bound, 
the main domain is similar to the L-kynurenine bound structure but the C-terminal domain 
has moved to the same position occupied in the open conformation observed in the PfKMO* 




Figure 1.20: Representation of the secondary structure elements of the protein chain in the 
structure of PfKMO* with inhibitor GM303 (magenta), PfKMO* with L-kynurenine (green) 
and PfKMO* in the absence of substrate (cyan). 
 
The inability of PfKMO* to form the closed conformation when the inhibitors are bound is 
the proposed reason for these compounds not acting as effector molecules. In the presence of 
these inhibitors and in the absence of L-kynurenine, no consumption of NADPH can be 
detected suggesting that the FAD cofactor is not being reduced and therefore cannot form a 
hydroperoxyflavin. These compounds represent a very interesting and potentially clinically 




1.5.3 Characterisation of enzyme inhibition 
The Michaelis-Menten equation is used to describe enzyme reactions where the enzyme and 
substrate reversibly interact to form an enzyme-substrate complex that can then irreversibly 
react resulting in free enzyme and product (Equation 1.1). 
157
 By graphically plotting the 
observed rate of reaction against substrate concentration, this equation is used to determine 
the values of Vmax and the Michaelis-Menten constant which indicates the affinity of the 
enzyme for the substrate. 
𝑣 =  
𝑉𝑚𝑎𝑥 [𝑆]
𝐾𝑀+[𝑆]
+ 𝑆  E + S ⇌ ES → E + P 
Equation 1.1: The Michaelis-Menten equation and a general formula for the reaction 
described where ν is reaction rate, Vmax is the maximum rate, [S] is substrate concentration, 
KM is the Michaelis-Menten equation, E is the enzyme, S is the substrate and P is the 
product. 
 
Inhibitors can interact with the enzyme or enzyme-substrate complex to inhibit the reaction 
in different ways that affect the values of KM and Vmax as summarised below:   
 Competitive inhibitors reversibly compete with the substrate for binding to the 
enzyme, usually in the active site, resulting in an unchanged Vmax and an increased 
KM 
 Non-competitive inhibitors bind to an allosteric site decreasing the catalytic activity 
of the enzyme but not its affinity for the substrate resulting in an unchanged KM and 
a decreased Vmax 
 Mixed inhibitors can bind both to the enzyme and the enzyme-substrate complex and 
decrease the catalytic activity of the enzyme and the affinity of the enzyme for the 
substrate resulting in a decreased Vmax and increased KM 
 Uncompetitive inhibitors bind to the enzyme-substrate complex and increase the 
affinity of the enzyme for the substrate and decrease the catalytic activity of the 
enzyme resulting in a decreased KM and Vmax 
The in vitro effect of an inhibitor on an enzyme can be investigated by determining the rate 
of reaction at various substrate concentrations at a series of inhibitor concentrations. The 
Dixon plot can be used to determine the value of Ki by plotting the reciprocal of reaction rate 
against the inhibitor concentration. 
158
 A disadvantage of this method is that it does not 
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always clearly show the difference between competitive and mixed inhibition so it is often 
complemented by a graph of substrate concentration divided by reaction rate plotted against 
inhibitor concentration. 
159
 This combination allows the determination of both Ki and the 
type of inhibition observed (Figure 1.21). The Dixon plot is also known to be less reliable 




Figure 1.21: Dixon plots (left) and s/v against i (right) for each type of enzyme inhibition 
where s is substrate concentration, v is reaction rate and i is inhibitor concentration. Taken 





1.6 Protein crystallisation 
 
1.6.1 Protein crystals  
Protein crystals have long-range order as they consist of identical repeating units called unit 
cells. Unit cells can contain multiple protein molecules which are related to each other by 
symmetry elements that can include translational, rotational and screw axes. The space group 
assigned to a crystal denotes the symmetry elements that relate the molecules in the unit cell 
as well as the relative dimensions and angles of the unit cell. 
A common method to crystallise proteins is vapour diffusion in which a drop containing the 
protein and well solution is either suspended above a well solution on a glass coverslip 
(hanging drop vapour diffusion) or placed on a bridge surrounded by the well solution 
(sitting drop vapour diffusion) in a sealed environment. Vapour diffusion results in water 
from the drop transferring to the well solution over time increasing both the protein and 
precipitant concentration in the drop until equilibrium is reached. For successful 
crystallisation this results in conditions changing from the undersaturation zone to the 
nucleation zone (Figure 1.22). In the nucleation zone, a nucleus from which crystal growth 
can occur is formed. As protein crystals start to form, the concentration of protein in the drop 
decreases, causing the conditions to move into the metastable zone if crystallisation is 
sufficiently slow and controlled.  
 
Figure 1.22: Phase diagram representing conditions in which nucleation, crystallisation and 
precipitation can occur with protein concentration plotted against an adjustable 
experimental parameter e.g. precipitant concentration. Taken from N. E. Chayen. 161 
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Protein crystals are, on average, 50% solvent with ordered water molecules close to the 
protein interacting specifically with the protein molecule that will be seen in the electron-




1.6.2 The phase problem 
When x-rays are diffracted by the electron density of atoms in the crystal, the reflected x-
rays are detected by the detector which measures both the position and intensity of the 
reflection. Detectable reflections in the diffraction image require the constructive 
interference of diffracted x-rays. This only occurs when Bragg’s Law (Equation 1.2) is 
fulfilled for a set of Miller indices (Figure 1.21). Parallel planes in the unit cell are described 
by using the Miller indices, hkl, where the values of h, k and l indicate the number of planes 
that intersect the x, y and z axes of the unit cell. 
2𝑑ℎ𝑘𝑙 sin 𝜃 = 𝑛𝜆    (1.2) 
Equation 1.2: Bragg’s Law where θ is the diffraction angle, dhkl is the spacing between the 
hkl planes, n is an integer and λ is the wavelength of the x-ray radiation.  
 
Figure 1.21: The relationship between dhkl and θ, taken from G. Rhodes p56.
162 The red dots 
are lattice points located on parallel planes indicated by the black dots. The purple arrows 
represent x-rays R1 and R2 and the spacing between the planes, dhkl, is equal to vector AB. 
When 2dhklsinθ (where θ is the diffraction angle) is equal to an integer multiplied by the 
wavelength of the x-rays, then the x-rays interfere constructively. 
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The diffracted x-rays are periodic waves with amplitude, frequency and phase. Any periodic 
function can be described as a sum of terms in the form below (Equations 1.3 – 1.5). 
162
  
𝑓(𝑥) =  ∑ 𝐹ℎ
𝑛
ℎ=0
[cos 2𝜋 (ℎ𝑥) + 𝑖 sin 2𝜋 (ℎ𝑥)]    (1.3)  
𝑓(𝑥) =  ∑ 𝐹ℎ
ℎ
𝑒2𝜋𝑖(ℎ𝑥)    (1.4)  
𝑓(𝑥, 𝑦, 𝑧) =  ∑ ∑ ∑ 𝐹ℎ𝑘𝑙
𝑙𝑘ℎ
𝑒2𝜋𝑖(ℎ𝑥+𝑘𝑦+𝑙𝑧)    (1.5) 
Equation 1.3 describes a general periodic function as the sum of Fourier terms dependant 
on cos and sin where F is amplitude and h is frequency. Equation 1.4 is a simplification of 
1.3 using complex number theory. Equation 1.5 is a general formula for a periodic function 
in three dimensions. 
 
The square root of the intensity of a reflection in the diffraction image is proportional to the 
structure factor. The structure factor is the sum of the contribution to each reflection from 
each atom in the unit cell (Equations 1.6 and 1.7). 
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𝑓ℎ𝑘𝑙 =  𝑓𝑗 𝑒
2𝜋𝑖(ℎ𝑥𝑗+𝑘𝑦𝑗+𝑙𝑧𝑗)    (1.6) 




    (1.7) 
Equation 1.6 describes the contribution of an atom, j, to a reflection in the diffraction 
pattern where fj is the atomic scattering factor of atom j which depends on the chemical 
identity of the atom and (xj, yj, zj) are the coordinates in real space of atom j. Equation 1.7 
defines the structure factor, Fhkl as the sum of the contributions of each atom in the 
structure to the reflection. 
 
As the structure factor, Fhkl, is dependent on the identity and position of atoms within the unit 
cell (Equation 1.7), it can also be described in terms of electron density per unit volume. By 
considering the electron density in infinitesimally small units of volume, this relationship can 
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be expressed as a Fourier transform (Equation 1.8). The electron density can then be 
expressed in the reverse Fourier transform (Equation 1.9) using a triple sum rather than an 




To calculate the electron density and create an electron density map of the protein molecule 
from Equation 1.9 it is necessary to know the amplitude, frequency and phase of the 
diffracted waves but the phase is unknown and cannot be experimentally determined. This is 
the phase problem which must be solved for every reflection.  
𝐹ℎ𝑘𝑙 = ∫  𝜌(𝑥, 𝑦, 𝑧)
 
𝑉
 𝑒2𝜋𝑖(ℎ𝑥+𝑘𝑦+𝑙𝑧) 𝑑𝑉    (1.8) 
𝜌(𝑥, 𝑦, 𝑧) =  
1
𝑉
∑ ∑ ∑ 𝐹ℎ𝑘𝑙
𝑙𝑘ℎ
 𝑒−2𝜋𝑖(ℎ𝑥+𝑘𝑦+𝑙𝑧)    (1.9) 
Equation 1.8 expresses the structure factor as the integral of the electron density where 
ρ(x,y,z) is the electron density at coordinates (x,y,z), Fhkl is the structure factor and V is unit 
cell volume. Equation 1.9 expresses electron density as the Fourier transform of the 
structure factor. 
 
The phase problem can be solved either by isomorphous replacement methods with heavy 
atoms e.g. mercury, or by using anomalous scattering by an element such as selenium. In 
multiple isomorphous replacement, a heavy atom that diffracts strongly is incorporated, often 
by soaking, into the protein crystal. The intensities of spots in the diffraction image differ in 
the data sets of the protein and the protein with heavy atom incorporated. This difference is 
used to determine the structure factors for the heavy atoms.  
The difference in the structure factors of the data set of the protein with heavy atoms and the 
native protein is used to calculate the difference Patterson function. This function is used to 
make the Patterson map which contains peaks corresponding to vectors between atoms. As 
there are only a few heavy atoms in each unit cell, it is possible for the position of the heavy 
atoms to be determined computationally from the peaks in the Patterson map. This process 
often has to be repeated with another heavy atom that binds at a different position and from 
all the information calculated from the data sets, only one possible solution for the phases 
remains. Multiwavelength anomalous dispersion is a similar process but all the data required 
can be generated from one crystal using synchrotron radiation where the wavelength can be 
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changed. Some atoms, including selenium, can absorb x-rays, but this absorption drops at a 
wavelength specific to that element called the absorption edge.  
Molecular replacement methods can be used to solve a structure if there is a homologous 
structure that has previously been solved. Molecular replacement programs use the 
previously solved structure as a model inserted into the unit cell of the unsolved data to 
attempt to find a solution that fits the experimental data. 
162
 The molecular replacement 
program Molrep uses translation and rotation functions to find the correct position of protein 
molecules in the unit cell using model of a previously solved homologous protein. The 







Inhibition of KMO has been identified as a potentially beneficial therapeutic strategy in 
diseases including Huntington’s disease, Alzheimer’s disease and acute pancreatitis. There is 
therefore a need to develop potent inhibitors of KMO that do not act as effectors. In this 
work a set of novel KMO inhibitors is assayed with PfKMO* to investigate the effects of 
substituents on the Ki value. Crystallisation of PfKMO* with some of these inhibitors was 
undertaken to further understand how they bind and what important interactions are formed 
between the inhibitor and the protein to gain insights useful for developing more potent 
inhibitors that may lead in the future to the development of KMO inhibitors that can be used 
clinically. 
Recently crystal structures of PfKMO* and S. cerevisiae KMO have been obtained. These 
structures have provided valuable insights into the chemistry of KMO but a thorough 
characterisation of residues in the active site has not yet been completed. In this work, 
residues in the active site of PfKMO* are investigated using kinetic and crystallographic 
techniques to investigate proteins that have mutations in the active site. The information 
gained in this work will complement the previously obtained structures and be useful in 
confirming whether the hypotheses made about the roles and importance of residues in the 
active site are correct. 
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A further aspect of this work is to characterise the role of residues in the active site of 
PfKMO* that are not conserved in the human KMO enzyme. The only residue not conserved 
is H320, which is a phenylalanine in the human enzyme. Characterisation of this residue may 
provide insights into potential differences in the active site properties of the two enzymes 
and indicate whether PfKMO* is a good model for understanding the human enzyme and 
also whether the inhibitors shown to be effective in inhibiting PfKMO* are likely to be 




Chapter 2: Materials and Methods 
 
 
2.1 Site-directed mutagenesis using megaprimer PCR 
 
The megaprimer method contains two rounds of PCR. 
164
 In the first round the primer for the 
mutation and the flanking primer for the end of the gene closest to the mutation site are 
added to the PCR mixture. The result is a megaprimer which is then used as a primer for the 
second round of PCR in which the whole of the gene is amplified. After each round of PCR 
the DNA product is purified before being used in further steps. After the gene is amplified 
with the mutation introduced, it is digested with restriction enzymes and then ligated into a 
pET17b plasmid. The plasmid is then transformed into competent cells and sequenced to 
confirm that the desired mutation has been achieved. 
 
2.1.1 Primer design  
The primers used for the megaprimer PCR are given in Table 2.1. The combination of these 
individual primers used to obtain each desired mutation is listed in Table 2.2.  
T7 Promoter TAATACGACTCAGTATAGGG 
T7 Terminator GCTAGTTATTGCTCAGAGG 
N Terminator (F) primer GAAGAGATATACATATGACTGCTACAGACAAGGC 
R84K GTGATGATGCGTGGGAAAATGGTGCATGTG 
Y98A CTGCAGCCAGCCGGACGTGATGAC 
N369S (reverse complement) CTCCACGTAGCTTTCCAGGGC 
Y404F (reverse complement) GACCATGCTGAAACGCGGGATAAAACG 
Table 2.1: Primer sequences used for megaprimer PCR. The bases highlighted in yellow are 
those changed to make the mutation in the amino acid sequence, those underlined were 




Mutation Mutation primer Flanking Primer in PCR 1 Flanking Primer in PCR 2 
R84K R84K T7 Promoter T7 Terminator 
N369S N369S T7 Terminator T7 Promoter 
Y404F Y404F T7 Terminator T7 Promoter 
Table 2.2: Combination of primers used for each mutation made using megaprimer PCR.  
 
2.1.2 PCR 1 
The composition of a typical PCR 1 reaction is given in Table 2.3. The reactions were set up 
in a 0.2 ml sterile tube and were made to a volume of 50 µl using elution buffer (from a 
QIAprep® Spin Miniprep kit). The flanking primer used was either the T7 promoter or 
terminator primer depending on which site was nearer to the mutation site. 
2.5 µl 10× ThermoPol buffer 
0.25 mM dNTPs 
1 µl template plasmid 
0.4 µM flanking primer  
0.4 µM mutation primer  
1 Unit Vent polymerase  
Table 2.3: Typical PCR 1 composition 
 
The typical reaction conditions are given below in Table 2.4. Vent polymerase was added 
during the first 50 ºC step. 
 Temperature (ºC) Time (s) No. of Cycles 
Stage One 96 60 1 
Stage Two 96 




60 +1 per cycle 
30 
Stage Three 72 300 1 




2.1.3 Purification of PCR product 
The PCR product was purified by extraction from a 1% w/v agarose gel. The gel was 
prepared by heating genetic analysis grade agarose in TAE (0.04 M Tris, 0.05 M EDTA    
pH 8.0 and 0.02 M glacial acetic acid) buffer. Ethidium bromide was added to the cooled 
buffer to allow visualisation of the DNA bands under UV light. 
Samples were prepared by adding 6× Bromophenol Blue loading dye to the PCR mixture. 
The samples were loaded into the gel once it had been set and the gel was run in TAE buffer 
at 110 mV. The DNA band was separated from the gel using a PureLink Quick Gel 
Extraction Kit (Life Technologies) and was eluted in 40 µl of Elution Buffer. This was 
stored at -20 ºC until required. 
The yield from the gel was often low so for some reactions the PCR mixture was directly 
purified using either a gel extraction kit or a QIAquick® PCR Purification Kit (QIAgen). A 
few µl of the PCR product was reserved to run on a gel to check that only one DNA band 
could be observed. 
 
2.1.4 PCR 2 
The typical composition of a PCR 2 reaction is given in Table 2.5. The reaction was made to 
final volume of 50 µl using elution buffer. The megaprimer volume was often varied to 
achieve a successful reaction.  
2.5 µl of 10× ThermoPol Buffer 
0.25 mM dNTPs 
2 mM MgCl2 or MgSO4 
0.4 µM flanking primer 
2 µl plasmid template 
15 µl megaprimer  
1 Unit of Vent polymerase. 
Table 2.5: Typical composition of PCR 2 
 
The typical conditions for a PCR 2 are given in Table 2.6. The reaction was purified as 
described above for PCR 1 and stored at -20 ºC until required. 
50 
 
 Temperature (ºC) Time (s) Number of Cycles 
Stage One 96 60 1 







Stage Three 96 




60 + 1 per cycle 
25 
Stage Four 72 300 1 
Table 2.6: Typical conditions for PCR 2 
 
2.1.5 Digestion 
Prior to ligation into a pET17b plasmid, the PCR product had to be digested with Type II 
restriction enzymes. The purified PCR product was incubated at 37 ºC for 3 hours with 5 µl 
of 10× NEB (New England Biolabs) Buffer 4 and 0.04 Units each of Nde1 and Xho1.  
The digestion reaction was quenched either by running the reaction mixture on a 0.8% w/v 
agarose gel followed by an extraction kit as described above in Section 2.1.3 or by heating 
the reaction mixture to 80 ºC for ten minutes. 
The pET17b plasmid was also digested before the ligation reaction, using the same 
procedure described above. The plasmid was extracted using a QIAprep® Spin Miniprep kit 
(QIAgen) from 10 ml cultures of E. coli cells that had been grown for 16 hours at 37 ºC (as 
described in section 2.3.2) before harvesting by centrifugation. 
 
2.1.6 Ligation 
The digested PCR product was ligated into a digested pET17b plasmid prepared as described 
in Section 2.1.5. The reactions were carried out at 4 ºC overnight. A typical ligation reaction 
contained 1 µl pET17b, 4 µl insert, 2 µl T4 DNA ligase buffer and 1 µl T4 DNA ligase made 
to a final volume of 10 µl using elution buffer (from a QIAprep® Spin Miniprep kit). 
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2.1.7 Transformation of high efficiency cloning cells 
The ligation product was used to transform NEB 5-alpha Competent E. coli (High 
Efficiency) Cells. The cells were defrosted on ice before 30 µl was transferred to a sterile 15 
ml polypropylene tube and incubated on ice with 5 µl of ligation product. The cells were 
heat-shocked at 42 ºC for 40 seconds before a further 5 minutes on ice. Approximately     
950 µl LB or SOC (Table 2.10) was added and the cells were incubated at 37 ºC for 1 hour. 
100 µl of cells were spread onto a warm sterile agar plate (prepared as described in Section 
2.3.1) which was incubated at 37 ºC overnight. 
 
2.1.8 Submission of samples for Sanger Sequencing 
Cells were grown from an individual colony in 10 ml LB with 50 µg/ml ampicillin (as 
described in Section 2.3.2) overnight at 37 ºC with shaking at 200 rpm. The cells were 
harvested by centrifugation and the plasmids were extracted using a QIAprep® Spin 
Miniprep kit (QIAgen). 
Samples containing 5 µl plasmid and 1 µl of 3.2 µM primer were submitted for sequencing. 
One sample with each flanking primer (T7 promoter or terminator) was submitted for 
sequencing. The Sanger Sequencing was performed by The Genepool at the University of 
Edinburgh and the data obtained is listed in Appendix 1. 
 
2.1.9 Transformation of BL21 (DE3) E. coli cells 
Plasmids which were found to contain the desired mutation were used to transform BL21 
(DE3) E. coli cells in order to express active PfKMO protein. 
The competent cells were defrosted on ice and 30 µl of cells was mixed with 5 µl plasmid in 
a sterile 1.2 ml Eppendorf tube. The tubes were gently tapped to mix and then heat-shocked 
in a 42 ºC water bath for 20 seconds before returning to ice. Approximately 1 ml of SOC or 
LB was added (as described in Table 2.10) and the cells were incubated at 37 ºC for 1 hour. 
100 µl of the cells was spread onto a dry warm agar plate which was then incubated 
overnight at 37 ºC. 
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2.2 Site Directed Mutagenesis using a Quikchange protocol 
 
Other mutations were made using a Quikchange II Site-Directed Mutagenesis kit (Agilent 
technologies) with an adapted primer design strategy using primers that have long overhang 
regions. 
165
 The primers were designed to contain the mutations near the 5 end and to have 
long overhanging regions in 3´ end. The pairs of primers for each mutation were therefore 
not complimentary. The primers used in this protocol are listed below in Table 2.7. 
Primer Primer Sequence (5´ – 3´) 
R84A forward CGCGGGGCTATGGTTCATGTGCCGGGCACG 
R84A reverse CACCATGGCCCCACGCATCATCACCGCTTC 
H320F forward CCGTTCTTTGGCCAAGGCATGAACTGTGCA 
H320F reverse CTGGCCAAAGAAGGGTACCATGGGATGGGC 
Y404A forward CCGCGTGCCAGCATGGTCACCTTCAGCCGC 
Y404A reverse CATGCTGGCACGTGGGATAAAACGCGTCGG 
Table 2.7: Primers designed for the Quikchange protocol written from 5´ to 3´. The bases 
highlighted in yellow indicate the changes made to obtain the required mutation and those 
underlined show changes made to improve primer properties but that do not affect the 
amino acid sequence. 
 
2.2.1 PCR Conditions 
The PCR was a one-pot process set up in a 0.2 ml sterile tube using the reagents provided in 
the Agilent QuikChange II Site-Directed Mutagenesis kit. The typical composition is given 
in Table 2.8 below and was made to a final volume of 50 µl using sterilised H2O. The only 
varied parameters were the volumes of plasmid and primer used. 
5 µl 10× reaction buffer 
1 µl dNTPs (proprietary mix) 
2 µl template plasmid 
2.5 µl forward primer 
2.5 µl reverse primer 
2.5 Units PfuUltra High-Fidelity DNA polymerase 
Table 2.8: Typical composition of QuikChange PCR. 
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The typical reaction conditions are given in Table 2.9 below. The reaction was performed in 
a Techne TC3000 thermal cycler. 
 Temperature (ºC) Time (minutes) Number of cycles 
Stage One 95 5 1 












Table 2.9: Typical conditions for QuikChange PCR. 
 
2.2.2 Digestion of template plasmid 
To remove the template plasmid which would not contain the desired mutation, the PCR 
mixture was then incubated with a Type 1 restriction enzyme. 
5 Units of DpnI were added directly to the reaction mixture. The tube was centrifuged briefly 
to thoroughly mix the contents and the digest was incubated at 37 ºC for 1 hour. 
 
2.2.3 Transformation of competent cells 
After incubation with DpnI, the PCR mixture was used to transform competent cells, either 
the XL-1 Blue Supercompetent cells provided in the kit, as described below, or into NEB 5-
alpha E. coli (High Efficiency) cells as described above in Section 2.1.7. 
The transformation into XL-1 Blue Supercompetent cells was carried out in a cold, sterile 14 
ml polypropylene tube. 50 µl of cells were mixed with 1 µl PCR product on ice. The tubes 
were gently rotated to mix the contents and were incubated on ice for 30 minutes. The cells 
were then heat-shocked at 42 ºC for 40 seconds before the tubes were returned to ice. 
After 2 minutes on ice, 0.5 ml LB was added to the transformations and the tubes were 
incubated for 1 hour at 37 ºC. 100 µl of the cells were spread onto agar plates as described in 




2.3 Cell growth and protein expression 
 
2.3.1 Media 
The media used are listed in Table 2.10 below. All media was adjusted to pH 7.0 with NaOH 
and autoclaved at 121 ºC for 20 minutes before use. 
LB media 10 g/l tryptone 
5 g/l yeast extract 
5 g/l NaCl 
LB Agar LB media with 15 g/l agar 
SOC media 20 g/l tryptone 
5 g/l yeast extract 
8.56 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
20 mM glucose 
Table 2.10: Media used to grow cells for cloning and protein expression 
 
LB agar plates were prepared with autoclaved LB agar cooled to 40 ºC before 50 µg/ml 
ampicillin was added. The media was poured into sterile Petri plates and stored at 4 ºC until 
shortly before use when the plates were incubated at 37 ºC for 1 hour. 
 
2.3.2 BL21 (DE3) E. coli cells 
PfKMO protein was produced in BL21 (DE3) E. coli cells containing a pET17b vector with 
the KMO gene. The cell growth was initiated in 30 ml sterile tubes containing 10 ml LB and 
50 µg/ml ampicillin. Once inoculated with the BL21 (DE3) E. coli cells, the tubes were 
incubated for approximately 20 hours at 37 ºC with shaking at 180 rpm. 
To produce active protein, cells were grown slowly in a second overnight step. 1 l of LB 
with 50 µg/ml ampicillin in a 1 l Nalgene flask was inoculated with 10 ml cell culture. Cells 
were grown at 22 ºC with shaking at 180 rpm for 16 hours.  
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Cells were harvested by centrifugation in at 8289 g for 7 minutes and the cell mass obtained 
was stored at -20 ºC until required. 
 
 
2.4 Protein purification 
 
2.4.1 PfKMO purification 
The compositions of the buffers used in the purification are listed in Table 2.11. The buffers 
were made using deionised water and the pH was adjusted using NaOH. Before use the 
buffers were filtered through a 0.22 µm filter. 
The BL21 (DE3) E. coli cells were defrosted on ice and resuspended in 10 ml (per gram cell 
weight) lysis buffer supplemented with 0.2 mM PMSF. Cells were lysed by sonication for an 
approximate total of 1-2 minutes on ice in bursts of 20 seconds each followed by a minimum 
of one minute to cool on ice. Sonicated cells were centrifuged at 38759 g for 1 hour. The 
supernatant was filtered, before further purification, using 0.22 µm syringe-driven filters. 
The filtered protein solution was loaded onto a 60 ml FPLC Q-Sepharose 26/10 column pre-
equilibrated with lysis buffer. The column was connected to an Akta FPLC pump. A yellow 
band was observed on the column. The column was washed with 400 ml wash buffer before 
PfKMO was eluted using 500 ml elution buffer. Fractions were collected in an automated 
fraction collector. The elution of PfKMO was monitored using UV absorbance at 280 nm 
and a kinetic assay (as described in Section 2.5.1) and fractions found to contain PfKMO 
were pooled.  
PfKMO in the pooled fractions was precipitated by slow addition of 300 ml ammonium 
sulfate buffer on ice. After 30 minutes the mixture was centrifuged at 38759 g for 20 minutes 
at 4 ºC. The supernatant was discarded and the yellow pellets could be stored at -20 ºC prior 
to further purification. 
PfKMO was further purified using size exclusion chromatography. The column and buffer 

















Table 2.11: Composition of buffers used for in purification 
 
PfKMO purified for kinetic assays was purified using either G25 Sephadex column using 
gravity at 4 ºC or a 120 ml S75 column connected to an Akta FPLC pump. This protocol 
used size exclusion purification buffer 1.  
PfKMO was resuspended in a minimum volume of size exclusion buffer 1 and concentrated 
to a total volume of 2 ml using VIVASPIN MW 30000 concentrators. When the G25 column 
was used, the protein was loaded onto the pre-washed column and eluted as a single fraction 
judged by eye. Alternatively, the protein could be loaded onto the S75 column using a 2 ml 
loop and eluted in a single fraction using the absorbance at 280 nm as a guide for fraction 
collection. After size exclusion chromatography, PfKMO was adjusted to the required 
concentration and flash frozen in liquid nitrogen before being stored at -80 ºC.  
Lysis buffer 20 mM HEPES, pH 7.5 
10 mM NaCl 
1 mM DTT 
PMSF stock 0.2 M PMSF in ethanol 
Wash buffer 20 mM HEPES, pH 7.5 
50 mM NaCl 
1 mM DTT 
Elution buffer 20 mM HEPES, pH 7.5 
110 mM NaCl 
1 mM DTT 
Ammonium sulfate buffer 20 mM HEPES, pH 7.5 
75% (saturated) ammonium sulfate 
1 mM DTT 
Size exclusion buffer 1 20 mM HEPES, pH 6.8 
10 mM NaCl 
1 mM DTT 
Size exclusion buffer 2 (for 
crystallography) 
20 mM HEPES, pH 6.8 
110 mM sodium acetate 
1 mM DTT 
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Highly pure samples were required for crystallography and this was achieved using the S75 
column pre-equilibrated in size exclusion buffer 2. PfKMO was resuspended in a minimum 
volume of size exclusion buffer 2 and concentrated to a total volume of 2 ml as described 
above. Pure PfKMO was collected as a single fraction. The protein was concentrated again 
and then diluted to adjust the concentration of sodium acetate to approximately 10 mM. 
PfKMO was concentrated to 240 µM and stored in 50 µl aliquots at -80 ºC after flash 
freezing in liquid nitrogen. 
 
2.4.2 SDS-PAGE 
The success of the purification was confirmed using SDS-PAGE. Protein samples were 
denatured by heating in boiling water for 5 minutes. The samples were then mixed with an 
equal volume of 2x NuPAGE® LDS sample buffer and then loaded into a pre-cast 
NuPAGE® Novex® 4-12% Bis-Tris SDS-PAGE gel run in NuPAGE® MES SDS running 
buffer. A protein marker (SeeBlue® or SeeBlue® Plus 2 Pre-Stained Standard) was also 
loaded into the gel to allow determination of approximate molecular weight. 
Once the gel had run for 1 hour, it was removed from the plastic casing and stained using 
Coomassie Blue stain (Table 2.12) for 45 minutes with gentle shaking. The gel was then 
gently shaken in a destain solution (Table 2.12) for one hour and then overnight in water. An 
image of the destained gel was obtained before disposal. 
Coomassie Blue Stain 0.1% Coomassie Brilliant Blue 
40% methanol 
10% acetic acid 
Destain solution 40% methanol 
10% acetic acid 





2.5 Kinetic Assays 
 
2.5.1 Purification assay 
A kinetic assay was used during purification to check for the presence of active PfKMO in 
fractions eluted from the Q-Sepharose anion-exchange column. This 1 ml cuvette assay 
monitored absorbance at 340 nm for 0.5 minutes using a Varian Cary 50 Probe UV-visible 
spectrophotometer. The typical composition of the assay is given in Table 2.13 below made 
to a total volume of 1 ml using 20 mM HEPES buffer, pH 8.0. The wavelength was chosen 
because NADPH absorbs at 340 nm but NADP
+
 does not so that as NADPH reduces the 
FAD cofactor, the absorbance detected at this wavelength decreases with decreasing 
concentration of NADPH. 
220 µM NADPH 
200 µM L-kynurenine 
50 µl PfKMO sample 
Table 2.13: Composition of purification cuvette assay 
 
2.5.2 Michaelis-Menten Kinetics 
The Michaelis-Menten parameters, KM and kcat, were determined using a 1 ml cuvette assay 
monitored at 340 nm for 0.5 minutes using a Varian Cary 50 Probe UV-Vis 
spectrophotometer. The typical composition of the assay is given in Table 2.14. Each sample 
had a different concentration of L-kynurenine while NADPH was held in excess. 
20 mM HEPES buffer, pH 8.0 
250 µM NADPH 
20 µl L-kynurenine (various concentrations) 
10 µl PfKMO (10 – 30 µM) 
Table 2.14: Typical composition of Michaelis-Menten kinetic assay 
 






60 ∗ 𝜀(𝑁𝐴𝐷𝑃𝐻 𝑎𝑡 340 𝑛𝑚) ∗ [𝑒𝑛𝑧𝑦𝑚𝑒]
 
Equation 2.1: Calculation of enzyme turnover (s-1) where ΔAbsorbance is the change in 
absorbance at 340 nm (min-1) and ε is the molar absorption coefficient of NADPH at 340 nm 
which is 6200 M-1cm-1.  
 
The Michaelis-Menten parameters were obtained by plotting the turnover values against      
L-kynurenine concentration in Origin 8.5.1. Assays were performed in triplicate to obtain 
accurate values. 
 
2.5.3 Inhibition assays 
A similar kinetic assay was used to determine the Ki values for a range of inhibitor 
compounds. Data were collected exactly as in Section 2.5.2 but both the kynurenine and 
inhibitor concentrations were varied. The composition of a typical assay sample is given 
below in Table 2.15. 
935 µl 25 mM HEPES, pH 8.0 
25 µl 10 mM NADPH 
20 µl kynurenine (concentration varies) 
10 µl inhibitor (concentration varies) 
10 µl PfKMO (10 – 30 µM) 
Table 2.15: Composition of typical inhibition assay 
 
A typical assay consisted of 25 measurements combining 5 kynurenine concentrations and 5 
inhibitor concentrations. The inhibitor and kynurenine concentrations were combined 
randomly during the assay to decrease statistical error. As the inhibitor stocks were prepared 
using DMSO to solubilise the organic compounds, the samples containing 0 µM inhibitor 
contained an equal volume DMSO to replace the inhibitor as a control 
Assays were performed in triplicate and the data were analysed using the Erithacus Software 





2.7.1 Hanging drop vapour diffusion 
The hanging drop vapour diffusion method was used to grow crystals of PfKMO either with 
no ligands in the active site or with kynurenine, substrate analogues or inhibitors bound in 
the active site.  
Crystals were grown in 24 well plates, either Linbro or VDX, with 0.5 ml well solution in 
each well. The well solutions were varied to find the optimum conditions but typically 
contained 1.0M HEPES buffer pH 7.0, PEG 4K, isopropanol, glycerol and a salt, usually 
either NaCl or sodium tartrate.  
Hanging drops consisting of a 1:1 mixture of 240 µM PfKMO and well solution were 
suspended from a siliconized glass cover-slip over the well solution. The slide was sealed to 
the edges of the well using soft white paraffin. The trays were wrapped in aluminium foil to 
block out light. The trays were stored at 4 ºC and left undisturbed for at least 24 hours before 
being checked for crystals. 
 
2.7.2 Sitting drop vapour diffusion 
The sitting drop vapour diffusion method was used to grow PfKMO crystals with inhibitor 
molecules bound in the active site. The sitting drops were set up in Greiner Bio-one 
CrystalBridge™ in 24 well plates using a 1:1 mixture of 240 µM PfKMO and well solution. 
The well solutions were set up as described above in Section 2.7.1. The trays were wrapped 
in aluminium foil and stored at 4 ºC. Crystals were usually observed within one week. 
 
2.7.3 Data collection 
All data were collected on the macromolecular beamlines at the Diamond Light Source at 
Harwell Campus, Didcot, Oxfordshire. The crystals were transported to the Diamond Light 
Source in sample holders kept in liquid nitrogen. 
Before the crystals were frozen in liquid nitrogen, they were cyroprotected using ethylene 
glycol. Crystals grown in hanging drops were picked up in cryoloops and exposed to 10% 
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and then 20% ethylene glycol solutions prepared using the appropriate well solution 
conditions. Crystals were flash-cooled in liquid nitrogen in a sample holder. Crystals grown 
in sitting drops were cryoprotected by adding 1 µl ethylene glycol directly to the drop before 
freezing on a loop. 
 
2.7.4 Data processing 
The diffraction images obtained from data collection were processed using iMosflm which 
determines the intensity of each reflection and the unit cell parameters. 
166
 The mtz files 
generated were processed further using programs supported by CCP4i (Collaborative 
Computer Project, number 4). 
167
 The Laue group was determined using POINTLESS, scaled 




Molecular replacement was carried out using MOLREP which required the SCALA output 
and a model of a similar protein to obtain the phases (a PDB file of previously solved 
PfKMO in the appropriate space group was used). 
163
 The model was refined using 
REFMAC5 and after each round of refinement, the structure was validated using Coot. 
170,171
 
Ligands were added to the model where appropriate in Coot after the dictionary and the 
three-dimensional coordinates in PDB format were generated from a two-dimensional 




2.8 Presentation of data in figures and tables 
 
Figures containing cartoon or stick representations of crystallographic structures throughout 




Figures of kinetic data fitted to the Michaelis-Menten equation were prepared using Origin 
8.5.1 (Origin Lab, Northampton, MA). Accurate determination of Ki values by simultaneous 
non-linear regression analysis was carried out using GraFit 3.0, Erithacus software. 
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Representations of chemical structures of small molecules were made using ChemDraw® 
Prime 15.0 (PerkinElmer software).  
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Chapter 3: Inhibition of PfKMO* 
 
3.1 Development of novel KMO inhibitors 
 
A novel scaffold for KMO inhibitor compounds was developed in collaboration with Dr 
Gavin Milne, University of St Andrews, who synthesised this set of compounds as part of his 
PhD thesis (Figure 3.1). The initial scaffold has a number of similarities to the Ro 61-8048 
compound as both contain an aromatic ring with a nitro-substituent and a heterocycle. 
Investigations into extending the structure of the initial scaffold led to the development of 
the final scaffold. The aim of developing this series of compounds was to make potent KMO 
inhibitors that did not contain the 3-NO2 group thought to be associated with toxicity in Ro 
61-8048. In addition, the aim was to develop compounds that would not act as effectors that 
allow reduction of the FAD cofactor by NADPH but cannot be hydroxylated resulting in the 
unstable hydroperoxyflavin decaying with release of H2O2.  
 
Figure 3.1: The structures of Ro 61-8048 and the initial and final scaffolds of the novel 
inhibitor compounds. PfKMO* inhibition was obtained using compounds based on the 
initial scaffold. This was then developed to the final scaffold from which more potent 
PfKMO* inhibitors were designed. 
 
The aim of further developing this series of compounds was to investigate the effect of 
substituents on both of the aromatic rings to obtain potent inhibitors. The results for 
compounds with only a hydrogen atom at R2 or with a 3,4-diOMe substituent were 
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investigated in previous work (Table 3.1). Ro 61-8048 was assayed against PfKMO* under 




 Compound Name R1 R2 
% activity 
decrease 
Ki value (μM) 
Ro 61-8048    1.03 ± 0.27 
GM302 3-H H 10.3 ± 9.5  
GM339 3-Me H 8.4 ± 9.6  
GM348 3-OMe H 7.0 ± 5.1  
GM342 3-F H 1.3 ± 8.0  
GM304 3-CF3 H 22.6 ± 12.1  
GM307 4-Br H 21.3 ± 10.9  
GM340 3-Cl H 22.0 ± 3.6 2.77 ± 0.43 
GM308 3-Br H 13.0 ± 9.2 1.581 ± 0.197 
GM303 3,4-diCl H 95.0 ± 3.2 0.115 ± 0.011 
GM328 H 3,4-diOMe 5.4 ± 4.6  
GM366 3-Me 3,4-diOMe 2.2 ± 7.7  
GM467 3-OMe 3,4-diOMe 20.3 ± 5.1  
GM367 3-F 3,4-diOMe 17.7 ± 9.1  
GM457 3-CF3 3,4-diOMe 39.7 ± 13.6  
GM469 4-Br 3,4-diOMe 44.3 ± 13.6  
GM466 3-Cl 3,4-diOMe 56.4 ± 9.6 0.782 ± 0.054 
GM440 3-Br 3,4-diOMe 62.4 ± 10.9 1.330 ± 0.084 
GM347 3,4-diCl 3,4-diOMe 94.4 ± 1.9 0.065 ± 0.020 
 Table 3.1: Table showing Ki assay results and activity tests using 10 μM inhibitor to 
measure the percentage decrease in activity for compounds based on the final scaffold of 
GM compounds quoted from previous work. The Ki assays were conducted in cuvettes with 
PfKMO* as described in Section 2.5.3. 143 
 
Comparing the two sets of compounds in Table 3.1, it can be seen that the effects of R1 
substitution are more significant than R2. Compounds with either no substituent or with 
electron-donating substituents at R1 (GM302, GM339, GM328 and GM366) were poor 
inhibitors of PfKMO*. Chloro- and bromo-substitution at R1 can be used in place of the     
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3-NO2 group, which is present in Ro 61-8048, while maintaining an inhibitory effect. It can 
be seen by comparing GM340, GM308, GM307 and GM303 that di-chloro substitution was 
particularly effective compared to monosubstitution with either chlorine or bromine in the   
3- and 4- positions. GM303 was the first compound in this series shown to have greater 
potency than Ro 61-8048. 
It can be seen that potency of the chloro/bromo-substituted compounds is also enhanced by 
di-OMe substitution on the other aromatic ring (GM compounds 340 and 466, 308 and 440, 
307 and 469, and 308 and 347). This effect is particularly pronounced with R1 chloro-
substituted compounds compared to the 3-Br substituted compounds. In the case of GM347, 
a compound had now been developed with a Ki value approximately 15× smaller than that of 
Ro 61-8048, and the subsequent compounds in this series were designed with 3,4-dichloro 




Compound Name R1 R2 Ki value (μM) 
GM303 3,4-diCl H 0.115 ± 0.011 
GM347 3,4-diCl 3,4-diOMe 0.065 ± 0.020 
GM729 3,4-diCl 3,4-diOH 0.067 ± 0.018 
GM760 3,4-diCl 3-OPO(OEt)2, 4-OMe 0.020 ± 0.004 
GM769 3,4-diCl 3-OMe, 4-OPO(OEt2) 0.017 ± 0.002 
GM854 3,4-diCl 3-OMe, 4-OCH2CO2H 0.029 ± 0.012 
Table 3.2: Table containing Ki values for compounds with 3,4-dichloro substitution on the 
R1 aromatic ring. 143,176 
 
The compounds with 3,4-dichloro substituents at R1 were all potent inhibitors with R2 
substitution contributing less to the degree of potency. 3,4-diOH and 3,4-diOMe substitution 
results in almost equally potent compounds (GM347 and GM729). Large substituents were 
tolerated in both meta- and para- positions with no significant differences in the measured Ki 
values observed between GM760, GM769 and GM854.  
Four of these inhibitors, GM303, GM347, GM760 and GM769, have been crystallised with 
PfKMO* in previous work in the P6122 space group. 
143
 A comparison of the structures of 
PfKMO* with L-kynurenine bound and with GM303 bound shows that the 3,4-dichloro 
substituted ring binds in the same position as the aromatic ring of L-kynurenine, in close 
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proximity to the isoalloxazine moiety of the FAD cofactor, but the large size of GM303 
results in displacement of residues in the active site (Figure 3.2). All the inhibitors 
crystallised to date cause a displacement of R84 disrupting the interactions important for the 
closed conformation resulting in a movement of the C-terminal domain away from the active 
site. N369 is in a slightly different position able to interact with the carbonyl group of 
GM303. There is a slight conformational change affecting F319 and H320. With the 
displacement of R84, E372 and M373 are not held in close proximity to the active site and 
move further from the ligands. The positions of Y98, Y404 and the majority of the 
hydrophobic active site residues are unaffected.  
 
Figure 3.2: A comparison of some active site residues of PfKMO* with L-kynurenine (left, 
cyan) and GM303 (right, pink) bound with the isoalloxazine moiety of the FAD cofactor 
(yellow). In the presence of GM303, Arg84 is displaced relative to its position in the 
presence of L-kynurenine, Asn369 and Tyr404 appears to interact with GM303. The 
displacement of Arg84 in the presence of GM303 prevents the formation of any interaction 
between Arg84 and Glu372, which is observed in the presence of L-kynurenine. 143  
 
The set of structures of PfKMO*: inhibitor complexes have shown that there is more than 
one mode of inhibitor binding. The structure of PfKMO* with GM760 bound shows the      
3-OPO(OEt)2, 4-OMe substituted aromatic ring in a different position than in the structure 
with GM303 causing movement of some active site residues (Figure 3.3). The change in the 
inhibitor position starts with the orientation of the carbonyl, which in GM303 is orientated 
towards N369 (Figure 3.3). In the structure containing GM760, the carbonyl is oriented in 
the opposite direction but the position of N369 is unaffected. The position of Y404 is 
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different in these structures with Y404 in the structure of PfKMO* with GM760 able to 




Figure 3.3:  A comparison of the residues in close proximity to inhibitors bound in the active 
site in the structures of PfKMO* with GM303 (left) and GM760 (right). In the structure of 
PfKMO* with GM303 (teal) bound, the carbonyl of GM303 is able to interact with Asn369, 
the amide nitrogen is 2.6 Å from the hydroxyl group of Y404 and part of the heterocyclic 
ring is within 4 Å of the carbonyl of His320. In the structure of PfKMO* with GM760 (pink) 
bound, the GM760 amide carbonyl is over 6 Å from Asn369. Y404 is significantly displaced 
and is able to interact with Glu372. The carbonyl of His320 is now within 4 Å of both the 
amide carbonyl and the heterocyclic moiety. 
 
This series of novel inhibitors contains a number of promising compounds that are more 
potent than any previously reported inhibitors. In addition to this, they are true inhibitors in 
that they prevent the FAD cofactor from being reduced by NADPH, which results in H2O2 
production observed with effector molecules. 
143
 This series also does not break Lipinski’s 
“rule of five” for the following criteria: they have molecular weight of less than 500 Da, 
fewer than 5 hydrogen bond donors, fewer than 10 hydrogen bond acceptors. 
177
 The 
solubility of these compounds may present problems, as currently only GM760 and GM769 
have been solubilised in water although the solubility of the newest series of compounds 
remains to be investigated. 
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There are other compounds in this series which required characterisation to further explore 
the effect of substitution on the aromatic ring that, when the inhibitor is bound, is closest to 
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the C-terminal domain both to investigate the effect of any potential interactions between the 
substituents and PfKMO* and also to understand the different modes of inhibitor binding. 




3.2 Purification of PfKMO* 
 
The purification of PfKMO*, prior to use in kinetic assays and crystallisation, was carried 
out as outlined in Section 2.4 with no differences in procedure required to obtain any of the 
PfKMO* mutations discussed in this thesis. Typical chromatograms, SDS-PAGE and UV-
visible spectrum obtained during the purification of PfKMO* are presented below.  
The first column used in PfKMO* purification is a Q-Sepharose anion-exchange column. 
The supernatant obtained after centrifugation of cell debris was filtered and loaded onto the 
column with 10 mM NaCl present in the buffer (Section 2.4.1). The concentration of NaCl 
was increased to 50 mM before the elution of PfKMO* in 110 mM NaCl to obtain fractions 
of higher purity. A typical chromatogram (Figure 3.4) shows the absorbance at 280 nm of the 
column eluent. 
 
Figure 3.4: Typical chromatogram obtained showing absorbance at 280 nm of eluent from 
the Q-Sepharose column against volume in ml. The lysis buffer contained 20 mM HEPES, pH 
7.5, 10 mM NaCl and 1 mM DTT. After the soluble fraction from cell lysis was loaded, the 
concentration of NaCl was increased to 50 mM NaCl. After other proteins had been eluted 
at this concentration of NaCl, the elution buffer, 110 mM NaCl, was used to elute the 




After ammonium sulfate precipitation, PfKMO* was resuspended and concentrated before 
loading onto a S200 gel filtration column. The purified protein was collected as a single 
fraction when an increase in the UV-visible absorbance at 280 nm was observed at 
approximately 170 ml after column loading. 
 
Figure 3.5: Typical chromatogram obtained showing absorbance at 280 nm of eluent from 
the S200 gel filtration column against volume in ml. The column was equilibrated in 2 
column volumes buffer before the protein was loaded (at 0 ml). A single fraction of PfKMO* 
was collected. 
 
To determine the purity of PfKMO* obtained, an SDS-PAGE gel of samples taken during 
the purification process was run (Section 2.4.2). A typical SDS-PAGE obtained is shown 
below with samples taken throughout the purification process (Figure 3.6).  
    
Figure 3.6: Typical SDS-PAGE gel of samples collected during PfKMO* purification. The 
marker used is SeeBlue Pre-Stained Protein Standard (Invitrogen) with the weights of the 









standards given in kiloDaltons; Lane 1 is supernatant obtained after centrifugation of lysed 
cells; Lane 2 is flow-through from the Q-Sepharose column; Lane 3 is the pooled fractions 
containing PfKMO* from the Q-Sepharose column; Lane 4 is PfKMO* after ammonium 
sulfate precipitation; Lane 5 is the fraction from the S200 column, Lane 6 is the 
concentrated fraction from the S200 column. 
 
The UV-visible spectrum of a sample of purified PfKMO* was obtained after each 
purification and the concentration determined using the known molar absorption coefficient 
of PfKMO at 450 nm. 
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 The concentration of the sample could then be adjusted as required, 
with protein used in crystallographic trials concentrated to 240 μM before storage at -20 ºC. 
 
Figure 3.7: A typical UV-visible spectrum of a PfKMO* sample. The FAD cofactor absorbs at 
450 nm with a molar absorption coefficient of 12300 M-1cm-1 allowing determination of the 
concentration of PfKMO*. This sample has a concentration of 30.7 μM. 
 
 
3.3 Kinetic analysis of novel GM compounds 
 
A final series of GM inhibitor compounds (Figure 3.4) were assayed with PfKMO* using the 
method described in Section 2.5.3. All of the compounds investigated were expected to be 
good inhibitors of PfKMO* as they had 3,4-dichloro substitution on the aromatic ring which 
binds close to the isoalloxazine ring which has shown to be important for potent inhibition. 
These compounds have different substituents on the aromatic ring furthest from the active 




importance of interactions between this moiety of the inhibitor and the residues of the         
C-terminal domain of the protein. 
 
Compound Name R 
GM862 3-OMe, 4-OH 
GM843 3-OH, 4-OMe 
GM849 3-OCH2CO2Me, 4-OMe 
GM855 3-OCH2CO2Et, 4-OMe 
GM859 3-OSO2NH2, 4-OMe 
Figure 3.8: General structure of inhibitors with a table listing the substituents of each 
inhibitor compound. 
 
The inhibition assay monitored the formation of NADP
+
 by measuring the decrease in 




 at this 
wavelength. In the absence of L-kynurenine, no formation of NADP
+
 was observed, 
indicating that these inhibitors are not effector molecules. The change in absorption at 340 
nm was measured in the presence of different concentrations of each inhibitor and               
L-kynurenine. From this data it was possible to determine an approximate Ki value using a 
Dixon plot (Figure 3.5). 
 
Figure 3.9: Dixon plot of the inhibition assay with PfKMO* and GM843. The data show the 
reciprocal rate observed with different concentrations of both GM843 and L-kynurenine. A 
line of best fit is fitted to the data points for each L-kynurenine concentration. The lines 
intersect where x = -Ki. 
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To determine the type of inhibition behaviour for each compound assayed with PfKMO*, the 
L-kynurenine concentration divided by the rate ([L-kynurenine/v] was plotted against the 
inhibitor concentration (Figure 3.10). Parallel lines plotted for data points at each 




Figure 3.10: Graph of [L-kynurenine]/v against [GM843]. The parallel lines as seen above 
are indicative of competitive inhibition. 
 
To obtain a more accurate Ki value, the inhibition assay results were analysed using 
simultaneous non-linear regression analysis methods in GraFit 3.0 (Erithacus Software), 
from which the Ki value was obtained for each compound (Table 3.3). 
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 The graphical 
output from this program, together with the Dixon plots, is given in full for each compound 
in Appendix 3. 
Compound Name R substituent Ki value (nM) 
GM862 3-OMe, 4-OH 82.4 ± 10.0 
GM843 3-OH, 4-OMe 73.3 ± 9.7 
GM849 3-OCH2CO2Me, 4-OMe -13.0 ± 8.9 * 
GM855 3-OCH2CO2Et, 4-OMe 19.8 ± 8.7 
GM859 3-OSO2NH2, 4-OMe 61.0 ± 12.8 
Table 3.3: Ki assay results for final series of GM compounds. Values were calculated using 
GraFit with explicit weighting.  
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* The value obtained in GraFit for GM849 is a negative value. The reason for this is likely to 
be that the Ki value is very low and there may be some error so perhaps the program is 
unable to calculate a possible value. The value obtained for GM849 without weighting is 
47.7 ± 7.8 nM. 
While all the compounds in this series are potent inhibitors with Ki values in the nanomolar 
range, the more potent compounds are those with larger substituents at the meta position as 
can be seen comparing GM843 with GM859, GM849 and GM855. However, from the 
earlier data GM760 and GM769 have very similar Ki values showing that the large 
substituent could be at either the meta or para position. This trend suggests that a large 
substituent is required for the most potent inhibitors but its role is in disruption of the 
interactions between the C-terminal domain and the main domain of the protein. The identity 
of the large substituent does affect the potency observed as seen in the difference between 
the Ki value observed for GM859 and those of GM769, GM760, GM849 and GM855. The 
sulfonamide substituent present in GM859 results in a less potent inhibitor than the esters or 
phosphate esters.   
 
 
3.4 Structure of PfKMO* with GM862 
 
Crystals of PfKMO* with GM862 (Figure 3.11) bound in the active site were grown using 
sitting drop vapour diffusion at 4 ºC. The drop was set up in a Greiner Bio-One 
CrystalBridge™ and consisted of a 1:1 mixture of 240 μM PfKMO* and well solution. The 
bulk well solution contained 0.1 M HEPES buffer pH 7.0, 12% PEG 4K, 6% glycerol, 10 
mM sodium tartrate and 10% isopropanol. An aliquot of the bulk well solution, 
supplemented with 1 mM GM862, was used in setting up the drops as the inhibitor was not 
added to the bulk solution in order to minimise the amount of inhibitor used at this stage. 
The crystal was cryoprotected by adding 1 μl ethylene glycol directly to the drop before it 
was flash-frozen in liquid N2. The data were collected on the i04 beamline at the Diamond 
Light Source, Oxfordshire. The images were collected with an oscillation of 0.2º with a total 





Figure 3.11: Structure of GM862 
 
The diffraction images were processed using iMosflm and Scala as described in Section 
2.7.4. The space group was found to be P6122 and the resolution of the structure is 1.98 Å 
with Rmerge of 0.213 (0.606 in the highest resolution shell). The unit cell dimensions were 
determined to be a = b = 117.0 Å, c = 418.1 Å with angles of α = β = 90º, γ = 120º. The very 
large dimensions of the unit cell, particularly side c, resulted in small spot separation, which 
initially resulted in unsuccessful data processing. This was overcome by fixing the value of 
the mosaicity at 0.07 throughout processing in iMosflm, but this decreased value of the 
mosaicity could be responsible for the relatively high value of Rmerge in the highest resolution 
shell. There were three PfKMO* monomers in the asymmetric unit, each with one FAD 
cofactor bound non-covalently, one GM862 molecule was present in the active site of each 
PfKMO* and 483 waters were found in the asymmetric unit.  
The model of the GM862 bound structure was obtained using Molrep for molecular 
replacement with a previously obtained PfKMO* inhibitor bound structure as a model. The 
structure was refined using Refmac5 and manually edited in Coot. The final Rfactor was 
0.2183 and the Rfree was 0.2561 (full data processing statistics are in Appendix 2 Table 
A2.1). The structure of PfKMO* with GM862 bound was highly similar to that of PfKMO* 
with GM303 with few differences (Figure 3.12) except that the residues of the loop from 
M373 leading to the C-terminal domain were not found in the GM862 bound structure and 




Figure 3.12: Representation of the structure of PfKMO* Chain B (green) with GM862 
(orange) with FAD cofactor (yellow) aligned with PfKMO* (cyan) with GM303 (pink) with 
FAD cofactor (pink). Residues 374 – 379, which form the loop between the main domain 
and the C-terminal domain, are all absent in the structure of PfKMO* with GM862. 
 
The differences in the structure of PfKMO* with GM862 bound in the active site compared 
to that of PfKMO* with L-kynurenine are consistent with those observed previously with 
other of these novel inhibitor compounds. 
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 The 3,4-dichloro substituted ring binds in close 
proximity to the isoalloxazine moiety of the FAD cofactor but the other aromatic ring 
extends out of the active site causing significant conformational change including disruption 
of the interactions important for the closed conformation to occur, resulting in movement of 
the C-terminal domain to the open conformation (Figure 3.13). The structure of PfKMO* 






Figure 3.13: Comparison of the structures of PfKMO* with GM862, Chain B (green) and 
those of PfKMO* in the presence of L-kynurenine (lilac) and PfKMO* in the absence of 
substrate (cyan). The position of the C-terminal domain of PfKMO* with GM862 is similar to 
the open conformation observed in the structure of PfKMO* in the absence of substrate. 
 
 rmsd (Å) 
PfKMO* with no substrate (Chain A) 1.11 
PfKMO* with L-kynurenine 1.56 
PfKMO* with GM303 (Chain A) 0.24 
Table 3.4: The rmsd values obtained in a pairwise comparison of PfKMO* with GM862 
bound Chain A with other PfKMO* structures. The comparison was made using the protein 
structure comparison service PDBeFold at European Bioinformatics Institute 
(http://www.ebi.ac.uk/msd-srv/ssm), authored by E. Krissinel and K. Henrick. 178 
 
The GM862 ligand was prepared using the PRODRG server to generate three-dimensional 
PDB coordinates and a library file from the two-dimensional structure of the ligand and was 
added to the structure using Coot to position it in the active site. The electron density for the 
position of the 3,4-dichloro substituted ring and the heterocycle was clear in all three of the 
PfKMO* monomers allowing for easy positioning of this part of the molecule into the 
model. Electron density that could accommodate the amide was also seen in all three chains 
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but there was little electron density for the 3-OMe, 4-OH substituted aromatic ring. After 
refining the model in the absence of GM862 to view the omit map, it was not possible to 
locate the 3-OMe, 4-OH substituted aromatic moiety in any of the three chains so a partial 
GM862 was modelled into the electron density (Figure 3.14).  
In Chain A, there is the clearest suggestion of unmodelled density in close proximity to 
Y404 that may be caused by the presence of this ring but the evidence is not sufficiently 
clear to allow the complete ligand to be modelled into the active site. The reason for this 
aromatic ring not being clearly visible in the Fo-Fc map could be that it is mobile and is able 
to rotate or that the inhibitor has been hydrolysed.  
 
Figure 3.14: Fo-Fc map (green, positive; red, negative) for PfKMO* Chain A with GM862 
bound. The isoalloxazine moiety of the FAD cofactor is shown to the right and Y404 to the 
left of GM862 as shown. The map is contoured at 3.00 σ. Similar maps were obtained for 
Chains B and C but with less unmodelled density close to Y404 than observed with Chain A. 
 
There are several residues within 4 Å of GM862 in the Chain B PfKMO* active site, some 
of which are likely to form interactions with the inhibitor including N369 and Y404 (Figure 
3.15). The carbonyl of GM862 is visible in all three protein chains and is oriented towards 
N369 in a potentially important interaction for ligand binding. The complete sidechain of 
E372 could not be observed in the electron density map so its exact orientation is not known. 
There are no residues likely to be in close proximity to the 3-OMe, 4-OH substituted 
aromatic ring except for Y404 and there is no obvious potential for interactions between the 







Figure 3.15: Residues in the active site of PfKMO* (green) with GM862 (orange) with the 
isoalloxazine moiety of the FAD cofactor (yellow). Some residues have been omitted for 
clarity. Distances between active site residues and GM862 are shown with values in Å. 
Residues Tyr404 and Asn369 are in close proximity with GM862 and the carbonyl of His320 
is within 4 Å of the heterocyclic moiety of GM862. The displacement of Arg84 away from 
the active site suggests that the other aromatic ring could be present although not 
observed in the electron density map. The whole of the Glu372 sidechain was not visible in 
the electron density map. 
 
In the previously solved structure of PfKMO* with GM347 bound in the active site, it was 
not possible to determine the position of this aromatic ring in any of the protein chains. 
GM347 is a very similar compound, but with 3,4-diOMe substitution rather than 3-OMe,    
4-OH substitution on the aromatic ring. In the structure of PfKMO* with GM347 the 
carbonyl is orientated towards N369, the same as is observed in all the protein chains in the 
structure of PfKMO* with GM862. The reason that this area of the molecule is not visible 
has not been determined but it could be the result of freedom of movement or hydrolysis or 
decomposition of the inhibitor resulting in a lack of unambiguous electron density in the map 






3.5 Structure of PfKMO* with GM849 
 
Crystals of PfKMO* with GM849 (Figure 3.16) bound in the active site were obtained by 
sitting drop vapour diffusion at 4 ºC. The sitting drop was set up in a Greiner Bio-One 
CrystalBridge™ and consisted of a 1:1 mixture of 240 μM PfKMO* and well solution. The 
bulk well solution contained 0.1 M HEPES buffer, pH 7.0, 14% PEG 4K, 6% glycerol,       
10 mM sodium tartrate and 10% isopropanol. GM849 was not added directly to the bulk well 
solution but was added to a small aliquot of well solution to a final concentration of 1 mM 
which was used to set up the drop, in order to minimise the amount used in crystallisation 
trials. The crystal was cryoprotected prior to flash-freezing in liquid N2 by adding 1 μl of 
ethylene glycol directly to the sitting drop. Data were collected on the i03 beamline at the 
Diamond Light Source, Oxfordshire. The images were collected with an oscillation of 0.2º 
with a total rotation of 120º with 0.2 s per image collected. The beam wavelength was 0.97 Å 
and intensity was 60%. 
 
Figure 3.16: Structure of GM849 
 
The diffraction images collected were processed using iMosflm and Scala as described in 
Section 2.7.4. The space group was found to be P6122 and the unit cell dimensions were a = 
b = 116.7 Å, c = 419.2 Å with the angles α = β = 90º, γ = 120º (data processing statistics are 
listed in Appendix 2, Table A2.1). The value of the mosaicity was fixed at 0.1 throughout 
processing in iMosflm because the large cell dimensions resulted in very small spot 
separation. The maximum resolution that could be obtained in Scala was 3.26 Å with Rmerge 
of 0.198 (0.421 in the highest resolution shell). Molecular replacement was carried out with 
Molrep using a previously solved inhibitor-bound structure of PfKMO* as a similar model. 
The asymmetric unit contained three molecules of PfKMO*, each with a non-covalently 
bound FAD cofactor. Only eight waters could be added to the model by Coot, probably due 
to the resolution. Rigid body and restrained refinement was carried out in Refmac5 and the 
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resulting Rfactor was 0.1904 and the Rfree was 0.2858. Due to the resolution of the structure, a 
number of the residue sidechains could not be added to the model completely as their 
orientation could not be accurately determined.  
The position of the entire GM849 ligand, prepared using the PRODRG server, could not be 
conclusively determined. In Chain B there is evidence in the Fo-Fc map for the presence of 
GM849 (Figure 3.17) although the position of the 3- OCH2CO2Me, 4-OMe substituted 
aromatic ring could not be determined. The carbonyl appears to be orientated in the same 
position as observed in the structure of PfKMO* with GM303 and not like that of PfKMO* 
with GM760, a hypothesis supported by the position of Y404, for which there is clear 
evidence in the 2Fo-Fc map.  
 
Figure 3.17: Fo-Fc map (green, positive; red, negative) contoured at 3.00 σ for the structure 
of PfKMO* with GM849 bound, Chain B with residues Y98 (top left) and Y404 (bottom left) 
visible. The structure was refined with no ligand in the model to create the omit map. A 
partial fragment of GM849 was then modelled into the positive region of the Fo-Fc map. 
This chain had the clearest evidence for the position of GM849, with the 3,4-dichloro 
substituted aromatic ring and the heterocyclic moiety in close proximity to the FAD 
cofactor. It was not possible to determine the position and orientation of the 3-
OCH2CO2Me, 4-OMe substituted aromatic ring in any of the three PfKMO* molecules in the 
asymmetric unit. 
 
In the other PfKMO* molecules in the asymmetric unit, the evidence for the position of 
GM849 was weaker (Figure 3.18) although it was possible in Chain C to observed some 






was not possible to determine the orientation of this ring. Due to the poor resolution of this 
structure, the evidence for the position of GM849 is weak and a higher resolution structure 
of PfKMO* with GM849 is required to provide more conclusive evidence. 
 
 
Figure 3.18: Fo-Fc maps (green, positive) for PfKMO* with GM849 in Chains A and C, both 
contoured at 3.00 σ. In Chain C, there is evidence for the 3,4-dichloro and heterocyclic 
moiety as well as some evidence for the other aromatic ring although not evidence to 
accurately determine its position. There is no clear evidence for the position of the carbonyl 
of GM849 in this chain although Y404 (to the left of GM849) can be positioned accurately 
which suggests that the carbonyl is orientated in the direction of N369 otherwise it is too 
close to the hydroxyl group of Y404. In Chain A there is considerably less evidence for the 
position of GM849 and only a smaller fragment of GM849 could be modelled into the active 
site of PfKMO*.  
 
The overall structure was similar to that of PfKMO* with GM303 with no major 
conformational changes observed as a result of GM849 binding (Table 3.5). There are slight 
differences between the two structures and there may be differences in the positions of 
GM849 and GM303 but a higher resolution structure of PfKMO* with GM849 will be 







 rmsd (Å) 
PfKMO* (no ligand) (Chain A) 1.04 
PfKMO* with L-kynurenine 1.46 
PfKMO* with GM303 (Chain A) 0.48 
Table 3.5: The rmsd values obtained in a pairwise comparison of PfKMO* with GM849 
bound Chain A with other PfKMO* structures. The structure of PfKMO* with GM849 is most 
similar to that of PfKMO* with GM303 and least similar to that with L-kynurenine bound, a 
structure in which PfKMO* is in the closed conformation. The comparison was made using 
the protein structure comparison service PDBeFold. 178 
 
 
3.6 Structure of PfKMO* with GM859 
 
Crystals of PfKMO* with GM859 (Figure 3.19) bound in the active site were obtained by 
sitting drop vapour diffusion at 4 ºC. The drop was set up in a Greiner Bio-One 
CrystalBridge™ and consisted of a 1:1 mixture of 240 μM PfKMO* and well solution. The 
well solution consisted of 0.1 M HEPES buffer pH 7.0, 14% PEG 4K, 6% glycerol, 10 mM 
sodium tartrate and 10% isopropanol. GM859 was not added directly to the bulk well 
solution but was added to a small aliquot of well solution to a final concentration of 1 mM 
which was used to set up the drop to minimise the amount of GM859 used in crystallisation 
trials. The crystal was cryoprotected by adding 1 μl ethylene glycol directly to the drop and 
the crystal was flash-frozen in liquid N2. Data were collected on the i04 beamline at the 
Diamond Light Source, Oxfordshire. The images were collected with an oscillation of 0.2º 
with a total rotation of 120º with 0.2 s per image collected. The beam wavelength was 0.979 
Å and intensity was 65.12%. 
 
Figure 3.19: Structure of GM859 
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The diffraction images collected were analysed as described in Section 2.7.4 using iMosflm 
and Scala. The unit cell was found to have dimensions of a = 117.0, b = 117.0, c = 419.2 Å 
with angles α = β = 90º, γ = 120º and the space group was P6122. The extremely large unit 
cell resulted in extremely small spot separation so the mosaicity was fixed at 0.07 to achieve 
successful processing of the data. The resolution was determined to be 2.6 Å and the Rmerge is 
0.224 overall but 0.543 for the highest resolution shell (data processing statistics are listed in 
Appendix 2 Table A2.1).  
Molecular replacement was carried out with Molrep using a model of an inhibitor bound 
structure that had been solved in previous work. There were three protein monomers in the 
asymmetric unit, each with one non-covalently bound FAD cofactor and one GM859 
molecule bound and 425 water molecules were identified. Refinement was carried out in 
Refmac5 and Coot was used to inspect how the model fitted the map. The final value of Rfree 
was 0.2025 and the Rfactor was 0.2628. The GM859 ligand was added to the model after it 
had been prepared by submitting a two-dimensional version of the structure to the PRODRG 
server to generate the three-dimensional PDB coordinates and the .cif library file. 
The structure of PfKMO* with GM859 bound consists of the main domain of the protein and 
the C-terminal domain and is very similar to the structure of PfKMO* with GM303 bound in 
the active site. The C-terminal domain is moved away from the main domain of the protein 
in the open conformation to accommodate the large GM859 which is bound partially in the 
active site consistent with other structures of PfKMO* with related inhibitor compounds 
with the structure of PfKMO* with GM859 being more similar to the structure of PfKMO* 
in the absence of ligand than that of PfKMO* with L-kynurenine (Table 3.6). The ligand can 
be observed with the 3,4-dichloro substituted aromatic ring located in close proximity to the 
isoalloxazine ring of the FAD cofactor. 
 rmsd (Å) 
PfKMO* (no ligand) (Chain A) 1.00 
PfKMO* with L-kynurenine 1.49 
PfKMO* with GM303 (Chain A) 0.39 
Table 3.6: The rmsd values obtained in a pairwise comparison of PfKMO* with GM859 
bound Chain A with other PfKMO* structures. The comparison was made using the protein 




The electron density map contained a large unoccupied volume of density located partially 
within the active site, into which GM859 was modelled prior to further refinement (Figure 
3.20). GM859 could easily be modelled into this density which contained the 3,4-dichloro 
aromatic ring in close proximity to the isoalloxazine moiety of the FAD cofactor and the 
other aromatic ring extending out beyond the active site. The electron density for the 
sidechain of Y404 is also clear and shows the aromatic ring of this residue close to one of the 
aromatic rings of GM859.  
 
Figure 3.20: Fo-Fc map (green, positive; red, negative) for PfKMO* (cyan) with GM859 
(purple) after refinement in Refmac5 with no ligand modelled in the active site. The whole 
of GM859 was then modelled into the active site. The sidechain of Y404 can be seen above 
GM859 in this view. The map is contoured at 3.06 σ. 
 
Potential interactions between PfKMO* and GM859 can be observed in the structure which 
are likely to contribute to the strong binding of GM859 observed in kinetic analysis as the Ki 
value is 61.0 ± 12.8 nM. The sulfonamide group of GM859 (Figure 3.21) is located out of 
the active site and appears to be sufficiently close to interact with the hydroxyl groups of 
E372, potentially forming hydrogen bonds with this residue. Y404 is also in close proximity 
to GM859 with the hydroxyl group of this residue 3 Å distant from the amide nitrogen. The 
position of this aromatic ring may potentially allow for a π-stacking interaction. The 







Figure 3.21: GM859 (pink) in the active site of PfKMO* (green). The 3,4-dichloro substituted 
aromatic ring is in close proximity to the FAD cofactor (yellow). The sulfonamide 
substituent appears to be interacting with Glu372. The amide carbonyl is approximately   
3.5 Å from Asn369 and the amide nitrogen is 3.0 Å from the hydroxyl group of Tyr404. The 
heterocycle is within 4 Å of the carbonyl of His320. All distances indicated in the figure are 
in Å. 
 
The structure of PfKMO* with GM859 bound is very similar to that of the PfKMO* with 
GM303 bound, a structure obtained in previous work. 
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 The active sites of these two 
PfKMO*: inhibitor complexes show the residues in almost exactly the same positions which 
shows that the sulfonamide group can be incorporated into the available space without 
disruption to the structure of PfKMO* (Figure 3.22). It is likely that the interactions between 
the sulfonamide of GM859 and E372 are an important contribution to the lower Ki observed 




Figure 3.22: Comparison of residues in the active site of PfKMO* (green) with GM859 (light 
pink) with FAD cofactor (yellow) with those in the structure of PfKMO* (cyan) and GM303 
(bright pink) and FAD cofactor (orange). Some of the active site residues have been omitted 
for clarity.  
 
The other mode of binding observed in previous work with these novel inhibitors (Section 
3.1) is seen with compounds with large substituents such as GM760, which has a phosphate 
group that cannot be accommodated in the space near E372. This results in a change in the 
orientation of the inhibitor, starting at the amide group and resulting in the aromatic ring 
outside of the active site displacing Y404. As GM859 also has a large substituent on the 3´ 
position of the aromatic ring, it was considered possible that it might bind in the same 
orientation as GM760; however, the sulfonamide substituent is located close to the helix 
containing E372. It is possible that this substituent on the aromatic ring of GM859 is one of 
the largest that can be accommodated sterically at this location and that any larger 







This novel series of inhibitor compounds is based on the structure of Ro 61-8048, but in 
assays with PfKMO* have shown greater potency and do not contain the potentially toxic   
3-NO2 substituent observed in Ro 61-8048. In the absence of substrate, no consumption of 
NADPH by PfKMO* could be observed in the presence of these inhibitors, demonstrating 
that these are true inhibitors rather than non-substrate effector molecules.  
In this work, a small series of inhibitors was assayed against PfKMO* to investigate the 
effect of substitution on an aromatic ring that has been shown not to fit completely within the 
active site.  All the inhibitors in this series were potent and the Ki values were determined to 
be below 100 nM suggesting that the substitution on this ring is not critical for inhibition. 
The trend in the values obtained suggested that large substituents result in particularly potent 
inhibitors, particularly GM855. The structure of PfKMO* with GM862 showed that the 3,4-
dichloro-substituted aromatic ring binds in the active site in close proximity to the 
isoalloxazine moiety of the FAD cofactor but no electron density for the aromatic ring of 
GM862 located out of the active site was observed in the omit map. This could be the result 
of flexibility in this part of the ligand as this structure is similar to those of PfKMO* with 
GM303 and GM347 from previous work with R84 displaced away from the active site and 
the C-terminal domain is in the open conformation. The structure of PfKMO* with GM859 
did contain the complete structure of the ligand and showed the inhibitor binding in a similar 
position and orientation to GM303 but with a potential interaction between the sulfonamide 
substituent and E372 that is likely to contribute to the lower Ki value obtained for GM859. 
From the structure of PfKMO* with GM859, a schematic of GM859 binding in the active 
site illustrating the effect of inhibitor binding on the position of active site residues and the 
likely interactions formed between the inhibitor and PfKMO* resulting in potent inhibition 
(Figure 3.23).  
The other inhibitors studied in this thesis are likely to bind in a similar position, preventing 
the closed conformation from occurring, with PfKMO* remaining in the open conformation 
when the inhibitors are bound in the active site. This is likely to be the main reason, rather 
than a specific interaction, why these inhibitors are not effectors like m-nitrobenzoylalanine 
and 3,4-dichlorobenzoylalanine. The previously studied effector molecules are smaller 
molecules that would be able to fit within the active site environment therefore allowing the 
closed conformation to occur. The inability of PfKMO* to be in the closed conformation 
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when these novel inhibitors are bound could prevent the reduction of the FAD cofactor by 
NADPH. The series of novel inhibitors studied in this work are all larger molecules that 
extend beyond the active site displacing R84 and prevent the formation of interactions 
between R84, E372 and the C-terminal domain residues Y382 and R386 that are 
hypothesised to be necessary for the closed conformation to occur. 
 
Figure 3.23: Schematic view of GM859 in the active site of PfKMO*. When GM859 binds, 
the 3,4-dichloro substituted aromatic ring binds in the active site in a similar position and 
orientation to the aromatic ring of L-kynurenine in the substrate-bound structures. This 
inhibitor is large and forms interactions with active site residues including N369 and Y404. 
R84 is pushed downwards (in this perspective) away from the position it occupies in the 
structure of PfKMO* with L-kynurenine. This allows the sulfonamide moiety of GM859 to 
interact with E372, a residue implicated in control of the movement between the open and 
closed conformations. This also results in the C-terminal domain being unable to move 
closer to the active site to form the closed conformation due to the size of GM859, which 
extends beyond the active site. 
 
Unfortunately it was not possible to obtain the structure of PfKMO* with either GM843 or 
GM855 bound or a high resolution structure with GM849 resulting in some uncertainty over 
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the position of the aromatic rings of GM855 and GM849 which contain particularly large 
substituents and could be binding in the same mode as GM760. 
The series of compounds studied in this thesis are part of a larger group of compounds which 
contain particularly promising inhibitors including GM849, GM855, GM760 and GM769. In 
future work it would be particularly interesting to assay these inhibitors with human KMO to 
confirm that they inhibit the human enzyme and to identify potential lead compounds that 
could lead to the development of a drug that could be used for patients with conditions in 






Chapter 4: Characterisation of Substrate Binding 
 
 
4.1: Residues involved in substrate binding 
  
PfKMO* active site residues thought to be important in substrate binding were initially 
proposed from sequence analysis and then identified in the PfKMO* structure solved by M. 
Wilkinson. The roles of selected residues were investigated using site directed mutagenesis 
and then the resulting proteins were studied using steady-state kinetics and crystallography, 
thus allowing comparison with PfKMO*. 
From the L-kynurenine bound structure of PfKMO* a number of residues in close proximity 
to the substrate were identified as potentially interacting with it (Figure 4.1). The distances 
indicated in the figure are approximations due to the low resolution (3.4 Å) of this structure; 
however, it is clear that Y98 and N369 are sufficiently close to be involved in hydrogen 
bonding interactions and R84 appears to be interacting with the carboxylate moiety of         
L-kynurenine. Y404 could also potentially be involved in interacting with the carboxylate 
even though the distance in this model is approximately 4 Å from the hydroxyl group of 
Y404 to the substrate carboxylate, which is likely to be too far, even given the positional 




Figure 4.1: Residues in the active site of PfKMO* with FAD cofactor (yellow) and                   
L-kynurenine (cyan). Distances between L-kynurenine and some active site residues are 
indicated in Å. The carboxylate moiety of L-kynurenine could potentially interact with 
Arg84, Tyr98, Asn369 and Tyr404. The amine is 3.1 Å from the carbonyl of His320. The 
aromatic ring is in close proximity to the FAD cofactor. 
 
Most of the residues in the active site of PfKMO* are conserved in KMO enzymes from 
different species (Figure 4.2) with the exceptions of I106 and H320. The residues thought to 
be important in interactions with the substrate, including R84, Y404 and Y98, are conserved 
in all KMOs. 
S.cerevisiae       ------------------------------------------------------------ 
C.albicans         ------------------------------------------------------------ 
Homo sapiens       ------------------------------------------------------------ 
R. norvegicus      ------------------------------------------------------------ 
Drosophila         MFVATPLHLVGFPQQHQTTIDTIYCPSDIISWLNISPASCLASISIPSSFRCQRASRTVM 60 
PfKMO              ------------------------------------------------------------ 
Xant.sacchari      ------------------------------------------------------------ 
                                                                                
 
S.cerevisiae       ---MSES----------------------VAIIGAGLVGCLAALAFSKEGYNVTLYDFRQ 35 
C.albicans         ---MSEEESQKT-----------------IGIVGAGLVGCLAALAFAKKGYDVTLFEYRP 40 
Homo sapiens       ---MDSSVIQRK----------------KVAVIGGGLVGSLQACFLAKRNFQIDVYEARE 41 
R. norvegicus      ---MASSDTEGK----------------RVVVIGGGLVGALNACFLAKRNFQVDVYEARE 41 
Drosophila         SPGIVSQEVNGRQEPTEAARDERHGRRRRVAVIGAGLVGSLAALNFARMGNHVDLYEYRE 120 
PfKMO              ---MTATDNA-----------------RQVTIIGAGLAGTLVARLLARNGWQVNLFERRP 40 
Xant.sacchari      ---MNASP-------------------RSITLIGAGLAGSLLAILLSRQGWQVTVYERRG 38 
                      :                         : ::*.**.* * *  ::: . .: ::: *  
 
S.cerevisiae       DPRLDTTKNKNLKSINLAISARGIDALKSIDPDACEHILQDMIPMKGRMIHDLKG-RQES 94 
C.albicans         DPRTVDSSKRNLRSINLAVSSRGIRALQYVDPAMADRILENVIPMKGRMIHDITGTKQES 100 
Homo sapiens       DTRVATFTRG--RSINLALSHRGRQALKAVG--LEDQIVSQGIPMRARMIHSLSG-KKSA 96 
R. norvegicus      DIRVANFMRG--RSINLALSYRGRQALKAVG--LEDQIVSKGVPMKARMIHSLSG-KKSA 96 
Drosophila         DIRQALVVQG--RSINLALSQRGRKALAAVG--LEQEVLATAIPMRGRMLHDVRG-NSSV 175 
PfKMO              DPRIETGARG--RSINLALAERGAHALRLAG--LEREVLAEAVMMRGRMVHVPGT-PPNL 95 
Xant.sacchari      DPRVHDYERG--RSINLALAERGLHVLRQAG--ADAAVMAKAVMMRGRMVHFADG-HQQL 93 
                   * *     .   :*****:: **  .*   .      ::   : *:.**:*       .  
 
S.cerevisiae       QLYG-LHGEAINSINRSVLNNSLLDELEKS-TTELKFGHKLVKIEWTDDKQICHFAIGED 152 
C.albicans         QVYG-LNGESINSIDRSFLNNCLLDELDKS-NVKILFKHKLVKLDTSN---ACRMTFIDG 155 
Homo sapiens       IPYG-TKSQYILSVSRENLNKDLLTAAEKYPNVKMHFNHRLLKCNPEE----GMITVLGS 151 
R. norvegicus      IPYG-NKSQYILSISREKLNKDLLTAVESYPNAKVHFGHKLSKCCPEE----GILTMLGP 151 
Drosophila         VLYDPINNQCLYSVGRRQLNEVLLNACDKLPNIRCHFEHKLTSANLRE----GSMEFRNP 231 
PfKMO              QPYGRDDSEVIWSINRDRLNRILLDGAEAA-GASIHFNLGLDSVDFAR----QRLTLSNV 150 
Xant.sacchari      QRYGRDDSEVIWSVHRNDLNITLLQLAEQA-GARIHFYRRLHTVDFDAG---YARFIDDR 149 
                     *.  ..:   *: *  **  **   :        *   * .             .    
 
S.cerevisiae       LKAPHTEKYDFVIGCDGAYSATRSQMQRKVEMDFSQEYMNLRYIELYIPPTEEFKPNYGG 212 
C.albicans         HNDAKTSTFDFVVGCDGAHSQFRYHLQKTMRMDYSQKYIDMQYLELYIPPSEDAN----N 211 
Homo sapiens       DKVPKDVTCDLIVGCDGAYSTVRSHLMKKPRFDYSQQYIPHGYMELTIPP-------KNG 204 
R. norvegicus      NKVPRDITCDLIVGCDGAYSTVRAHLMKKPRFDYSQQYIPHGYMELTIPP-------KNG 204 
Drosophila         AKEAVAAHADLIVGCDGAFSSVRQXXVRLPGFNYSQEYIETGYLELCIPS-------KSG 284 
PfKMO              SGERLEKRFHLLIGADGCNSAVRQAMASVVDLGEHLETQPHGYKELQITP------EASA 204 
Xant.sacchari      DDQPHDIRFDSMIGADGAGSALRAAMQRKAPMAEHIEFLDHSYKELEIPP------GADG 203 
                            . ::*.**. *  *        :    :     * ** *..           
 
S.cerevisiae       NFAIAPDHLHIWPRHKFMLIALANSDGSFTSTFFGSKD---------QISDLITSKSRVR 263 
C.albicans         KFSIDANHLHIWPRHNFMLIALANKDGSFTSTFFSPWS---------VIEGISSSQE-FV 261 
Homo sapiens       DYAMEPNYLHIWPRNTFMMIALPNMNKSFTCTLFMPFE---------EFEKLLTSND-VV 254 
R. norvegicus      EYAMEPNCLHIWPRNAFMMIALPNMDKSFTCTLFMSFE---------EFEKLPTHSD-VL 254 
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Drosophila         DFQMPANYLHIWPRNTFMMIALPNQDKSFTVTLSMPFE---------IFAGIQNQND-LL 334 
PfKMO              QFNLEPNALHIWPHGDYMCIALPNLDRSFTVTLFLHHQSPAAQPASPCFAQLVDGHA-AR 263 
Xant.sacchari      GFRIEANALHIWPRGHYMCIALPNHEGTFTVTLFLPNK------GEPSFATVRNGEE-AL 256 
                    : : .: *****:  :* ***.* : :** *:    .          :  :         
 
S.cerevisiae       EFLIKNFPDIINIMDLDDAVKRFITYPKESLVCVNCKPYDVPGGKAILLGDAAHAMVPFY 323 
C.albicans         EFFRHNFPDAVGLIGEDALSSAFKSNPRGSLMQVSCYPYSN--GKGIILGDAAHSMVPFY 319 
Homo sapiens       DFFQKYFPDAIPLIGEKLLVQDFFLLPAQPMISVKCSSFHFK-SHCVLLGDAAHAIVPFF 313 
R. norvegicus      DFFQKNFPDAIPLMGEQALMRDFFLLPAQPMISVKCSPFHLK-SRCVLMGDAAHAIVPFF 313 
Drosophila         EFFKLNFRDALPLIGEQQLIKDFFKTRPQFLVSIKCRPYHYA-DKALILGDAAHAMVPYY 393 
PfKMO              RFFQRQFPDLSPMLD--SLEQDFEHHPTGKLATLRLTTWHVG-GQAVLLGDAAHPMVPFH 320 
Xant.sacchari      ALFARDFADALPLMP--QLAEHWEQHPPGLLGTLRLERWHLG-GRAVLLGDAAHAMVPFH 313 
                    ::   * *   ::        :       :  :    :    .: :::*****.:**:. 
 
S.cerevisiae       GQGMNCGFEDVRILMALLKKHSGDRSRAFTEYTQTRHKDLVSITELAKRNYKEMSHDVTS 383 
C.albicans         GQGMNCGFEDVRILMELIDTNNGDIEEAFKQYSAARKDDLDAICKLALDNYYEMSSKVVD 379 
Homo sapiens       GQGMNAGFEDCLVFDELMDKFSNDLSLCLPVFSRLRIPDDHAISDLSMYNYIEMRAHVNS 373 
R. norvegicus      GQGMNAGFEDCLVFDELMDKFNNDLSVCLPEFSRFRIPDDHAISDLSMYNYIEMRAHVNS 373 
Drosophila         GQGMNAGMEDVTLLTDILAKQLP-LDETLALFTESRWQDAFAICDLAMYNYVEMRDLTKR 452 
PfKMO              GQGMNCALEDAVALAEHLQSAAD-NASALAAFTAQRQPDALAIQAMALENYVEMSSKVAS 379 
Xant.sacchari      GQGMNCAFEDCAALAAHLQREPD-LARAYAAFEAERKPNAGAIQQMALENYVEMRDRVGD 372 
                   *****..:**   :   :             :   *  :  :*  ::  ** **   .   
 
S.cerevisiae       KRFLLRKKLDALFSIIMKDKWIPLYTMISFRSDISYSRALERAGKQTRILKFLESLTLGM 443 
C.albicans         IGYLIKKKLDYTLGKIFKNKWLPLYTMISFRDDIPYAKAIEIEKRQNRIMNNVGLGVLGT 439 
Homo sapiens       SWFIFQKNMERFLHAIMPSTFIPLYTMVTFSR-IRYHEAVQRWHWQKKVINKGLFFLGSL 432 
R. norvegicus      RWFLFQRLLDKFLHALMPSTFIPLYTMVAFTR-IRYHEAVLRWHWQKKVINRGLFVLGSL 432 
Drosophila         WTFRLRKWLDTLLFRLFPG-WIPLYNSVSFSS-MPYRQCIANRKWQDQLLKR-IFGATFL 509 
PfKMO              PTYLLERELGQIMAQRQPTRFIPRYSMVTFSR-LPYAQAMARGQIQEQLLKFAVANHSDL 438 
Xant.sacchari      AGFLLQRELGQALQARHPTRFVPHYTMVTFLR-TPYAQALERSEVQRDILVQATQGHSDL 431 
                     : :.: :   :       ::* *. ::*     * ..:     *  ::           
 
S.cerevisiae       LSIGG-YKLFKFLTRERS------------------------------------ 460 
C.albicans         AAVYGLVKLGQYWNRRQ------------------------------------- 456 
Homo sapiens       IAISSTYLLIHYMSPRSFLCLRRPWNWIAHFRNTTCFPAKAVDSLEQISNLISR 486 
R. norvegicus      VAIGSAYILVHHLSPRPLELLRSAWTGTSGHWN------RSADISPRVP--WSH 478 
Drosophila         AAIVTG----GAIYAQRFL----------------------------------- 524 
PfKMO              TSINLDAVEHEVTRCLPPLSHLC------------------------------- 461 
Xant.sacchari      SRIDWSWLERIVHARLAPLEGAH------------------------------- 454 
                     :                                                    
 
Figure 4.2: Alignment of KMO sequences generated using ClustalW. The highlighted 
residues are those with any atoms within 5 Å of L-kynurenine in the structure of PfKMO* 
with yellow indicating those that are conserved in all of these sequences and residues that 
are not conserved are highlighted in red. Residues aligned with PfKMO* H320 have a lesser 
degree of conservation across species than other active site residues. Sequences were 
obtained using BLAST. The accession numbers and UniProt codes respectively are 
Saccharomyces cerevisiae AJP85738.1, A0A0C5LRM7; Homo sapiens (human) CAA73613.1, 
O15229; Drosophila melanogaster AAC47351.1, A1Z746; Rattus norvegicus NP_067604.1, 
O88867; Candida albicans P87 KGU09898.1, A0A0A4AF15; Xanthomonas sacchari 
WP_043092154; A0A0A8DT66.  
 
A comparison of the active site of PfKMO* with that of S. cerevisiae KMO is useful as this 
structure (with the inhibitor UPF 648 bound) has a much higher resolution (2.14 Å) and can 





 A number of the residues in the active sites are not shown in this figure for 
clarity but these residues (I106, L213, I224, L226, P318, F319 using the PfKMO* sequence 
for labelling) are in almost exactly the same position and orientation in both structures.  
 
Figure 4.3: Some of the PfKMO* active site residues (green) with FAD cofactor (yellow) and 
L-kynurenine (orange) are shown with S. cerevisiae KMO residues (cyan) with FAD cofactor 
(yellow) and UPF 648 (magenta). For clarity, only the PfKMO* residues are labelled. 
Residues Arg84, Tyr98, Met222 and Phe238 are shown to be in very similar positions and 
orientations as the equivalent residues in the S. cerevisiae structure. Constructed using PDB 
4J36 and PfKMO* with L-kynurenine bound. 142,143 
 
The two active sites have many similarities including the position of the isoalloxazine moiety 
of the FAD cofactors and also residues R84 and Y98, both of which appear to be important 
in L-kynurenine/UPF 648 binding. As the S. cerevisiae KMO enzyme is disordered from 
residue 359 onwards when UPF 648 is bound and truncated at residue 394, there is no 
equivalent of the potential interactions between N369, M373 or Y404 and L-kynurenine 
observed in the PfKMO* structure. 
142
 The main difference between the two structures is in 
the position of H320 in PfKMO* and Y323 in S. cerevisiae KMO. The position of Y323 in 
S. cerevisiae KMO changes when ligand binds in the active site (Figure 1.17).  
The mutations R83K and R83A (R83 is the equivalent residue to R84 in the S. cerevisiae 
enzyme) have been made in S. cerevisiae KMO and are reported to be inactive, which would 





Therefore it would be interesting to examine R84 in PfKMO* as from the structures of 
PfKMO* it is thought that this residue interacts both with the substrate and with N369, and is 
important in the movement of the C-terminal domain upon substrate binding. 
143
  
In the structure of PfKMO* in the absence of substrate, small conformational changes are 
observed depending on the crystallisation conditions (Figure 4.4). In the presence of NaCl, 
the chloride anions bind to the protein close to the FAD cofactor and residues F319 and 
H320 resulting in conformational changes that cause two regions of the structure to resemble 
the structure in the presence of L-kynurenine. These are the loop from I44 – N54 which is 
not present in the structure in the absence of substrate crystallised using sodium tartrate 
rather than NaCl. In the structure with NaCl and no substrate, the loop is present and the 
residues are in a similar position to those in the structure of PfKMO* in the presence of       
L-kynurenine. The other change is from Y370 where the end of the helix resembles that of 
the  L-kynurenine bound structure, there is a flexible loop region from S375 – S379 in a 
different position than either of the other PfKMO* structures and from P380 onwards the 
residues are the same as in the structure in the absence of both substrate and NaCl. This is a 
mix of features observed in the closed and open conformations even though no L-kynurenine 
is bound. 
143
 Most of the substrate-free structures obtained in this work were crystallised in 
the presence of NaCl and the significance of these conformational changes were only 
realised at a later date; however, valuable insights into the effects of the mutations on the 
structure of PfKMO* were still gained. 
In this chapter three active site residues were investigated to characterise important 
interactions between L-kynurenine and PfKMO*. Y404 was investigated using the mutations 
Y404F and Y404A to ascertain whether this residue forms a hydrogen bond with the 
substrate. N369 was investigated using the conservative mutation N369S to examine the 
effect of this residue on binding. R84 was investigated with the conservative mutation R84K 
and also with R84A which was considered likely to cause major disruption to enzyme 





Figure 4.4: An overlay of the structure of PfKMO* in the absence of substrate (lilac) with 





In the active site of PfKMO* with L-kynurenine bound, it is possible that Y404 could be 
involved in a hydrogen bonding interaction with the carboxylate moiety of L-kynurenine but 
this interaction is uncertain as the distance over which this interaction would occur is 
approximately 4 Å, while a hydrogen bond would not normally be expected to be longer than 
~3 Å. The two mutations made to study this residue are Y404A and Y404F which will 
confirm whether there is an interaction between Y404 and L-kynurenine and determine the 





4.2.1 Y404A PfKMO* 
The mutation Y404A was made using QuikChange II PCR methods (sequence data in 
Appendix 1) and Y404A PfKMO* protein was expressed and purified using the methods in 
Chapter 2. The UV-visible absorbance scan of the protein is typical for PfKMO* and 
indicates that the FAD cofactor is bound (Figure 4.5). The protein was not sufficiently active 
for determination of the KM and kcat values using the kinetic assay described in Section 2.5.2 
which suggests that this residue is important for enzyme function although this does not 
provide any specific conclusions on the possible nature of the interaction of Y404 and the 
substrate.  
 
Figure 4.5: UV-visible spectrum of Y404A PfKMO*. The molar extinction coefficient, ε, of 
PfKMO* at 450 nm is 12300 M-1cm-1. The concentration of this sample is calculated to be 
27.6 μM.  
 
4.2.2 Kinetic analysis of Y404F PfKMO* 
The mutation Y404F was made using megaprimer PCR methods and the protein was 
expressed and purified as described in Chapter 2. A UV-visible scan of Y404F PfKMO* 




Figure 4.6: UV-visible spectrum of Y404F PfKMO*. The concentration of this sample is 8.8 
μM calculated from the PfKMO* molar extinction coefficient at 450 nm of 12300 M-1cm-1. 
 
The kinetic assay used to determine the kinetic parameters, KM and kcat (Section 2.5.2), was 
performed in triplicate and the parameters were determined using Origin 8.5.1 (Figure 4.7). 
 
Figure 4.7: Plot of turnover vs L-kynurenine concentration for Y404F PfKMO*. Data were 
fitted using the Michaelis-Menten equation.  
 
The L-kynurenine KM value determined for Y404F PfKMO* is an order of magnitude greater 
than that of PfKMO* confirming that the mutation has had an effect on substrate binding 
affinity, probably due to the loss of a hydrogen bond between Y404 and the carboxylate of 
the substrate (Table 4.1). The kcat value for Y404F PfKMO* is only slightly decreased 
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compared to that for PfKMO*. 
143
 These kinetic data therefore suggest that Y404 forms a 
hydrogen bond to the substrate and that the loss of this interaction is responsible for the 
increase in KM while kcat is unchanged. This implies that while Y404 is not required for the 
ability of PfKMO* to hydroxylate L-kynurenine, it is likely to be involved in substrate 
binding, suggesting that despite the apparent distance between the residue and L-kynurenine 
there is an interaction occurring. 







PfKMO*  8.8 ± 1.5 8.9 ± 1.1 1.01 
Y404F PfKMO* 96.5 ± 4.0 6.2 ± 0.1 0.06 
Table 4.1: The kinetic parameters, KM and kcat, and the catalytic efficiency determined for 
Y404F PfKMO* from the results of the assay described in Section 2.5.2 compared to those 
values obtained for PfKMO* in previous work. 143 
 
4.2.3 Structure of Y404F PfKMO* 
Crystals of Y404F PfKMO* were grown by hanging drop vapour diffusion at 4 ºC. The drop 
contained a 1:1 mixture of 240 μM Y404F PfKMO* and well solution. The well solution 
consisted of 0.1 M HEPES buffer pH 7.0, 10% PEG 4K, 8% glycerol, 10 mM NaCl, 10% 
isopropanol and 1 mM L-kynurenine. The crystal was cryoprotected by successive exposure 
to well solution containing 10% and then 20% ethylene glycol before it was flash-frozen in 
liquid N2. Data were collected on the i03 beamline at the Diamond Light Source, 
Oxfordshire. 
The diffraction images were processed using iMosflm and Scala as outlined in Section 2.7.4. 
The space group was fixed as P21221 as the first screw axis was not detected to a sufficiently 
high degree by POINTLESS. The unit cell dimensions are a = 103.6 Å, b = 133.8 Å, c = 
190.6 Å with angles α = β = γ = 90º. Molrep was used for molecular replacement with the 
structure of PfKMO* in the absence of substrate used to generate the model of the Y404F 
PfKMO* structure. The resolution of the structure was determined to be 2.7 Å with an 
overall Rmerge of 0.077 (data processing statistics listed in Appendix 2 Table A2.2). The 
asymmetric unit contained four Y404F PfKMO* molecules, each with one non-covalently 
bound FAD cofactor per monomer. There was no electron density for a ligand found in the 
active site of any of the protein chains. Three chloride anions were found, binding close to 
the FAD cofactor in Chains A, B and D and 152 water molecules were added to the model. 
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The Y404F PfKMO* structure was refined using Refmac5 and manually edited using Coot. 
After the final round of restrained refinement in Refmac5 the value of the Rfactor was 0.2154 
and Rfree was 0.2853.  
A comparison of the structures of Y404F PfKMO* and PfKMO* in the absence of substrate 
with and without NaCl (Table 4.2) shows that these structures are similar as expected as 
PfKMO* is in the open conformation in all three of these structures.  
 
 rmsd (Å) 
PfKMO* with NaCl and no substrate, Chain A 0.32 
PfKMO* with sodium tartrate and no substrate, Chain A 0.56 
PfKMO* with L-kynurenine 0.94 
Table 4.2: The rmsd values obtained in a pairwise comparison of Y404F PfKMO* Chain A 
with PfKMO* in the absence of substrate crystallised both in the presence and absence of 
NaCl and the structure of PfKMO* with L-kynurenine. The structure of Y404F PfKMO* was 
most similar to that of PfKMO* obtained in the absence of substrate with NaCl present in 
the crystallisation conditions. The comparison was made using the protein structure 
comparison service PDBeFold. 178 
 
At a resolution of 2.7 Å, most of the residue sidechains in Y404F PfKMO* were visible in 
the 2Fo – Fc density map and could be included in the structure. In the active site of Y404F 
PfKMO* many of the residues occupy similar positions to those in PfKMO* in the absence 
of substrate, with and without NaCl (Figure 4.8) although residues I106, I224 and L226 are 
not shown in the figure for clarity and the sidechains of I224 and L226 are not fully visible 






Figure 4.8: The residues in the active site and those close to residue 404 in the Y404F 
PfKMO* structure (green) overlaid with those in the PfKMO* structure in the absence of 
substrate (cyan) and PfKMO* with NaCl in the absence of substrate (lilac). 143 From this the 
differences between the structure of the active site of Y404F PfKMO* and PfKMO* that are 
unrelated to the presence of NaCl can be identified. These include a movement of Phe404, 
the backbone near His320 and Arg84. Some of the active site residues including Ile106, 
Leu224 and Ile226 have been omitted for clarity. 
 
The differences in the positions and orientations of the active site residues of Y404F 
PfKMO* relative to PfKMO* in the absence of substrate that are due to the presence of 
NaCl are a slight movement of N369 and F319 and significant displacement of residue M373 
which is now in the active site. There are also changes that can be observed between the 
structure of Y404F PfKMO* and PfKMO* with NaCl that reflect changes which could be 
caused by the mutation. These include a slight movement of R84 and Y98 as well as 
movement of F404 relative to Y404. There is also a change in the positions of the sidechains 
of F319 and the amide bond between these residues in the structures of Y404F PfKMO* and 
PfKMO* in the absence of substrate with NaCl. The movement of F404 relative to Y404 in 
both the other structures suggests that in the position of Y404 is such that the interaction 
between the hydroxyl of Y404 and L-kynurenine can form and when F404 is present, the 
interaction cannot form so the residue can occupy a slightly different orientation. 
Residues N369 and M373 are in the active site and are in a different position in the substrate-
free structures obtained in the presence of NaCl compared to that of PfKMO* in the absence 
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of both L-kynurenine and NaCl. These residues are located at the end of a helix which stops 
at residue 374 and becomes a loop leading to the C-terminal domain. The residues from 
N369 to S374 were visible in the electron density map for Y404F PfKMO* but residues 375 
– 378 were not. Residues from 379 onwards are in the same position in both the structures of 
Y404F PfKMO* and PfKMO* in the absence of substrate without NaCl. The positions of 
these residues are affected by the presence of NaCl and differ in the structures of Y404F 
PfKMO* and PfKMO* in the absence of substrate and NaCl (Figure 4.9), consistent with 
observations made in all the structures of PfKMO* crystallised with NaCl in the absence of 




Figure 4.9: Cartoon representation showing the secondary structure of residues 367 – 394 
in the structures of Y404F PfKMO* (cyan), PfKMO* in the absence of substrate (green), 
PfKMO* in the absence of substrate crystallised in the presence of NaCl (orange) and 
PfKMO* in the presence of L-kynurenine (magenta). Residues 375 – 378 are not present in 
the Y404F PfKMO* electron density map.  
 
Another area of difference between the structures of Y404F PfKMO* and PfKMO* in the 
absence of substrate caused by the presence of NaCl in the well solution is the loop 
consisting of residues I44 – N54 which is not present in the structure from the crystal grown 
with sodium tartrate. 
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 The positions of these residues in the structures of Y404F PfKMO* 
and PfKMO* with NaCl are similar to those observed in the structure of PfKMO* with              




Figure 4.10: Residues in the loop from R43 – L55 for Y404F PfKMO* (green), PfKMO* in the 
absences of substrate (cyan), PfKMO* with NaCl in the absence of substrate (light orange) 
and PfKMO* in the presence of L-kynurenine (magenta). A48 and R49 are not visible in the 
electron density of Y404F PfKMO* and Q45 – I53 are not visible in the PfKMO* structure in 
the absence of substrate. 
 
The mutation Y404F has not had a significant effect on the structure compared to that of 
PfKMO*. There are no major conformational changes but there are a few small differences 
in the active site of Y404F with differences observed in the positions of F319, H320 and 
F404 which are not attributable to the presence of NaCl. These findings are consistent with 
the kinetic data obtained which indicate that Y404F PfKMO* is capable of hydroxylating   
L-kynurenine although the KM is slightly raised relative to PfKMO*. 
 
4.2.4 Structure of Y404F PfKMO* with L-kynurenine 
Crystals of Y404F PfKMO* with L-kynurenine in the active site were obtained by hanging-
drop vapour diffusion at 4 ºC. The drop contained a 1:1 mixture of purified protein and well 
solution. The well solution contained 0.1 M HEPES buffer pH 7.0, 10% PEG 4K, 8% 
glycerol, 10 mM NaCl, 10% isopropanol and 1 mM L-kynurenine, the same conditions as 
Y404F PfKMO* in Section 4.2.3. The crystal was cryoprotected by successive exposure to 
well solution containing 10% and 20% ethylene glycol before being frozen in liquid N2. Data 
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were collected on the i02 beamline at the Diamond Light Source, Oxfordshire with an 
oscillation of 0.3º over a rotation of 180º with a time of 0.3 s per image. The beam 
wavelength was 0.98 Å and the intensity was 60%. The data were processed using iMosflm 
and CCP4i as outlined in Section 2.7.4 and the processing statistics are listed in Appendix 2 
Table A.2.  
The space group of the Y404F PfKMO* crystal was determined to be I4122, the same as 
those for PfKMO* with L-kynurenine bound, and there was one protein molecule in the 
asymmetric unit. The Matthews test showed that this Y404F PfKMO* crystal was 
approximately 83% solvent. The Y404F PfKMO* crystals grown in these conditions did not 
diffract to a high resolution and the best data set obtained had a resolution of 3.95 Å 
although attempts were made to obtain higher quality crystals by altering the growth 
conditions. Molecular replacement was carried out with Molrep using the PfKMO* with     
L-kynurenine bound structure as a model. The Y404F PfKMO* structure was refined using 
Refmac5 and edited in Coot before further refinement. 
This dataset had Rfactor of 0.2602 and Rfree of 0.2914 and B factors of 36.5 Å suggesting that 
these data are not particularly good quality and that further work refining this structure and 
editing it is unlikely to make significant valid improvements and is also problematic at this 
low resolution. The Ramachandran analysis in Coot showed that 10.5% of residues were 
outliers suggesting that the positions and angles of some residues in the structure are likely to 
be highly unreliable. These problems are likely to be due to the low resolution preventing 
accurate positioning of the atoms in the electron density map, presumably as a consequence 
of the high solvent content of the crystal. 
The poor resolution of this structure means that many of the sidechains are not visible in the 
electron density and it is not possible to gain an understanding of subtle changes caused by 
the Y404F mutation; however, the main chain of the protein had clear electron density and 
the structure appeared to be very similar to that of PfKMO* with L-kynurenine bound (Table 
4.3). There are a few differences in the overall structure including a number of short regions 
where, in the structure of PfKMO*, there are β-sheets as part of the Rossmann fold, unlike 
Y404F PfKMO*. This is probably a result of the poor resolution and is unlikely to be a 
genuine difference in the two structures as the presence of a Rossmann fold is a key feature 
of Class A flavoprotein aromatic hydroxylases. 
97
 There are also a few residues in the Y404F 
PfKMO* structure which did not have any electron density; these were 375-378 and 436-
437, which are both loops in the PfKMO* with L-kynurenine bound structure. There were 
very few differences in the sidechains of Y404F PfKMO* that were visible in the electron 
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density map compared to those of PfKMO* that were not likely to be the result of the poor 
resolution so the mutation appears to have had little effect that can be seen at this resolution 
on the overall structure in the presence of substrate. 
 
 rmsd (Å) 
PfKMO* with L-kynurenine 0.77 
PfKMO* in the absence of substrate, Chain A 0.98 
Table 4.3: The rmsd values obtained in a pairwise comparison of Y404F PfKMO* with           
L-kynurenine with the structures of PfKMO* in the presence and absence of L-kynurenine. 
The structure of Y404F PfKMO* was more similar to that of PfKMO* obtained in the 
presence of L-kynurenine, both structures in the closed conformation. The difference 
between the two rmsd values above is small, possibly a result of the poor resolution of the 
structure. The comparison was made using the protein structure comparison service 
PDBeFold. 178 
 
The exact position of L-kynurenine in the active site was ambiguous, and in the final round 
of refinement there was a small area of electron density in the active site which could 
potentially be from part of the substrate, but there was no density for the aromatic ring of    
L-kynurenine (Figure 4.11). By comparing this structure to that of PfKMO* with substrate 
bound, this electron density could be from the carboxylate group of L-kynurenine and also 
part of the R84 sidechain but it is not sufficiently clear in the Y404F PfKMO* structure to be 
certain of either the position of the substrate or the R84 sidechain at this resolution. The 
substrate is assumed to be present, due to the I4122 space group and the overall similarity 
with the bound structure of PfKMO*, especially as both structures are in the closed 
conformation with the C-terminal domain closer to the main domain and active site than is 






Figure 4.11: The Fo-Fc map of Y404F PfKMO* with L-kynurenine bound (green, positive; red, 
negative) contoured at 3.00 σ with the superimposed model of PfKMO* with L-kynurenine 
bound (blue) of which the substrate and the R84 sidechain are shown. The alignment of the 
two structures was made using the DALI server. 179 There is some unmodelled density in the 
active site which could be the result of the presence of the substrate and the R84 but as 
there is no evidence for the presence of the aromatic ring of L-kynurenine, it was not 
possible to add the substrate to the model of Y404F PfKMO* with L-kynurenine bound. 
 
Few of the residues in the active site of Y404F PfKMO* have any electron density for the 
sidechains so it is difficult to make comparisons between PfKMO* and Y404F PfKMO*; 
however, there is density for F404 which shows the residue is in a similar position to that of 
Y404 (Figure 4.12) but the orientation is different. This could be due to the low quality of 
the structure and it is not possible to be certain of this slight difference; however it is could 
potentially represent a real difference in orientation that could be the result of the loss of the 
hydrogen bond interaction between Y404 and the substrate resulting in a different orientation 
for F404 becoming more favourable. The sidechains of H320 and N369 are present in the 
active site and are in similar positions in both structures.  The position of the isoalloxazine 
ring of the FAD cofactors is also slightly different, but again this likely to be caused by the 
resolution of the Y404F PfKMO* structure rather than represent a major difference between 
the two structures. The region around residue 404 appears to be highly similar in both 
structures suggesting that this mutation has not caused any local conformational changes in 
the protein structure. This is consistent with the kinetic data in Section 4.2.2, as the loss of 








Figure 4.12: Active site residues of Y404F PfKMO* (pink) overlaid with those from the 
structure of PfKMO* (green) with L-kynurenine bound (cyan) with FAD cofactors (pale 
yellow and yellow respectively). Some of the residues with sidechains present in the model 
of the PfKMO* structure only are not shown for clarity (Ile106, Met222, Leu224 and 
Met373). Slight differences in the orientation of His320, Asn369 and Tyr404/Phe404 can be 
observed although these could be due only to the poor resolution and quality of the Y404F 
PfKMO* structure. 
 
The resolution of the structure of Y404F PfKMO* with L-kynurenine bound is 3.95 Å 
meaning that it is difficult to draw any reliable conclusions from the structure; however the 
structure is clearly similar to PfKMO* with substrate bound as from the backbone, which 
can be observed from the electron density map, there are no observable conformational 
changes. This is consistent with the kinetic data and with the higher resolution structure of 
Y404F PfKMO* in the absence of substrate, and would support the hypothesis that this 








In the structure of PfKMO* with L-kynurenine bound, it appears that N369 may interact with 
the carboxylate moiety of the substrate. The mutation made to investigate the role of this 
residue is N369S and this protein was studied kinetically and crystallised both in the absence 
of ligand and with 3,4-dichlorobenzoylalanine, an effector molecule, in the active site.  
 
4.3.1 Steady state kinetic analysis of N369S PfKMO* 
The mutation N369S was made in the gene of PfKMO* using the megaprimer PCR method 
and was expressed and purified using the methods described in Chapter 2. The UV-visible 
spectrum of the N369S PfKMO* was obtained (Figure 4.13).  
 
Figure 4.13: UV-visible spectrum of N369S PfKMO*. The concentration was determined to 
be 8.2 μM. 
 
N369S PfKMO* was active and it was possible to obtain the kinetic parameters KM and kcat 




Figure 4.14: Graph of turnover plotted against L-kynurenine concentration fitted to the 
Michaelis-Menten equation using Origin 8.5.1. 
 
The mutation N369S has caused a small increase in the KM value (Table 4.4) which would 
suggest that this residue interacts with the substrate and the mutation affects this interaction 
but that it does not have a significant effect on the ability of the enzyme to bind                    
L-kynurenine nor has this mutation had an effect on the kcat value which is very similar for 
both N369S PfKMO* and PfKMO*. 
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PfKMO*  8.8 ± 1.5 8.9 ± 1.1 1.01 
N369S PfKMO* 27.7 ± 3.3 4.5 ± 0.2 0.16 
Table 4.4: The kinetic parameters, KM and kcat, and the catalytic efficiency determined for 
N369S PfKMO* from the results of the assay described in Section 2.5.2 compared to those 
values obtained for PfKMO* in previous work. 143 
 
4.3.2 Structure of N369S PfKMO* 
Crystals of PfKMO* N369S were obtained by hanging drop vapour diffusion at 4 ºC. The 
drop was a 1:1 mixture of N369S PfKMO* and well solution. The well solution contained 
0.1 M HEPES pH 7.0, 9% PEG 4K, 10 mM NaCl, 10% glycerol, 10% isopropanol and 1 
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mM L-kynurenine. Although the substrate was present in the drop, there was no electron 
density for any substrate molecule in the active site. The crystal was cryoprotected in a well-
solution containing 10% ethylene glycol and flash-frozen in liquid nitrogen.  
Data were collected on the i03 beamline at the Diamond Light Source, Oxfordshire. Data 
was collected with an oscillation of 0.2º over a rotation of 120º and an exposure time of 
0.2s/image, beam wavelength of 0.976 Å, and beam intensity of 25%. The images were 
processed using iMosflm and Scala. The space group was found to be P21221, the same as the 
structure of PfKMO* in the absence of substrate. The asymmetric unit contained four protein 
molecules, each with one non-covalently bound FAD cofactor and had cell dimensions of a = 
104.85 Å, b = 133.96 Å, c = 188.32 Å, α = β = γ = 90º (processing statistics are listed in full 
in Appendix 2 Table A2.3).  One chloride anion was identified as binding close to the FAD 
cofactor for each PfKMO* and 323 waters were found in the asymmetric unit. Molecular 
replacement was carried out using Molrep using the structure of PfKMO* in the absence of 
substrate which was expected to be quite similar. The structure was refined using Refmac5 
and after refining and validation the Rfactor was 0.2290 and Rfree was 0.2752.  
The resolution of the structure is 2.38 Å, which is sufficient to see most of the residues and 
their sidechains in the electron density map; however, there were residues for which the 
sidechain positions could not be determined and there were some residues for which there 
was no density in the 2Fo-Fc map. Some of the missing regions, including residues 46 – 47, 
207 – 209 and 245 – 246, correspond to loops in the PfKMO* structure and could be flexible 
regions in the crystal structure of N369S PfKMO* for reasons unrelated to the N369S 
mutation (Figure 4.15). The other missing regions including residues 203 – 206 and 373 – 




Figure 4.15: Two views of N369S PfKMO* Chain A in cartoon form to represent the 
secondary structure elements coloured with N-terminal in blue and C-terminal in red. The 
FAD cofactor is in red to contrast with the colours in the main domain. The residues at each 
end of a break in Chain A where there is no electron density are labelled.  
 
There are slight differences between the structure of N369S PfKMO* and PfKMO* in the 
absence of substrate including the positions of residues from 195 – 250 that appear to be the 
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result of the electron density map of N369S PfKMO* being of lesser quality in this region, 
and it is difficult to position some of the residues with such a high degree of certainty. 
Throughout the structure the vast majority of sidechains that are completely visible in the 
electron density map of N369S PfKMO* are in the same orientation as those in the structure 
of PfKMO* in the absence of substrate. 
The structure of N369S PfKMO* is similar to those of PfKMO* in the absence of substrate 
(Table 4.5), structures which are in the open conformation observed when no ligand is bound 
in the active site resulting in movement of the C-terminal domain away from the main 
domain of the protein. As this structure was obtained in the presence of NaCl, it is slightly 
more similar to the PfKMO* structure in the absence of substrate crystallised in the presence 
of NaCl compared to that crystallised with sodium tartrate present.   
 rmsd (Å) 
PfKMO* in the absence of substrate, with NaCl, Chain A 0.33 
PfKMO* in the absence of substrate, no NaCl, Chain A 0.47 
PfKMO* with L-kynurenine 0.90 
Table 4.5: The rmsd values obtained in a pairwise comparison of N369S PfKMO* Chain A in 
the absence of substrate with the structures of PfKMO* in absence of L-kynurenine with 
and without the presence of NaCl and the structure of PfKMO* with L-kynurenine bound. 
The values were obtained using PDBeFold. 178 
 
There are very few differences in the active site of N369S PfKMO* compared to PfKMO* 
with NaCl in the absence of substrate (Figure 4.16). There is a slight difference in the 
positions of F319 and H320 similar to that seen with Y404F PfKMO* (Section 4.2.3). There 
is also a change in the orientation of S369 relative to N369 so that the sidechain occupies a 
very similar position to that in the structure of PfKMO* in the absence of both NaCl and 
substrate. The change in the position of the F319 carbonyl means that there is no interaction 
between this carbonyl and S369 unlike in the PfKMO* structure with NaCl where an 




Figure 4.16: Selected active site residues in N369S PfKMO* (green) overlaid with residues in 
PfKMO* in the absence of substrate (cyan) and PfKMO* with NaCl in the absence of 
substrate (lilac). Other active site residues have been omitted for clarity. The differences 
that are due to the N369S mutation rather than the presence of NaCl (comparing the green 
and lilac residues) are changes to the positions of Arg84, Phe319, the amide bond between 
Phe319 and His320, and Ser369 which is orientated in a different direction than Asn369 in 
the PfKMO* structure with NaCl in the absence of substrate. 
 
The mutation N369S has had very little effect on the structure of PfKMO* in the absence of 
substrate as no major changes were observed when comparing the structure of N369S 
PfKMO* with that of PfKMO* in the absence of substrate. This finding is consistent with 
the kinetic results for N369S PfKMO* where there is little change in either the KM or kcat 
values obtained.  
 
4.2.3 Structure of N369S PfKMO* with 3,4-dichlorobenzoylalanine 
Crystals of N369S PfKMO* with the substrate analogue, 3,4-dichlorobenzoylalanine bound 
in the active site were grown using the hanging drop vapour diffusion method at 4 ºC. The 
drop contained a 1:1 mixture of the purified protein and the well solution. The well solution 
consisted of 0.1 M HEPES pH 7.0 buffer, 10 mM NaCl, 8% PEG 4K, 8% glycerol, 10% 
isopropanol and 1 mM 3,4-dichlorobenzoylalanine. The crystal was sequentially exposed to 
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well solutions containing 10% and 20% ethylene glycol before being flash-frozen in liquid 
N2.  
Data were collected on the i03 beamline at the Diamond Light Source, Oxfordshire. The data 
was collected with an oscillation of 0.3º over a rotation of 180º and an exposure time of 
0.3s/image, beam wavelength of 0.976 Å and beam wavelength of 0.976 Å and intensity of 
40%. The images were processed using iMosflm and Scala as described in Section 2.7.4. The 
space group was found to be I4122 with unit cell dimensions of a = b = 150.1 Å, c = 274.0 Å, 
α = β = γ = 90º (full details in Appendix 2 Table A2.3) and the data had a resolution of 3.98 
Å. Molrep was used to generate the model of the structure using the PfKMO* structure with 
L-kynurenine bound as a model. The structure was refined using Refmac5 and edited using 
Coot after each refinement times with a final Rfactor of 0.2610 and Rfree of 0.3362.                
3,4-dichlorobenzoylalanine was added to the model in Coot after generating the three-
dimensional coordinates and library of restraints using PRODRG. 
The high value of Rfree and the resolution of this structure mean that while it is useful for 
providing some information on the general similarities and any major differences between 
N369S PfKMO* with 3,4-dichlorobenzoylalanine bound and the structure of PfKMO* with 
L-kynurenine, it is not a reliable guide to subtle differences in the protein structure caused by 
the N369S mutation.  
At this resolution, many of the sidechains of N369S PfKMO* were not visible in the electron 
density map. Using Coot with data at this resolution was problematic and there are a large 
number of outliers on the Ramachandran plot (18%) which deteriorated with successive 
refinement using Refmac5. While it would be possible to examine every residue using Coot 
and alter the angles to remove Ramachandran outliers and to create the likely secondary 
structure elements, actual improvements to data quality are only likely to be made by 
growing crystals in different conditions. Efforts were made to increase the resolution of data 
obtained using crystals grown in similar conditions, but these were unsuccessful.  
The electron density map did clearly indicate the approximate positions of residues in the 
protein chain and comparing N369S PfKMO* to the structure of PfKMO*, the main chain as 
represented in cartoon form (Figure 4.17) is similar. There are significant differences though 
in the secondary structure which is probably caused by the issues with the data rather than 
changes caused by the mutation. These difference are that in N369S PfKMO* there are 
residues which would be expected to be part of an α-helix or β-sheet but are in a loop, a 
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notable example of this are the β-sheets of the Rossmann fold which are not β-sheets in the 
N369S PfKMO* structure.  
 
Figure 4.17: Overlay of the secondary structures represented in cartoon form of N369S 
PfKMO* (purple) with 3,4-dichlorobenzoylalanine potentially bound in the active site and 
PfKMO* (green) with L-kynurenine bound in the active site. The two structures are similar 
but there are regions of loops in the N369S PfKMO* where there are β-sheets or α-helices 
in the PfKMO* structure. These differences are probably due to the quality of the structure 
rather than major conformational changes as the kinetic results show that the mutation 
N369S does not have a significant effect on PfKMO*. 
 
A comparison of the structure of N369S PfKMO* in the presence of 3,4-
dichlorobenzoylalanine to those of  PfKMO* in the presence and absence of L-kynurenine 
confirms that this structure resembles more closely the structure of PfKMO* with                 
L-kynurenine (Table 4.6). The rmsd values obtained were lower than expected probably due 
to the low quality of this structure caused by the low resolution. This result supports the 
hypothesis that 3,4-dichlorobenzoylalanine is bound in this N369S PfKMO* structure as the 





 rmsd (Å) 
PfKMO* with L-kynurenine 0.84 
PfKMO* in the absence of substrate, Chain A 1.13 
Table 4.6: The rmsd values obtained in a pairwise comparison of N369S PfKMO* with      
3,4-dichlorobenzoylalanine with the structures of PfKMO* in the presence and absence of 
L-kynurenine. The values were obtained using PDBeFold. 178 These values are lower than 
those above in Table 4.5 which probably reflects the poor quality of this structure rather 
than more significant structural changes. 
 
There is some electron density that suggests the presence of the ligand in the active site, but 
this was in close proximity to residues P318 – H320 so it was not possible to model           
3,4-dichlorobenzoylalanine into the active site of N369S PfKMO* (Figure 4.18). As this 
structure is in the closed conformation and the mutation has little effect on the KM value 
compared to PfKMO*, it is probable that ligand is bound but that at this resolution it is not 
possible to see conclusive evidence for its presence in the active site. 
  
Figure 4.18: Fo-Fc for the structure of N369S PfKMO* refined in the absence of ligand in the 
active site contoured at 3.00 σ. There are areas (green, positive) that may be due to the 
presence of 3,4-dichlorobenzoylalanine but there is not sufficient evidence to accurately 
determine the position and orientation of the ligand. 
 
In the structure of N369S PfKMO*, there are no conformational changes in close proximity 
to the N369S mutation but S369 is orientated in a different direction and would therefore not 








There are few differences between the active site of this structure and that of PfKMO* with 
L-kynurenine but because of the poor resolution of this structure, no conclusions can be 
drawn. As N369S PfKMO* is an active enzyme, this would suggest that the loss of any 
interactions involving N369 are not particularly critical for the enzyme to function 
effectively; however, with the poor resolution of this structure it is not possible to be certain 
of the reliability of the position of the N369 sidechain.  
 
Figure 4.19: In the structure of N369S PfKMO* in the presence of 3,4-
dichlorobenzoylalanine (green), Ser369 is orientated towards the backbone of residues 
Pro318 – His320. In the structure of PfKMO* (lilac) in the presence of L-kynurenine (cyan), 
the position of Asn369 allows for an interaction between this residue and L-kynurenine 
which cannot form when the mutation is made. The carbonyl of His320 is closer to the 
amide of L-kynurenine in the PfKMO* structure although the significance of this difference 
is unclear due to the low resolution of the N369S PfKMO* structure. 
 
The structure of N369S PfKMO* with 3,4-dichlorobenzoylalanine is not particularly high 
quality and has a resolution of 3.98 Å. There are only a few conclusions that can be drawn 
from this structure, including the overall similarity between this structure and PfKMO* with 








4.4.1 R84A PfKMO* 
The mutation R84A was introduced to the PfKMO* gene using the QuikChange II kit and 
the R84A PfKMO* protein was expressed and purified using the methods described in 
Chapter 2 and the UV-visible spectrum was obtained (Figure 4.20). This mutation made the 
protein inactive and no enzyme activity was detected using the assay described in Section 




Figure 4.20: UV-visible spectrum of 27.7 μM R84A PfKMO*. 
 
This is consistent with the information gained from the structure of PfKMO* as this residue 
interacts with the carboxylate group of L-kynurenine and is likely to be involved in one of 
the most important interactions for substrate binding. In addition, R84 appears to interact 
with N369 and is also involved in the interactions responsible for the C-terminal domain 
movement observed when substrate binds. 
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 By making the non-conservative mutation to 
an alanine none of these interactions can be maintained and therefore it is not surprising that 
the enzyme activity is not detected using the assay. This loss of activity is also consistent 








4.4.2 Kinetic analysis of R84K PfKMO* 
The protein R84K PfKMO* was expressed and purified using the methods described in 
Chapter 2 after the mutation was made in the gene using the megaprimer PCR method. The 
UV-visible spectrum of R84K PfKMO* was obtained after purification (Figure 4.21).  
 
Figure 4.21: UV-visible spectrum of 25.1 μM R84K PfKMO*. 
 
The values of KM and kcat could not be determined using the kinetic assay in Section 2.5.2 as 
a change in absorbance could not be detected suggesting that the enzyme is inactive. This 
would suggest that the role of R84 is critical for enzyme function as suggested above in 
Section 4.4.1 as even a conservative mutation to R84K results in inactive protein. Although a 
lysine residue could potentially be involved in some of the interactions thought to be formed 
by R84, it is possible that K84 is not able to form strong interactions with either the 
carboxylate moiety of L-kynurenine or E372, an interaction hypothesised to be critical for 
conformational change between the open and closed conformations of PfKMO*. The 
inactivity of R84K PfKMO* could be caused by the mutation having an significant effect on 
the structure of the protein so this protein was crystallised to further understand the role of 







4.4.3 Structure of R84K PfKMO* 
Crystals of R84K PfKMO* were obtained by hanging drop vapour diffusion at 4 ºC. The 
drop contained a 1:1 mixture of the purified protein and the well solution which consisted of 
0.1 M HEPES buffer, pH 7.0, 14% PEG 4K, 7.5% glycerol, 10 mM NaCl, 10% isopropanol 
and 1 mM L-kynurenine. Although L-kynurenine was present, only substrate-free crystals 
were obtained and in the absence of L-kynurenine significant precipitation was observed in 
the hanging drops. The data were collected on the i02 beamline at the Diamond Light 
Source, Oxfordshire. The data were collected with an oscillation of 0.2º over a rotation of 
120º with exposure time of 0.2 s/image. The beam wavelength was 1.00 Å and intensity was 
65%. 
The diffraction images collected were processed using iMosflm and Scala as discussed in 
Section 2.7.4 and the resolution was determined to be 2.45 Å. The space group is P21221, the 
same as the other structures obtained with no ligand bound in the active site, and there were 
four R84K PfKMO* molecules, one chloride found near the FAD of each PfKMO* and 274 
water molecules in the asymmetric unit. The unit cell dimensions were found to be a = 105.5 
Å, b = 133.7 Å and c = 187.6 Å with angles α = β = γ = 90º (the processing statistics are 
listed in Table A2.4 in Appendix 2). Molecular replacement was carried out using Molrep 
and the model was refined using Refmac5 using rigid body refinement and subsequent 
rounds of restrained refinement and TLS refinement with editing carried out manually in 
Coot after each refinement in Refmac5. The final Rfactor was 0.2225 and Rfree = 0.2794. 
The structure of R84K PfKMO* with no substrate bound in the active site has many 
similarities with that of PfKMO*. The FAD cofactor is non-covalently bound in the main 
domain of the protein and the C-terminal domain is observed in the open conformation 
(Figure 4.22). While some of the residue sidechains in this structure could not be observed 
clearly in the electron-density map, the structure of R84K PfKMO* contains residues from 
Asn6 to Ser461 without any breaks in two of the chains, with only a maximum of six 




Figure 4.22: The structure of one of the chains of R84K PfKMO* represented in cartoon 
form to show the secondary structure. The protein chain colour is blue at the N-terminus 
and red at the C-terminus with the FAD cofactor shown in red.  
 
Comparing the structure of R84K PfKMO* to the structures of PfKMO* obtained in 
previous work confirmed that R84K PfKMO* was most similar to the structures obtained in 
the absence of L-kynurenine, which were also crystallised in the open conformation with the 
C-terminal domain further from the main domain (Table 4.7). There are some differences 
observed between the structures of R84K PfKMO* and PfKMO* in the absence of substrate 
particularly in the region close to the start of the C-terminal domain, thought to have to be 
caused by the presence of NaCl in the growth conditions and are therefore not a result of the 
R84K mutation. 
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 This is reflected in the difference between the rmsd values for R84K 
PfKMO* compared to PfKMO* in the absence of L-kynurenine with and without NaCl in 






 rmsd (Å) 
PfKMO* in the absence of substrate, with NaCl, Chain A 0.42 
PfKMO* in the absence of substrate, no NaCl, Chain A 0.62 
PfKMO* with L-kynurenine 0.87 
Table 4.7: The rmsd values obtained in a pairwise comparison of R84K PfKMO* Chain A in 
the absence of substrate with the structures of PfKMO* in absence of L-kynurenine with 
and without NaCl and the structure of PfKMO* with L-kynurenine bound. The values were 
obtained using PDBeFold. 178 
 
The sidechain of K84 is completely visible in the active site of three of the four R84K 
PfKMO* molecules in the active site. K84 is located in the active site but not in the same 
position as R84 in the PfKMO* structure with NaCl in the absence of substrate (Figure 
4.23).  
 
Figure 4.23: The 2Fo-Fc map (blue) contoured at 1.00 σ for R84K PfKMO* Chain A (blue) with 
the model of K84 (green) with R84 from the structure of PfKMO* in the absence of 
substrate in the presence of NaCl (purple). 
 
The other differences observed in the R84K PfKMO* active is a very slight change in the 







Figure 4.24: The 2Fo-Fc map for R84K PfKMO* (blue) contoured at 1.50 σ with the model of 
the structure (green) and the structure of PfKMO* in the absence of substrate (NaCl) 
(purple).  
 
In the active site of R84K PfKMO*, there are very few differences that can be observed 
between this structure and that of PfKMO* in the absence of substrate with or without NaCl 
(Figure 4.25). There only difference is a slight change in the position of K84 compared to 
R84 where K84 is further from the active site. This structure differs from Y404F PfKMO* 
(Section 4.2.3) and N369S PfKMO* (Section 4.3.2) in that this is the only structure obtained 
with F319 and H320 in the same position as the structure of PfKMO* with NaCl in the 
absence of substrate. This degree of similarity between the structure of R84K PfKMO* and 
PfKMO* in the absence of substrate was unexpected given the lack of activity observed with 







Figure 4.25: Residues in the active site of R84K PfKMO* (green) overlaid with those in the 
structures of PfKMO* in the absence of substrate (cyan) and PfKMO* with NaCl in the 
absence of substrate (lilac). The structure of R84K PfKMO* closely resembles that of 
PfKMO* with NaCl except in the position of Lys84 which is moved further from the active 





The characterisation of the active site of PfKMO* has focussed on three residues identified 
in the crystal structure as being potentially important in substrate binding. These were Y404, 
hypothesised to form a hydrogen bond with the substrate, N369 thought to interact with the 
carboxylate moiety of L-kynurenine and R84 considered important for substrate binding and 
conformational change. These residues were studied using active site mutants which were 
purified and then characterised kinetically and structurally to identify and explain any 
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changes in PfKMO* properties. Further mutations had been planned; however, it was not 
possible to successfully make them during this project. 
Residue Y404 was investigated with two mutations, Y404A and Y404F. Y404A PfKMO* 
was found to be inactive indicating that a non-conservative change is not tolerated at this 
position. Y404F PfKMO* was active and kinetic data showed a raised KM suggesting that 
Y404 forms a hydrogen bond with the carboxylate moiety of L-kynurenine that is involved in 
substrate binding but is not essential. The structure of Y404F PfKMO* was obtained in the 
P21221 space group in the open conformation and only slight changes were observed 
between this structure and that of PfKMO* in the absence of substrate. The structure was 
also obtained in the I4122 space group at a poor resolution and there was not sufficient data 
to accurately determine the position of L-kynurenine. 
The conservative mutation N369S was made to investigate the role of N369 and was 
observed to have little effect on the kinetic properties of this enzyme. The structure of 
N369S PfKMO* was obtained without substrate binding in the active site and was similar to 
that of PfKMO* with a slight change in the position of S369 which could allow the 
formation of hydrogen bond interaction with the carbonyl of F319. The structure of N369S 
PfKMO* was also obtained in the presence of the effector 3,4-dichlorobenzoylalanine This 
compound is structurally similar to L-kynurenine but cannot be hydroxylated by KMO. The 
structure was similar to that of PfKMO* with L-kynurenine bound but due to the poor 
resolution there was inconclusive evidence for the position of the ligand in the active site and 
few conclusions could be drawn from this structure. 
R84 is thought to form one of the most important interactions for substrate binding and is 
also implicated in the control of the conformational changes from open to closed that occur 
when substrate or small ligands are bound in the active site. In the closed conformation R84 
is part of a network of interactions that connect the active site to the C-terminal domain and 
mutating this residue was expected to have a significant effect on the enzyme properties. The 
mutation R84A caused PfKMO* to lose all measurable activity. The conservative mutation 
R84K was also made and no activity was detected with R84K PfKMO* in the kinetic assay. 
The structure of R84K in the open conformation was obtained but was remarkably similar to 
that of PfKMO* with no change in the conformation observed but a slight difference in the 
position of K84 away from the active site suggesting that this mutation may significantly 
compromise the ability of PfKMO* to bind L-kynurenine. 
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This information is the result of the first investigation of the role of R84, N369 and Y404 in 
the active site of PfKMO* and supports hypotheses made about the role of active site 
residues from previous structures of PfKMO* in the presence and absence of L-kynurenine. 
N369 is not particularly important for substrate binding although it is located just over 3 Å 
from the carboxylate moiety of L-kynurenine (Figure 4.26). Y404 is over 4 Å from              
L-kynurenine, from the structure of PfKMO* with L-kynurenine bound, however, this 
residue does appear to form a hydrogen bond with the carboxylate moiety that is important 
for the affinity of the enzyme for the substrate. R84 appears to be the key residue in the 
active site, important for binding L-kynurenine and also implicated in the conformational 
change observed on substrate binding and with even a conservative mutation at this residue, 
the ability of PfKMO* to hydroxylate L-kynurenine is severely affected. 
 
Figure 4.26: Schematic of the active site of PfKMO* with L-kynurenine bound in the active 
site. The aromatic ring binds in close proximity to the isoalloxazine moiety of the FAD 
cofactor. The carboxylate moiety of L-kynurenine is able to interact with active site residues 
including R84, Y98, N369 and Y404. 
 
By studying these residues, information on the interactions important to substrate binding 
has been gained and this has complemented the previous structural work on PfKMO* 
confirming some of the hypotheses about the role of residues in the active site and providing 
a more detailed understanding of this enzyme.  
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Chapter 5: Investigating the Role of Histidine 320 
 
5.1 Role of H320 in the active site 
 
H320 is located in the active site of PfKMO* on a loop close to the isoalloxazine moiety of 
the FAD cofactor, and the substrate L-kynurenine (Figure 5.1). From this structure of 
PfKMO*, H320 was not expected to be critical for substrate binding as the closest distance 
from this residue to L-kynurenine is 3.9 Å.  The distances between H320 and the surrounding 
residues in vicinity of the active site are also quite large suggesting that there are not 
significant interactions between them. 
 
Figure 5.1: View of H320 in the active site of PfKMO* with FAD cofactor (yellow) and           
L-kynurenine (cyan). Distances from the H320 to the nearest residues and L-kynurenine are 




H320 is of significant interest because from inspection of the crystal structure it is the only 
residue in the active site of PfKMO which is not conserved in the human enzyme (Figure 
5.2). This means that any changes in PfKMO kinetic behaviour on mutating this residue to 
the phenylalanine residue present in the human enzyme could indicate possible differences 
between the human and PfKMO enzymes that are relevant to substrate binding and inhibitor 
design.  
 
humanKMO        MDSSVIQRKKVAVIGGGLVGSLQACFLAKRNFQIDVYEAREDTRVATFTRG--RSINLAL 58 
ScKMO           ------MSESVAIIGAGLVGCLAALAFSKEGYNVTLYDFRQDPRLDTTKNKNLKSINLAI 54 
PfKMO           -MTATDNARQVTIIGAGLAGTLVARLLARNGWQVNLFERRPDPRIETGARG--RSINLAL 57 
                        ..*::**.**.* * *  :::..::: ::: * *.*: *  .   :*****: 
 
humanKMO        SHRGRQALKAVG--LEDQIVSQGIPMRARMIHSLSGKKSAIPYG-TKSQYILSVSRENLN 115 
ScKMO           SARGIDALKSIDPDACEHILQDMIPMKGRMIHDLKGRQESQLYG-LHGEAINSINRSVLN 113 
PfKMO           AERGAHALRLAG--LEREVLAEAVMMRGRMVHVPGTPPNLQPYGRDDSEVIWSINRDRLN 115 
                : ** .**:  .     .:: : : *:.**:*      .   **  ..: * *:.*. ** 
 
humanKMO        KDLLTAAEKYPNVKMHFNHRLLKCNPEEG---MITVLGSD-KVPKDVTCDLIVGCDGAYS 171 
ScKMO           NSLLDELEKS-TTELKFGHKLVKIEWTDDKQICHFAIGEDLKAPHTEKYDFVIGCDGAYS 172 
PfKMO           RILLDGAEAA-GASIHFNLGLDSVDFARQRLTLSNVSGER----LEKRFHLLIGADGCNS 170 
                . **   *    ..::*.  * . :          . *.          .:::*.**. * 
 
humanKMO        TVRSHLMKKPRFDYSQQYIPHGYMELTIPP-------KNGDYAMEPNYLHIWPRNTFMMI 224 
ScKMO           ATRSQMQRKVEMDFSQEYMNLRYIELYIPPTEEFKPNYGGNFAIAPDHLHIWPRHKFMLI 232 
PfKMO           AVRQAMASVVDLGEHLETQPHGYKELQITP------EASAQFNLEPNALHIWPHGDYMCI 224 
                :.*. :     :.   :     * ** *.*        ..:: : *: *****:  :* * 
 
humanKMO        ALPNMNKSFTCTLFMPFEE--------FEKLLTSN-DVVDFFQKYFPDAIPLIGEKLLVQ 275 
ScKMO           ALANSDGSFTSTFFGSKDQ--------ISDLITSKSRVREFLIKNFPDIINIMDLDDAVK 284 
PfKMO           ALPNLDRSFTVTLFLHHQSPAAQPASPCFAQLVDGHAARRFFQRQFPDLSPMLDS--LEQ 282 
                **.* : *** *:*   :.            :..   .  *: : ***   ::.     : 
 
humanKMO        DFFLLPAQPMISVKCSSFHFKS-HCVLLGDAAHAIVPFFGQGMNAGFEDCLVFDELMDKF 334 
ScKMO           RFITYPKESLVCVNCKPYDVPGGKAILLGDAAHAMVPFYGQGMNCGFEDVRILMALLKKH 344 
PfKMO           DFEHHPTGKLATLRLTTWHVGG-QAVLLGDAAHPMVPFHGQGMNCALEDAVALAEHLQSA 341 
                 *   *   :  :. ..:.. . :.:*******.:***.*****..:**   :   :..  
 
humanKMO        SNDLSLCLPVFSRLRIPDDHAISDLSMYNYIEMRAHVNSSWFIFQKNMERFLHAIMPSTF 394 
ScKMO           SGDRSRAFTEYTQTRHKDLVSITELAKRNYKEMSHDVTSKRFLLRKKLDALFSIIMKDKW 404 
PfKMO           ADNAS-ALAAFTAQRQPDALAIQAMALENYVEMSSKVASPTYLLERELGQIMAQRQPTRF 400 
                :.: * .:. ::  *  *  :*  ::  ** **  .* *  :::.:::  ::       : 
 
humanKMO        IPLYTMVTF-SRIRYHEAVQRWHWQKKVINKGLFFLGSLIAISSTYLLIHYMSPRSFLCL 453 
ScKMO           IPLYTMISFRSDISYSRALERAGKQTRILKFLESLTLGMLSIGGYKLFKFLTRERS---- 460 
PfKMO           IPRYSMVTF-SRLPYAQAMARGQIQEQLLKFAVANHSDLTSINLDAVEHEVTRCLPPLSH 459 
                ** *:*::* * : * .*: *   * ::::       .: :*.   :        .     
 
humanKMO        RRPWNWIAHFRNTTCFPAKAVDSLEQISNLISR 486 
ScKMO           --------------------------------- 
PfKMO           LC------------------------------- 461 
                                                  
Figure 5.2: Sequence alignment of the KMO gene sequences from Pseudomonas fluorescens 
(PfKMO), S. cerevisiae (ScKMO) and Homo sapiens (humanKMO). The residues in the active 
site of PfKMO* and the aligned residues are highlighted in yellow, except for H320 which is 
highlighted in red. The UniProt codes for Homo sapiens and S. cerevisiae KMO are O15229 
and A0A0C5LRM7 respectively. The sequences were found using BLAST and the alignment 
was made using ClustalW. 
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The equivalent of residue H320 is a tyrosine (Y323) in the S. cerevisiae KMO enzyme and in 
the crystal structures of this enzyme it can be seen the loop containing Y323 and surrounding 
residues is in the same position as that containing H320 in PfKMO* (Figure 5.3). 
142,143
 The 
tyrosine is orientated in a different direction than H320F with the ring and carboxylate 
pointing out of the active site away from the inhibitor UPF 648. The S. cerevisiae structure is 
of a truncated KMO and is disordered from residue 359 onwards in the presence of UPF 648 
so the position of F320 in H320F PfKMO* may not resemble that of Y323 in S. cerevisiae 
KMO.  
 
Figure 5.3: Overlay of active site residues in PfKMO* (green) with FAD cofactor (yellow) and 
L-kynurenine (orange) and S. cerevisiae KMO (cyan) with FAD cofactor (blue) and UPF 648 
(magenta). The labels refer to the number of that residue in the PfKMO sequence with the 
exception of Y323. Some residues have been omitted for clarity. Constructed using PDB 
4J36 and PfKMO*. 142,143  
 
In constructing and studying H320F PfKMO* the aim is to determine the extent to which 
this residue interacts with L-kynurenine bound in the active site and whether it contributes to 
the catalytic efficiency. By assaying H320F PfKMO* with novel inhibitor compounds and 
comparing the results to those with PfKMO*, potential differences in inhibitor binding in the 
active site that might be likely to occur in the human enzyme can be observed and this would 
give further confidence to the use of PfKMO* in testing for inhibitor molecules that would 
hopefully have applications after drug development in conditions affecting human patients.  
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5.2 Kinetic Analysis of H320F 
 
5.2.1 Michaelis-Menten kinetics 
The mutation H320F was introduced using the QuikChange PCR method and the H320F 
PfKMO* protein was expressed and purified using the methods described in Chapter 2. The 
UV-visible spectrum of H320F PfKMO* was obtained (Figure 5.4).  
 
Figure 5.4: UV-visible spectrum of H320F PfKMO*. The concentration of this sample was 
determined to be 12.2 μM from an absorbance measurement of 0.15 at 450 nm where 
PfKMO* has a molar extinction coefficient, ε, of 12300 M-1cm-1. 
 
The protein was assayed as described in Section 2.5.2 in triplicate to determine the KM and 
kcat values to determine the effects of the mutation and the data were analysed using Origin 




Figure 5.5: Plot of L-kynurenine concentration against turnover used to determine the value 
of KM and kcat. The graph was made in Origin 8.5.1 and the curve fitted using the Michaelis-
Menten equation.  
 
Compared to the values obtained for PfKMO*, it can be seen that H320F PfKMO* has a 
slightly raised KM and very slightly lowered kcat value, which suggests that the mutation has 
slightly decreased substrate affinity (Table 5.1). 
143
 This shows that this mutation has not had 
such a major effect on enzyme properties unlike mutations of residues involved in substrate 
binding (Chapter 4). 







PfKMO*  8.8 ± 1.5 8.9 ± 1.1 1.01 
H320F PfKMO* 18.0 ± 1.2 7.1 ± 0.2 0.39 
Table 5.1: The kinetic parameters, KM and kcat, and the catalytic efficiency determined for 
H320F PfKMO* from the results of the assay described in Section 2.5.2 compared to those 
values obtained for PfKMO* in previous work. 143 
 
5.2.2 Inhibition Assays 
Three similar inhibitor compounds (Figure 5.6) were assayed with H320F PfKMO* using 
the inhibition assay described in Section 2.5.3. These compounds are all known to be potent 
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inhibitors of PfKMO* and were evaluated with the H320F variant as a means of further 
analysing the role of this residue.  
 
Figure 5.6: General structure of the inhibitor compounds tested on H320F PfKMO*. 
 
The results obtained from the inhibition assays contain a number of interesting trends (Table 
5.2, with inhibition data in Appendix 3). All the Ki values obtained with H320F PfKMO* are 
significantly higher, a greater effect than might have been expected given the small change 
in KM observed with this enzyme compared to PfKMO*. 
The trend in the potency of the inhibitor compounds is not the same for H320F PfKMO* as 
it is for PfKMO*. For H320F PfKMO* the most potent inhibitor is GM862, followed by 
GM855 and GM843 which have very similar Ki values. This is different to the trend for 
PfKMO* where GM855 with the large meta- substituent has a markedly lower Ki value than 
the other two inhibitors which have a similar effect, with GM843 having a slightly lower Ki 
value than GM862. The most potent inhibitors of PfKMO* have been shown to contain large 
meta substituents and have 4-OMe substitution (Chapter 3). 
Compound R H320F PfKMO* Ki value (nM) PfKMO* Ki Value (nM) 
GM862 3-OMe, 4-OH 253.2 ± 30.3 82.4 ± 10.0 




394.1 ± 30.9 19.8 ± 8.7 
Table 5.2: Ki values obtained for three novel KMO inhibitors tested against H320F PfKMO* 
and PfKMO* with full data presented in Appendix 2. 
 
From these data alone, comparing the Ki values for GM843 and GM855 assayed with H320F 
PfKMO*, it can be seen that a large meta substituent does not result in a significant change 
in the Ki value. It appears that the area of the inhibitor molecule more important for potency 
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is the para substituent and that with H320F PfKMO* there is a slight preference for 4-OH 
compared to 4-OMe which was not observed in earlier work with PfKMO*. 
143
 
This change in the trend in Ki values is interesting as these substituents are on a part of the 
molecule which is known not to bind in the active site. This suggests that the mutation may 
have resulted in more changes to the enzyme than might have been expected due to the loss 
of an interaction between H320 and the inhibitor molecules. To investigate potential 
interactions the previously obtained structure of PfKMO* with GM760 was compared with 
the structure of PfKMO* with GM859 (Figure 5.7). 
143
 The amide carbonyl of GM760 is in 
closer proximity to H320 than that of GM859 but the shortest distances between H320 and 
GM760 over 3.5 Å. This suggests that strong interactions are not formed between H320F 
and the inhibitors but those inhibitors that bind in a similar position to GM760 are in closer 
proximity to H320 than those that bind in a similar position to GM859. Unfortunately no 
crystals of H320F PfKMO* with inhibitor compounds could be obtained.  
 
Figure 5.7: Overlay of the structures of PfKMO* (green) with GM760 (pink) and FAD 
cofactor (yellow) and that of PfKMO* (cyan) with GM859 (orange) and FAD cofactor (blue). 





5.3 Structure of H320F PfKMO*  
 
5.3.1 Initial attempts to crystallise H320F PfKMO* 
The first attempts to obtain a model of the structure of H320F PfKMO* used similar 
conditions to those used in obtaining the structure of PfKMO*. H320F PfKMO* crystals 
were only obtained in the presence of L-kynurenine, and unlike the other PfKMO* proteins 
with active site mutations, no crystals in the P21221 space group were obtained. 
Several attempts were made to obtain a data set of sufficient quality to make a good model 
but all the data collected was low resolution. The crystals all belonged to the I4122 space 
group (likely to contain L-kynurenine in the active site) and the resolution limit of each 
dataset was over 4 Å with very large B-factors, which meant that it was not possible to 
obtain the structure from crystals grown in these conditions. 
 
5.3.2 High resolution structure of H320F PfKMO* 
New conditions for growing crystals of PfKMO were shared by industrial collaborators who 
had had success in obtaining the structure of PfKMO at a higher resolution in the space 
group P21. These new conditions were used as a starting point for the crystallisation of 
H320F PfKMO* and crystals of H320F PfKMO*, both in the presence and absence of         
L-kynurenine, were obtained from which the structure of H320F PfKMO* was successfully 
solved (by Mark Taylor and Lindsay McGregor, members of the Mowat group). 
 
5.3.3 H320F PfKMO* in the presence of L-kynurenine 
The structure of H320F PfKMO* crystallised in the P21 space group in the presence of        
L-kynurenine has a resolution of 1.9 Å which is the highest obtained for a PfKMO* structure 
in the presence of substrate. The Rmerge was 0.039 overall (data processing statistics in 
Appendix 2, Table A2.5). This model has two H320F PfKMO* and 866 waters in the 
asymmetric unit. There was insufficient evidence in the electron density map to determine 
the position of L-kynurenine. 
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The structure of H320F PfKMO* in the presence of the substrate is similar to the structure of 
PfKMO* with L-kynurenine bound (Figure 5.8). The H320F PfKMO* structure contains a 
main domain and a C-terminal domain and has the non-covalently bound FAD present in a 
very similar position to that of the PfKMO* structure.  The overlay of the two structures in 
cartoon forms shows only a few differences in the two structures including the loop from 
residue 45-54 which is a flexible region visible in to the right of the protein as shown below 
(deep blue) and is the only region where there is a significant change in the position of 
residues visible in this overlay representation although there are some minor differences in 
the position of the helices of the C-terminal domain.  
 
 
Figure 5.8: The structure of H320F PfKMO* as a cartoon form with the N-terminus in deep 
blue and C-terminus in red is on the left. The FAD cofactor is shown in stick form in yellow. 
On the right is an overlay of the H320F PfKMO* structure (magenta) with the PfKMO* with 
L-kynurenine bound (green) with the FAD cofactors omitted for clarity. 
 
The active sites of H320F PfKMO* and L-kynurenine bound PfKMO* have many 
similarities, with many of the hydrophobic residues in almost exactly the same positions. 
H320 and F320 occupy very similar positions in the active site (Figure 5.9), as do N369 and 
R84 but there are significant differences in the position of the two tyrosine residues which 
are thought to interact with the substrate, Y98 and Y404. It is difficult to comment on the 
significance of this as the evidence for the presence of L-kynurenine in active site of H320F 
PfKMO* is not conclusive (Figure 5.10).  
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Y404 appears to have moved significantly closer to the carboxylate moiety of L-kynurenine 
with the distance from the hydroxyl to the carboxylate group decreasing from 4.1 Å to 2.8 Å 
in the H320F PfKMO* structure, assuming that the substrate is present and that it binds in 
the same position. There is a distance of 1.8 Å between the hydroxyl groups of Y404 in each 
structure. Y98 has moved further away from the active site in the H320F PfKMO* with a 1.1 
Å distance between the hydroxyl groups of this residue in both structures. 
 
 
Figure 5.9: An overlay view of some active site residues in PfKMO* (green) with                    
L-kynurenine (cyan) bound and H320F PfKMO* (magenta). The FAD cofactors from these 
structures are yellow and pink respectively. There is no unambiguous L-kynurenine 







Figure 5.10: The Fo-Fc map (left; green) contoured at 2.99 σ and the 2Fo-Fc map (right, blue) 
contoured at 1.5 σ of H320F PfKMO* in the presence of L-kynurenine. In the area where     
L-kynurenine is expected to bind, with the isoalloxazine moiety of the FAD cofactor visible 
to the right of this area, solvent molecules have been modelled into the active site but no 
area of unmodelled density that corresponds to L-kynurenine can be located in the Fo-Fc 
map. 
 
5.4.4 H320F PfKMO* in the absence of substrate 
The structure of H320F PfKMO* in the absence of ligand in the active site was obtained 
with a resolution of 1.81 Å in the P21 space group. The asymmetric unit contained two 
H320F PfKMO* and 383 waters (data statistics listed in Appendix 2 Table 2.5).  
The structures of H320F PfKMO* in the absence of substrate contains a number of 
differences with both the structure of PfKMO* in the absence of substrate and the structure 
of H320F PfKMO* in the presence of L-kynurenine. Compared with the structure of 
PfKMO* in the absence of substrate (Figure 5.11) the structures are similar with a slight 
difference in the position of the helices of the C-terminal domain and a movement of the 
loop containing residues F319 and F320. 
In a comparison of the structures of H320F PfKMO* crystallised in the presence and 
absence of substrate (Figure 5.12) there is a difference in the position of the C-terminal 
domain which moves away from the main domain to an open conformation in the active site, 
the residues 372 to 378 are a helix in the presence of L-kynurenine and a loop in the absence 
of substrate, and there is a previously unseen movement of the loop containing F320 in the 
two structures which is not observed in PfKMO* structures with the position of this region 




Figure 5.11: Overlay comparing the structure of H320F PfKMO* in the absence of substrate 
(cyan with blue FAD cofactor) with that of PfKMO* (green with yellow FAD cofactor). 
 
 
Figure 5.12: Structural changes in the event of substrate binding. H320F PfKMO* in the 
absence of L-kynurenine (cyan) with FAD cofactor (blue) is shown overlaid with the 




The structure of the active site residues of H320F PfKMO* in the absence of L-kynurenine 
contains some significant differences to that of PfKMO* (Figure 5.13). As seen with the 
structures in the presence of substrate in Section 5.3.2 above, there is a difference in the 
positions of the tyrosine residues with Y404 appearing further into the active site and Y98 
further away. There also appears to be a slight difference in the position of R84. The most 
significant change is in the region of H320. This loop in H320F PfKMO* is in a different 
position, affecting residues F319 and F320, with the F320 sidechain in the active site in a 
position that it could not occupy in the presence of substrate which supports the theory that 
L-kynurenine is bound in the other structure although this could not confirmed.  
 
Figure 5.13: The active sites in the absence of L-kynurenine of both PfKMO* (green) with 
FAD cofactor (yellow) and H320F PfKMO* (cyan) with FAD cofactor (blue). 
 
The structural differences between H320F PfKMO* in the presence and absence of             
L-kynurenine suggests that the movement of this loop is a conformational change that occurs 
in response to substrate binding in the active site (Figure 5.14). This conformational change 
in the loop is not observed in any other PfKMO* structure but a conformational change in 
this region does occur in S. cerevisiae KMO (Figure 1.17). Other changes that can be 
observed between the two structures including the movement of R84 away from the active 
site in the absence of substrate and a change in the position of N369 which is moved out 
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from the active site in the absence of L-kynurenine are differences that are all expected given 
the changes observed in PfKMO* when substrate binds.  
 
Figure 5.14: Conformational change in active site residues 318 – 320 in H320F PfKMO* in 
the presence and absence of L-kynurenine shown through the comparison of PfKMO* 
(purple) with L-kynurenine (purple), H320F PfKMO* in the presence of L-kynurenine (green) 





H320 is the only residue in the active site of PfKMO* that is not conserved in the human 
enzyme and investigation of this residue helps to validate results gained from studying 
PfKMO* as a source of insights into the chemistry of human KMO and development of 
inhibitors that could be used to inhibit human KMO. 
From the structure of PfKMO*, H320 is almost 4 Å from L-kynurenine and is not expected 
to have a significant effect on substrate binding, confirmed by the slight increase in KM 
observed with H320F PfKMO*. The results of the inhibition assays showed that there was a 
slight increase in all the Ki values and the trend in the Ki values observed for H320F 
PfKMO* is different with GM862 being the most potent of this group of inhibitors unlike the 
results with PfKMO* where this is the least potent of the group which is difficult to fully 
explain from these data alone. 
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The structure of H320F PfKMO* crystallised in both the presence and absence of                 
L-kynurenine has been obtained using new conditions provided by collaborators, although 
the electron density of the substrate is unclear. These structures revealed that when substrate 
binds to H320F PfKMO* there is a conformational change affecting the loop around F320 
resulting in F320 being in a similar position to H320 only when substrate is bound, but when 




Chapter 6: Conclusions and Future Work 
 
 
KMO is one of three enzymes that metabolises L-kynurenine as part of the kynurenine 
pathway of tryptophan metabolism. It is a Class A flavoprotein aromatic hydroxylase and 
converts L-kynurenine to 3-hydroxykynurenine in a reaction that requires NADPH, a non-
covalently bound FAD cofactor and oxygen. The mechanism of KMO has been shown in 
previous kinetic studies to be similar to those of other related flavoproteins including PHBH. 
There has been significant interest in characterising this enzyme and over the last three years 
the first KMO structures have been solved of the enzymes from Pseudomonas fluorescens 
and Saccharomyces cerevisiae.  KMO inhibition has been identified as a potentially 
beneficial therapeutic strategy in a number of conditions including Huntington’s disease, 
Alzheimer’s disease and acute pancreatitis. In studies on animal models of Huntington’s 
disease and Alzheimer’s disease KMO inhibition has been shown to have a beneficial effect 
preventing further neurodegeneration.  
The previously solved structures of PfKMO* revealed a conformational change that occurs 
on the binding of substrate where the C-terminal domain is in an open conformation in the 
absence of substrate positioned further from the main domain of the protein and in a closed 
conformation in presence of substrate. The closed conformation requires a network of 
interactions between the substrate, R84, E372, Y382 and R386. In previous work E372, 
Y382 and R386 have been mutated and with the disruption of these interactions, substrate is 
still able to bind but the C-terminal domain is between the closed and open conformations. 
This work also provided identification of all of the active site residues and it was possible to 
identify potential interactions between L-kynurenine and PfKMO* that were important for 
substrate binding. Characterisation of the active site of PfKMO* has been undertaken in this 
thesis with investigation of Y404, N369 and R84. The role of Y404 was investigated using 
the mutations Y404A, which resulted in an inactive protein, and Y404F which has a slightly 
raised KM. Y404F PfKMO* was crystallised without substrate in the active site revealing no 
major conformational change with slight changes in the position of some active site residues 
including F404. Y404F PfKMO* was also crystallised in the I4122 space group although 
there was not sufficient electron density to conclusively determine the position of                     
L-kynurenine. A slight change in the orientation of F404 relative to Y404 was observed. This 
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supports the hypothesis that Y404 forms a hydrogen bond with the carboxylate moiety of    
L-kynurenine without which the affinity of PfKMO* for the substrate is slightly affected but 
this interaction is not critical for catalysis and does not significantly affect the structure. 
N369 was hypothesised to interact with the substrate and was investigated through the 
mutation N369S, which had only a very slight effect on the kinetic properties. N369S 
PfKMO* was crystallised with no substrate bound in the active site and a few slight changes 
to the positions of S369, F319 and H320 were observed. The structure was obtained in the 
presence of 3,4-dichlorobenzoylalanine at a poor resolution so it was not possible to 
determine the position of the ligand in the active site. No major conformational changes were 
observed and not many of the sidechains of residues could be included in the structure. This 
would suggest that N369 is not is not critically important despite being in close proximity to 
the substrate and other active site residues. 
R84 is one of the more interesting residues in the active site as not only does it interact with 
the substrate but it appears to be extremely important for controlling conformational change 
in PfKMO*. R84A PfKMO* was found to be inactive. No activity could be detected for 
R84K PfKMO* although the KM is expected to be greatly affected by this mutation so 
perhaps extremely high enzyme concentrations would be required to observe activity. The 
structure of R84K PfKMO* without substrate bound was extremely similar to that of 
PfKMO*. A potential reason for the lack of activity observed with R84K PfKMO* could be 
that this enzyme cannot easily achieve the change from the open to the closed conformation.  
This study is the first characterisation of active site residues in PfKMO* and compliments 
the previous structural work by confirming the importance of some of these residues in 
substrate binding, such Y404. The evidence obtained from studying R84A and R84K 
PfKMO* showed for the first time how important this residue for enzyme function with loss 
of activity observed with even a conservative mutation. From this, it is hypothesised that the 
ability of PfKMO* to control the conformational change from open to closed upon substrate 
binding is critically important and depends on the interactions between R84 and both the 
substrate and the other residues involved in the conformational change. 
There are other residues in the active site, including Y98, which may be important for 
substrate binding and should be investigated. The kinetic and structural data obtained in this 
thesis would be complimented using isothermal titration calorimetry to obtain 
thermodynamic data which would confirm and strengthen the hypotheses made about the 
role of specific active site residues in substrate binding. The new conditions used to obtain 
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the structure of H320F PfKMO* could be used to obtain better resolution structures of 
mutated enzymes, particularly in the presence of L-kynurenine, and this may provide further 
insights into the effect of each mutation.  
In the absence of structural information many of the KMO inhibitors studied previously, 
including m-nitrobenzoylalanine and 3,4-dichlorobenzoylalanine, were based on the 
structure of L-kynurenine and are also effectors. Effectors bind to KMO allowing NADPH to 
reduce the FAD cofactor but as these compounds are not substrates and cannot be 
hydroxylated, there is decay of the unstable hydroperoxyflavin with release of H2O2 into the 
surrounding environment. A more promising inhibitor Ro 61-8048 has been shown to be 
efficacious in animal models of disease.  
In our group, we have investigated a series of novel potent inhibitors which do not act as 
effectors. In previous work it has been shown that parts of these compounds bind in the 
active site but due to their size, they do not entirely fit within it. In this thesis the final set of 
these compounds was assayed with PfKMO* and were shown to all have Ki values in the 
nanomolar range. The substituents on the ring outside the active site were found to affect the 
potency and large substituents were well tolerated with GM855 and GM849 being the most 
potent of this group. The structures of PfKMO* with three of these inhibitors bound were 
obtained using sitting drop vapour diffusion methods. GM859 was seen clearly in the 
structure and a potential interaction was observed between E372 and the sulfonamide moiety 
of the inhibitor which is the probable reason why this inhibitor is particularly potent (Figure 
6.1). With the other inhibitors, GM862 and GM849, that were crystallised with PfKMO* it 
was more difficult to find the aromatic ring furthest from the active site.  
These novel compounds are the most potent inhibitors of PfKMO* currently known. The 
potency of these compounds appears to arise from their ability to form several interactions 
with PfKMO* and also because they prevent the enzyme from forming the closed 
conformation as they are so large they do not fit entirely within the active site. This is likely 
to be the reason that these are true inhibitors rather than effectors and also confirms the vital 
importance of conformational dynamics for PfKMO* supporting both previous work with 





Figure 6.1: View of GM859 bound in the active site of PfKMO* with the FAD cofactor shown 
to the back of the active site close to the 3,4-dichlorosubstituted aromatic ring. The 
sulfonamide interacts with Glu372 and displaces Arg84 which causes PfKMO* to stay in the 
open conformation despite the presence of a ligand in the active site. Distances are 
indicated in Å. 
 
These inhibitors are very promising compounds and to assess whether they may lead to the 
development of clinically useful compounds, they should be assayed with the human KMO 
enzyme.  
Three of these inhibitors were assayed with H320F PfKMO* where the only residue in the 
active site which is not conserved between these residues was mutated to the phenylalanine, 
which is the residue found in the human enzyme. The Ki assay results suggest that the 
inhibitors are not as potent with H320F PfKMO* but they still inhibit the enzyme and, in the 
absence of substrate, no NADPH consumption was observed. This indicates that these 
inhibitors may perform well in assays with the human enzyme although these experiments 
would need to be carried out. 
H320F PfKMO* was found to have similar values of KM and kcat to PfKMO* suggesting that 
this residue is not important for substrate binding. The structure of H320F PfKMO* was 
obtained (with collaboration of other members of the Mowat research group) in the presence 
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and absence of L-kynurenine. The evidence of the presence of substrate in the active site was 
not unambiguous but a conformational change is observed from the structures of H320F 
PfKMO* involving residues F319 and F320 probably caused by substrate binding and this 
may be an important feature of the human enzyme.  
The characterisation of the active site of PfKMO* undertaken in this thesis has contributed 
to the understanding of KMO. The study of residues in the active site has identified 
interactions important for substrate binding. Characterisation of H320F PfKMO* has led to 
the identification of a conformational change which could occur in the human enzyme and 
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Appendix 1: Sequencing Data 
 
The success of making a mutation in the PfKMO gene was confirmed by submitting samples 
for Sanger sequencing as described in Section 2.1.8. The results are listed below for each 
sample with Sample 1 being the sample containing the T7 Promotor primer and Sample 2 



































































































































































































Appendix 2: Crystallography Data 
 
 
PfKMO* with inhibitors bound 
 
Inhibitor bound GM862 GM849 GM859 
Space group P6122 P6122 P6122 
Cell dimensions 
a = b, c (Å) 










Resolution (Å) 34.84 – 1.98  
(2.09 – 1.98) 
64.54 – 3.26 
(3.44 – 3.26) 
36.92 – 2.6  
(2.74 – 2.6) 
Rmerge 0.213 (0.606) 0.195 (0.421) 0.224 (0.543) 
Mean I/σ(I) 10.8 (4.2) 11.7 (6.8) 10.1 (4.4) 
Completeness (%) 99.9 (99.8) 100.0 (100.0) 100.0 (100.0) 
Multiplicity 11.6 (11.9) 11.1 (9.7) 11.8 (11.7) 
    
Rfree 0.2183 0.1904 0.2025 
Rfactor 0.2561 0.2858 0.2628 
Number of reflections 178080 39009 76545 
rmsd bond lengths (Å) 0.0193 0.0134 0.0133 
rmsd bond angles (º) 1.9220 1.6869 1.7143 
Ramachandran 
outliers (%) 
0.38  1.58 
Table A2.1: Data collection and refinement statistics for inhibitor bound PfKMO* crystals. 






 Substrate free L-kynurenine bound 
Space group P21221 I4122 
Cell dimensions 
a, b, c (Å) 
α = β = γ (º) 
 
103.6, 133.8, 190.6 
190 
 
149.5, 149.5, 271.3 
90 
Resolution (Å) 43.43 – 2.7 (2.85 – 2.7) 57.07 – 3.95 (4.16 – 3.95) 
Rmerge 0.077 (0.288) 0.109 (0.992) 
Mean I/σ(I) 9.9 (3.3) 13.6 (2.4) 
Completeness (%) 98.2 (98.5) 100.0 (100.0) 
Multiplicity 3.6 (3.7) 11.8 (12.7) 
   
Rfree 0.2154 0.2602 
Rfactor 0.2853 0.2914 
Number of reflections 96915 17436 
rmsd bond lengths (Å) 0.0131 0.0100 
rmsd bond angles (º) 1.7101 1.4646 
Ramachandran outliers (%) 2.97 10.49 
Table A2.2: Data collection and refinement statistics for Y404F PfKMO* crystals. The 






 Substrate free 3,4-dichlorobenzoylalanine bound 
Space group P21221 I4122 
Cell dimensions 
a, b, c (Å) 
α = β = γ (º) 
 
104.8, 134.00, 188.3 
90 
 
150.08, 150.08, 274.05 
90 
Resolution (Å) 43.44 - 2.38 (2.51- 2.38) 57.54 - 3.98 (4.20 - 3.98) 
Rmerge 0.065 (0.582) 0.076 (0.395) 
Mean I/σ(I) 13.0 (2.3) 15.2 (5.3) 
Completeness (%) 99.5 (99.6) 100.0 (100.0) 
Multiplicity 4.2 (4.2) 10.1 (10.5) 
   
Rfactor 0.2290 0.2610 
Rfree 0.2752 0.3362 
Number of reflections 143640 17436 
rmsd bond lengths (Å) 0.0146 0.0116 
rmsd bond angles (º) 1.6771 1.7603 
Ramachandran outliers (%) 2.59 18.04 
Table A2.3: Data collection and refinement statistics for N369S PfKMO* crystals. The 






 Substrate free 
Space group P21221 
Cell dimensions 
a, b, c (Å) 
α = β = γ (º) 
 
105.53, 133.74, 187.60 
90 
Resolution (Å) 35.35 – 2.45 (2.58 – 2.45) 
Rmerge 0.053 (0.358) 
Mean I/σ(I) 15.0 (3.5) 
Completeness (%) 99.2 (99.4) 




Number of reflections 130438 
rmsd bond lengths (Å) 0.0137 
rmsd bond angles (º) 1.6899 
Ramachandran outliers (%) 2.83 
Table A2.4: Data collection and refinement statistics for the R84K PfKMO* crystal. The 







 Substrate free With L-kynurenine 
Space group P21 P21 
Cell dimensions 
a, b, c (Å) 
α,  β, γ (º) 
 
68.26, 45.99, 74.99 
90, 104, 90 
 
69.50, 51.89, 136.48 
90, 104.11, 90 
Resolution (Å) 33.11 – 1.81 (1.91 – 1.81) 34.75 – 1.90 (2.01 – 1.90) 
Rmerge 0.038 (0.089) 0.039 (0.078) 
Mean I/σ(I) 17.8 (8.8) 17.5 (9.1) 
Completeness (%) 98.4 (95.1) 99.2 (96.9) 
Multiplicity 2.7 (2.5) 2.9 (2.6) 
   
Rfree 0.1548 0.1752 
Rfactor 0.2007 0.2260 
Number of reflections 58094 104428 
rmsd bond lengths (Å) 0.0183 0.0182 
rmsd bond angles (º) 1.8853 2.1067 
Ramachandran outliers (%) 0.67 1.55 
Table A2.5: Data collection and refinement statistics for the H320F PfKMO* crystal. The 





Appendix 3: Inhibition Data 
 




























































H320F PfKMO* inhibited by GM859 
 
 
 
 
 
[L-kynurenine (μM)] 
